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CHAPTER 1  
General Introduction 
 
Dissertation organization  
 
This dissertation is divided into six chapters. Chapter 1 is a general introduction to the thesis.  
Carbohydrates play important roles in biology; however, studies of the bioactivities of carbohydrates 
clearly fall behind studies regarding nucleic acids and peptides. This lag clearly in large part is due to 
the difficulties of obtaining homogenous carbohydrates from natural sources, and the challenges of 
synthesizing carbohydrates chemically. Whereas nucleic acids and peptides can be synthesized using 
automation as a routine practice, the synthesis of carbohydrates is still a difficult task. In this thesis, 
through the development of new methods, including multi-gram scale approaches to building blocks, 
amenable to automation for the solution and fluorous-assisted synthesis of complex carbohydrates, we 
discuss the progress toward solving the obstacles in the synthesis of carbohydrates.  
 
Chapter 2 was published in Organic Letters in 2011.1 This chapter discusses the synthesis of the first 
fluorous protecting group for phosphate and its application in carbohydrate synthesis. 
Fluorous-assisted synthesis provides a convenient way of purification, and has attracted significant 
attention in the past decade. The Pohl group has developed an automated solution-phase synthesis 
platform based in part on fluorous solid-phase extractions. A fluorous phosphate protecting group 
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based on halo ethyl protecting groups was designed and synthesized. The stability of this group 
towards acidic conditions and basic conditions has been determined. This protecting group can be 
used as a facile tag for purification and be removed under mild reducing conditions using zinc and 
ammonium formate. Synthesis of a disaccharide from Leishmania using this fluorous protecting 
group demonstrated the group’s stability to the acidic conditions necessary for glycosylation as well 
as its orthogonality to several other common protecting groups. 
 
Chapter 3 discusses the synthesis of a series of maltotriose phosphate as probes to be used in the 
study of glycogen storage diseases. There have been extensive studies regarding the synthesis of 
maltose structures, but the synthesis of maltose with a phosphate at either the 2- or 3-position of the 
glucose residue has received very little attention in the past. In this chapter, different synthetic 
strategies are presented depending on the position of the phosphate to find a general and efficient 
synthetic route of the maltose phosphates. Partially as an expansion of the work presented in chapter 2, 
the fluorous phosphate protecting group is evaluated in the synthesis of maltotriose phosphates to 
probe the feasibility and limitations of using this particular new fluorous protecting group.  
 
Chapter 4 was published in The Journal of Organic Chemistry in 2012.2 This chapter reports a new 
synthetic route for isobutyl-β-C-galactoside (IBCG). The synthesis of IBCG was reported by our 
group in 2003. Since then, the compound has attracted attention for its potential use in animal studies. 
However, the previous synthesis is not easily suitable for larger scale preparation. In this chapter, the 
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synthesis of IBCG was achieved in 5 steps from galactose in 81% overall yield without any 
chromatographic separation steps. This new route allows obtaining the multigram quantities of 
material required for animal studies more feasible. An optimized microwave-assisted reaction at high 
concentration was crucial to making the C-glycosidic linkage. In the synthesis, it was demonstrated 
that the protecting groups have a profound influence of the reactivity of the substrate. The key Wittig 
reaction to install the extra carbon on a per-O-silylated gives drastically improved yield compared 
with the reactions on the per-O-acetylated or -benzylated substrate. The co-authors, Basma Abdel 
Motaal and Marc Schmidt-Supprian in the Max Planck Institute of Biochemistry in Germany, showed 
in their cell-based assays that IBCG is also a promising inducer of gene expression in mammalian 
cells.  
 
Chapter 5 discusses the development of synthetic methods amenable to automation for the production 
of hyaluronic acid fragments, members of the glycosaminoglycan family. Obtaining homogeneous 
oligosaccharides for biological studies is a major goal of carbohydrate chemistry. However, the 
chemical synthesis of carbohydrates, especially glycosaminoglycans, is still a difficult task. Several 
different synthetic strategies to hyaluronic acid fragments were studied and compared. To overcome 
the severely reduced reactivity because of the strong electron withdrawing properties of the uronic 
acid, which is one of the major difficulties in glycosaminoglycan synthesis, a new method to install 
benzyl groups at the 4- and 6-positions on the trichloroacetyl protected glucosamine and at the 2- and 
3-positions on glucuronic acid allowed the synthesis of the more electron rich hyaluronic disaccharide 
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building blocks. Using fluorous assisted synthesis, a tetrasaccharide of hyaluronic acid was 
synthesized. The conditions developed should be readily applicable for future automated syntheses of 
this class of glycosaminoglycans.  
 
Chapter 6 discusses the conclusions and future directions for the entire thesis.  
 
References 
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Isobutyl-β-C-galactoside as a Substitute of Isopropylthiogalactoside for Exogenous Gene Induction in 
Mammalian Cells. J. Org. Chem. 2012, 77, 1539-1546. 
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CHAPTER 2 
 A Fluorous Phosphate Protecting Group with Applications to Carbohydrate Synthesis 
A paper published in Organic Letters1 
Lin Liu and Nicola L. B. Pohl 
 
Abstract 
 
 
 
The first fluorous protecting group for phosphate is reported. This group can be used as a facile tag 
for purification and be removed under mild reducing conditions using zinc and ammonium formate. 
Synthesis of a disaccharide from Leishmania using this fluorous protecting group demonstrated the 
group’s stability to the acidic conditions necessary for glycosylation as well as its orthogonality to 
several other common protecting groups. 
                                                        
1 Reprinted with permission from Organic Letters, 2011, 13(7), 1824 – 1827. Copyright 2011 American Chemical Society. 
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Introduction 
 
Phosphate groups are a common motif in a range of bioactive molecules. Phosphodiester bonds make 
up the backbone of nucleic acids, and phosphate groups are an important part of 
phospholipids.1,2 Phosphorylation is a key modification for numerous proteins, and many complex 
carbohydrates found on the cell surface are phosphorylated.3,4 Consequently, the chemistry of 
phosphate has received a lot of attention. One of the central problems in phosphate chemistry is the 
protecting group. The phosphate itself is acidic and charged at neutral pH and therefore difficult to 
carry through and purify by standard organic synthetic methods. Numerous protecting group 
strategies have been developed for the protection of the phosphate group, most of which have been 
used in the synthesis of nucleotides, especially on a solid phase.5 Given the growing interest in 
fluorous-assisted synthesis6,7 and our own interest in the synthesis of phosphate-containing complex 
carbohydrates, we were intrigued by the possibility of combining a protecting group for phosphate 
with a fluorous tag for easy purification using fluorous solid phase extraction (FSPE)8-13 of the 
protected compound. 
 
Many fluorous versions of protecting groups have been developed for a variety of functional groups. 
Our group has used fluorous tags as a handle for purification14-16 and also has shown that these 
fluorous tags/protecting groups could be used to directly array compounds for screening.17-21 However, 
surprisingly no fluorous protecting group for phosphate has yet been reported. Fluorous groups for the 
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temporary tagging of the hydroxyls or permanent tagging of the phosphates of nucleotides have been 
reported in the context of nucleic acid synthesis to assist separation, and some of these fluorous tags 
have been commercialized.22-25 However, since the tags for phosphates cannot be removed, they 
cannot serve a dual purpose also as a protecting group. We envisioned fluorous protecting groups for 
phosphates that could function as tags, but also could be removed under mild conditions when 
necessary, would be useful in the synthesis of phosphate-containing molecules (Figure 1), allowing 
both easy purification and a handle for microarray formation. Herein we report the design and 
synthesis of the first fluorous protecting group for phosphate and demonstrate its use in carbohydrate 
synthesis. 
 
Figure 1. Concept of the fluorous protecting and tagging group for phosphate. 
 
Results and Discussion  
In the search for a fluorous protecting group for phosphate, 3-(perfluorooctyl)propanol—which 
contains a C8F17 moiety with a simple three carbon alkyl linker and is commercially available—was a 
natural starting point. If this fluorous alkyl alcohol could be readily added and removed from a 
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phosphate, it could serve as a protecting group. To test the reactivity of this fluorous alcohol, a model 
study using dibenzyl 3-(perfluorooctyl)propyl phosphate was initiated. The benzyl groups on the 
phosphate ideally would serve as the same sort of “permanent” protecting group often used on the 
hydroxyls of carbohydrates that is removed by hydrogenolysis only at the very end of a synthesis. 
Generally alkyl protecting groups of phosphates are removed using small 
nucleophiles.26 Unfortunately, various nucleophiles such as azide or iodide served only to remove one 
of the benzyl groups in quantitative yields; the fluorous alcohol largely remained in position. 
 
In the continued search for a fluorous protecting group for phosphate that could be easily removed 
under conditions in which the benzyl phosphate was stable, a haloethyl ester of phosphate caught our 
attention. These haloethyl groups can generally be removed under mild reducing conditions. Fluorous 
bromo-alcohol 1, first reported in 1984,27 had shown use as a carbamate-type protecting group for 
amines associated with carbohydrate and peptide structures and could be deprotected using 
Zn/Ac2O/Et3N to provide an N-acetyl.28 We reasoned that this fluorous alcohol 1 with a bromide at the 
β-position could potentially be suitable for phosphate protection if conditions for its easy removal 
could be found. However, a concern was the extra stereogenic center of the haloalkyl group, coupled 
with the stereogenicity of the phosphate ester with a benzyl and a carbohydrate substituent and the 
chirality inherent in sugars; the resulting diastereomers could make separations and structure 
elucidation challenging enough to render the fluorous phosphate protecting group more trouble than it 
was worth. 
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Scheme 1. Synthesis of Fluorous Protected Dibenzyl Phosphate 
 
To first test the relative stability of the fluorous haloalkyl group and the benzyl group on phosphate, a 
simple dibenzyl phosphate was made using standard phosphoramidite chemistry (Scheme 1). The 
fluorous bromo-alcohol 1 was coupled with dibenzyl phosphoramidite 2 in the presence of tetrazole 
to yield phosphite 3, which was then oxidized to phosphate 4 using m-chloroperoxybenzoic acid 
(m-CPBA) in 98% yield in two steps after FSPE purification. Various conditions were tested to 
remove the fluorous protecting group, including Zn/NH4HCO2/CH3OH, Zn/HOAc/THF, and 
Pd/C/CH3OH/NH4HCO2.29,30 The reaction was monitored by TLC and 31P NMR. All of these 
conditions successfully removed the fluorous group on 4, yielding the desired phosphate 5, without 
removal of either benzyl group. The Zn/NH4HCO2 conditions in methanol provided the fastest and 
cleanest reaction. Further optimization of the deprotection conditions showed that by using 
Zn/NH4HCO2 in CH3CN/THF (4:1) the reaction could go to completion in 1−2 h. The resulting 
ammonium salt of phosphoric acid was purified by a short silica gel column using CH2Cl2/CH3OH as 
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the eluent with 1% NH4OH to remove the small amount of ZnBr2. The fluorous byproduct of the 
deprotection, the fluorous alkene, has a boiling point of 146−147 °C and could be removed easily by 
evaporation. The fraction was concentrated, followed by the addition of water, and subjected to 
lyophilization to give the pure product. 
 
To study the stability of this protecting group under typical acidic and basic conditions used to 
remove other protecting groups, compound 4 (0.006 M) was treated with 10% trifluoroacetic acid 
(TFA, 217 equiv) or 10% piperdine (168 equiv) in deuterated chloroform and monitored by1H NMR. 
Haloethyl compounds are known to be unstable to piperdine; our results showed only a 24-h half-life 
for the group. In contrast, the fluorous haloalkyl protecting group showed a half-life of over 120 h in 
the presence of 10% TFA, and no decomposition was found in the presence of 5 equiv of TsOH after 
48 h (Table 1). Compound 4 itself is stable at room temperature for several months. 
Table 1. Assessment of Protecting Group Stability 
                                    Percentage (%) Decomposition of 4 
Time (h)   0.5 12 24 48 72 96 120 
10% TFAa 0 9 17 31 33 42 45 
10% 
piperdinea 
0 21 50 91 100 -- -- 
5 equiv TsOHb 0 0 0 0 0 -- -- 
a) in CDCl3; b) in 9:1 CDCl3/CD3OD 
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Encouraged by these results, we decided to use this protecting group as a protecting group for a 
phosphate monoester on a carbohydrate to ascertain its affect on the separation and characterization of 
the resulting diastereomeric compounds. As before, we used a benzyl group as the second group on 
the phosphate ester, since the widely used benzyl group would not make a final deprotection scheme 
more complicated by the addition of another step. This strategy was first tested on a galactose 
monosaccharide (Scheme 2). 
 
Benzyl phosphoramidite 6 31 was coupled with fluorous bromo-alcohol 1 in the presence of tetrazole 
to yield the desired fluorous phosphoramidite 7. The 31P NMR of 7 reveals two peaks at 149.57 and 
149.44; these peaks reflect the diastereomeric nature of this compound based on the presence of two 
stereogenic centers. The product was then reacted with diisopropylidene galactose 8 32 and oxidized 
with t-BuOOH to afford the desired protected phosphate 10 in 90% yield after FSPE purification 
without the need of a silica gel column. Two sets of closely spaced peaks in the 31P NMR spectrum 
showed the influence of the newly added stereogenic center from the carbohydrate, theoretically 
resulting in four diastereomers. Even so, the 1H NMR spectrum of the product was still clean and did 
not show signs of a mixture. The chiral center on the fluorous bromo-alkylalcohol does not 
complicate the proton NMR analysis likely because of the remoteness of this center from the 
influence of the carbohydrate. However, 31P NMR can be used to ensure that the group has actually 
been successfully added. Removal of the protecting group using Zn/NH4HCO2/CH3OH required 6−8 
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h for completion whereas using CH3CN/THF (4:1) as the solvent reduced the reaction time to 1−2 h. 
A short silica gel column, followed by concentration and lyophilization, gave the product 11 as the 
ammonium salt in 80% yield. 
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Scheme 2. Fluorous Phosphite Synthesis, Addition to a Monosaccharide with Formation of the 
Phosphate Ester, and Deprotection of the Fluorous Tag 
 
We next wanted to probe the robustness of this new fluorous phosphate protecting group with a set of 
 13
glycosylation/deprotection conditions used in oligosaccharide synthesis by making a disaccharide 
from Leishmania 33(Scheme 3). To this end, galactose building block 12 was obtained 
from d-galactose.34 The benzylidene was opened selectively using Bu2BOTf and BH3THF35 to 
yield 13 with a free C-6 hydroxyl. Compound 13 was then coupled with fluorous 
phosphoramidite 7 to yield 14. At this stage, four closely spaced peaks in the 31P NMR spectrum (δ 
139.52, 139.44, 139.33, 139.26) revealed the product as four diastereomers as expected. After 
oxidation, phosphate 15 was purified by FSPE and obtained as the only product in 79% yield. The 31P 
NMR spectrum of 15 showed only two close peaks separated by just 0.01 ppm at −1.90 and −1.91. 
This small difference demonstrates that the chemical environments of the phosphorus in the 
diastereomeric products are close enough to make little difference in the31P NMR response. 
The p-methoxybenzyl (PMB) group at C-3 of compound 15 was removed with 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ),36 followed by FSPE purification, to 
afford16 with a free hydroxyl acceptor in 97% yield. The acceptor was coupled with 
trichloroacetimidate donor 1737 using trimethylsilyltriflate as a promoter followed by another FSPE to 
yield the desired disaccharide 18 in 94% yield. The fluorous protecting group was removed using 
Zn/NH4HCOO in CH3CN/THF within 2 h to yield the desired disaccharide 19 as the ammonium salt 
in 74% yield. 
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Scheme 3. Synthesis of a Leishmania Disaccharide 
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Conclusion 
 
In conclusion, a fluorous protecting group for the phosphate group was synthesized. Although this 
new protecting group contains a stereogenic center, this center does not complicate structure 
elucidation by 1H NMR and, in fact, adds diagnostic signals in the 13C and 31P NMR spectra. The 
fluorous phosphate protecting group greatly simplified the purification through the use of FSPE in the 
synthesis of phosphate-containing compounds. The fluorous bromo-ethanol could be removed easily 
under mild reducing conditions using zinc and ammonium formate in CH3CN/THF. The fluorous 
byproduct has a relatively low boiling point that allows its easy removal under reduced pressure. We 
are currently probing the utility of this new protecting group for the synthesis of a series of 
maltose-related phosphates and for solution-phase automated oligosaccharide synthesis. 
 
Experiment section 
 
General Methods: Reactions were performed using flame-dried glassware under argon using 
anhydrous solvents unless otherwise noted. Ambient temperature in the laboratory was usually 20 °C. 
CH2Cl2 and CH3CN were distilled freshly from CaH2. Zinc dust was obtained from Fisher and 
activated according to Purification of Laboratory Chemicals (5th Edition), 2003, Elsevier. Other 
commercially available reagents were obtained from Aldrich, Fisher or TCI and used as received. 
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Thin layer chromatography (TLC) was performed using glass backed Silica Gel HL TLC plates 
w/UV254 from Sorbent Technologies. Visualization of TLC plates was performed by UV, 5% sulfuric 
acid/ethanol, or p-anisaldehyde/ethanol. Silica gel flash chromatography was performed using silica 
gel (60 Å, 40-63 µm) from ZEOChem AG. 
 
The lyophilization was performed on a Labcono Freezone 4.5. Distilled water was used for the 
freezing of the sample for lyophilization. 
 
NMR spectra were recorded on a Agilent-Varian 400MR (400 MHz for 1H, 101 MHz for 13C, 
376MHz for 19F, 162 MHz for 31P), Varian VXR400 (400 MHz for 1H, 101 MHz for 13C) or Bruker 
DRX400 (400 MHz for 1H, 101 MHz for 13C, 162 MHz for 31P). Chemical shifts are reported in parts 
per million (ppm) on the δ scale. 13C, 31P spectra were obtained with 1H decoupling only unless 
otherwise noted. 1H NMR and 13C NMR taken in CDCl3 was referenced the solvent peak at 7.260 
ppm (1H) and 77.0 ppm (13C). 1H NMR and 13C NMR taken in d6-DMSO was referenced the solvent 
peak at 2.50 ppm (1H) and 39.5 ppm (13C). Note that due to the extensive 19F-13C and 31P-13C coupling 
and overlap in some of the 13C spectra, the coupling constants of those couplings are not reported. The 
peak values are listed instead. The assignments of 1H NMR peaks were made primarily from 2D 
1H-1H COSY and edited 1H-13C HSQC spectra. 1H-13C HMBC and 1H-1H TOCSY spectra were 
obtained to aid the assignments when necessary. 
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High resolution mass spectra (HRMS, ESI mode) were obtained using an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS at Iowa State University. For the fluorous phosphate containing 
compounds, acetonitrile was used instead of methanol in the ESI/MS to obtain reliable results.  
 
General Procedure for Fluorous Solid Phase Extraction (FSPE): A FSPE cartridge (2 g. Fluorous 
Technologies, Inc., Pittsburgh, PA) was preconditioned by passing 80:20 MeOH:H2O (6 mL) through 
it under a vacuum.  The crude mixture was loaded onto the cartridge by using no more than 2 mL of 
a 9:1 DMF:H2O solution. The non-fluorous containing compounds were eluted by passing 6-8 mL of 
80:20 MeOH:H2O through the cartridge. The fluorous containing compounds were eluted by passing 
6-8 mL of MeOH through the cartridge. The MeOH wash was concentrated under reduced pressure 
and the residue was coevaporated  with toluene to provide the fluorous compounds. The cartridge 
was regenerated by washing using acetone.  
 
Synthesis protocols and data of new compounds: 
C8F17
Br
P
BnO
O
OBn
O
 
Dibenzyl 2-bromo-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl phosphate (4). 
Fluorous bromo-alcohol 138 (0.5 mmol, 272 mg) was dissolved in CH3CN (3 mL) and tetrazole (0.72 
mmol, 50.4 mg) was added. The reaction was cooled to 0 °C and dibenzyl N,N-di 
isopropylphosphoramidite 2 (0.6 mmol, 207 mg) was added. The reaction was brought to ambient 
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temperature (20 °C), then stirred overnight. The reaction was cooled to –40 °C; a solution of 
mCPBA (1.0 mmol, 223 mg, 77% purity) in CH2Cl2 (4 mL) was added dropwise. The mixture was 
allowed to warm to ambient temperature and stirred for 2.5 h, then diluted with CH2Cl2, washed with 
10% Na2S2O3 (aq), sat NaHCO3 (aq) and dried over anhydrous Na2SO4. Solvents were removed under 
reduced pressure and the mixture was purified using FSPE to afford 4 as a white solid (396 mg, 0.49 
mmol, 98%).  
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.31 (m, 10H, ArH), 5.16 – 5.01 (m, 4H, OCH2Ph), 4.47 – 4.32 
(m, 2H, OCHHCBr, CHBr), 4.24 (dt, J = 11.2, 6.7 Hz, 1H, OCHHCBr); 
13C NMR (101 MHz, CDCl3) δ 135.36, 135.29, 128.77, 128.64, 128.09, 69.90, 69.85, 64.81, 43.89, 
43.80, 43.64, 43.56, 43.40, 43.31;  
31P NMR (162 MHz, CDCl3) δ -1.78;  
19F NMR (376 MHz, CDCl3) δ -80.73 (t, J = 10.0 Hz, 3F), -109.87 (ABq, J = 280 Hz, 1F), -113.11 
(ABq, J = 280 Hz, 1F), -118.55 (ABq, J = 295 Hz, 1F), -120.29 (ABq, J = 295 Hz, 1F), -121.40 – 
-121.99 (m, 6F), -122.69 (s, 2F), -126.08 (d, J = 7.6 Hz, 2F);  
HRMS calcd for C24H18BrF17O4P [M+H]+: 802.9849, found 802.9856. 
 
PBnO
O-NH4+
OBn
O
 
Ammonium dibenzyl phosphate (5). Compound 4 (110 mg, 0.014 mmol) was dissolved in CH3CN 
(2 mL) and 0.5 mL THF. NH4HCOO (56 mg, 0.89 mm0l) was added to the reaction followed by Zn 
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powder (40 mg, 0.61 mmol). The mixture was stirred for 2 h at ambient temperature, then filtered via 
Celite. The solid was washed with CH3OH. The filtrates were combined, concentrated, and purified 
via silica gel column using CH2Cl2/CH3OH (5:1) with 1% NH4OH as eluent to afford a white solid. 
Water was added to the solid and the mixture was lyophilized twice to afford the product 5 as a white 
solid (37 mg, 0.125 mol, 92%).  
1H NMR (400 MHz, d6-DMSO) δ 7.29 (s, 10H, ArH), 6.67 (bs, 4H, NH4), 4.81 (bs, 4H, OCH2Ph); 
13C NMR (101 MHz, d6-DMSO) δ 139.01, 128.56, 127.73, 127.61, 67.20;  
31P NMR (162 MHz, d6-DMSO) δ -2.79;  
HRMS calcd for C14H14O4P [M-NH4]-: 277.0635, found 277.0632 
 
P
N
OBn
C8F17
Br
O
 
Benzyl 2-bromo-3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 10-heptadecafluorodecyl 
diisopropylphosphoramidite (7). Fluorous bromo-alcohol 1 (227 mg, 0.42 mmol) and benzyl 
di(N,N-diisopropyl)phosphoramidite 639 (150 mg, 0.44 mmol) were dissolved in CH2Cl2 (3 mL). A 
solution of tetrazole (33 mg, 0.47 mmol) in THF (1.5 mL) was added to the reaction at ambient 
temperature. The mixture was stirred overnight. Et3N was added to the reaction and the mixture was 
concentrated. Silica gel column purification using hexanes/ethyl acetate (5:1) with 3% Et3N as eluent 
yielded product 7 as a colorless syrup (270 mg, 0.35 mmol, 83%).  
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.20 (m, 5H, ArH), 4.77 – 4.54 (m, 2H, OCH2Ph), 4.48 – 4.32 
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(m, 1H, CHBr), 4.20 – 4.02 (m, 1H, CHHCBr), 4.02 – 3.82 (m, 1H CHHCBr), 3.65-3.56 (m, 2H, 
CH(CH3)2), 1.19-1.15 (m, 3H, CH3), 1.14-1.12 (m, 6H, 2xCH3), 1.12 -1.10 (m,3H, CH3); 
13C NMR (101 MHz, CDCl3) δ 139.12, 139.05, 138.98, 128.31, 127.46, 127.46, 127.42, 127.07, 
127.07, 127.00, 65.71, 65.59, 65.53, 65.41, 62.40, 62.24, 62.05, 46.92, 46.89, 46.69, 46.62, 46.47, 
46.40, 46.24, 46.17, 46.00, 45.93, 43.33, 43.30, 43.21, 43.18, 24.55, 24.49, 24.42;  
31P NMR (162 MHz, CDCl3) δ 149.57, 149.44;  
19F NMR (376 MHz, CDCl3) δ -80.89 (t, J = 10.0 Hz, 3F), -109.22 (ABq, J = 280 Hz, 1F), -113.44 
(ABq, J = 280 Hz, 1F), -118.75 (ABq, J = 295 Hz, 1F), -120.42 (ABq, J = 295 Hz, 1F), -121.39 – 
-122.24 (m, 6F), -122.80 (s, 2F), -126.22 (dd, J = 14.2, 8.2 Hz, 2F);  
HRMS calcd for C23H25BrF17NO2P [M+H]+: 780.0529, found 780.0532.  
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6-(Benzyl 2-bromo-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl phosphate)-1,2: 3,4- 
di-O-isopropylidene-α-D-galactopyranose (10). 7 (170 mg, 0.22 mmol) and di-acetone galactose 
840 (170 mg, 0.66 mmol) was dissolved in CH2Cl2 (10 mL) at ambient temperature. 1 mL tetrazole in 
CH3CN (0.45 M) solution (0.45 mmol) was added dropwise and the mixture was stirred overnight. A 
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solution (5-6 M) of tBuOOH (200 µL ) in nonane was added, and the reaction was stirred for another 
4 h. The reaction was diluted with CH2Cl2, washed with sat NaHCO3 (aq) and dried with anhydrous 
Na2SO4. Solvents were removed under reduced pressure and the mixture was purified using FSPE to 
afford 10 as a white solid (188 mg, 0.196 mmol) in 90% yield.  
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.29 (m, 5H), 5.52 (d, J = 4.9 Hz, 1H, H-1), 5.13 (d, J = 8.1 Hz, 
2H, OCH2Ph), 4.61 (dd, J = 7.3, 2.9 Hz, 1H, H-3), 4.59 – 4.47 (m, 2H, CHBr, CHHCBr), 4.37-4.28(m, 
1H, CHHCBr), 4.33 (dd, J = 5.0, 2.5 Hz, 1H, H-2), 4.26 – 4.15 (m, 3H, H-4, H-6a, H-6b), 4.10 – 4.00 
(m, 1H, H-5), 1.56-1.51 (m, 3H, CH3), 1.51-1.41 (m, 3H, ), 1.31 (s, 6H, 2xCH3);  
13C NMR (101 MHz, CDCl3) δ 135.44, 135.37, 128.76, 128.68, 128.62, 128.58, 128.28, 128.07, 
128.05, 109.67, 109.64, 108.83, 108.81, 96.21, 70.63, 70.57, 70.33, 69.86, 69.83, 69.81, 69.77, 67.01, 
66.96, 66.92, 66.90, 66.85, 66.83, 66.77, 66.71, 66.69, 64.96, 64.89, 64.83, 43.71, 29.66, 25.82, 24.79, 
24.32;  
31P NMR (162 MHz, CDCl3) δ -1.98, -2.04, -2.12;  
19F NMR (376 MHz, CDCl3) δ -80.95 (dt, J = 18.1, 9.7 Hz, 3F), -109.99 (ABq, J = 285 Hz, 1F), 
-113.10 (ABq, J = 285 Hz, 1F), -118.56 (ABq, J = 295Hz, 1F), -120.32 (ABq, J = 295 Hz, 1F), 
-121.36 – -122.36 (m, 6F), -122.82 (s, 2F), -125.61 – -126.65 (m, 2F);  
HRMS calcd for C29H27BrF17O9PNa [M+Na]+: 977.0353, found 977.0358.  
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6-(Benzyl ammonium phosphate)-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (11). 
Compound 10 (35 mg, 0.036 mmol) was dissolved in CH3CN (2 mL) and THF (0.5 mL). NH4HCOO 
(28 mg, 0.44 mmol) was added to the reaction followed by Zn powder (20 mg, 0.30 mmol). The 
mixture was stirred for 2 h at ambient temperature, then filtered via Celite. The solid was washed with 
CH3OH. The filtrates were combined, concentrated, and purified via silica gel column using 
CH2Cl2/CH3OH 5:1 with 1% NH4OH as eluent to afford a white solid. Water was added to the solid 
and the mixture was lyophilized twice to afford the product 11 as a white solid (13 mg, 0.029 mol, 
80%).  
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.01 (m, 9H, ArH, NH4), 5.44 (bs, 1H, H-1), 5.01 (bs, 2H, 
OCH2Ph), 4.48 (bs, 1H, H-3), 4.24 (bs, 1H, H-2), 4.17 – 3.78 (m, 4H, H-4, H-5, H-6a, H-6b), 1.43 (s, 
3H, CH3), 1.35 (s, 3H, CH3), 1.30 – 1.16 (m, 6H, 2x CH3);  
13C NMR (101 MHz, CDCl3) δ 138.18, 128.04, 127.79, 127.11, 109.17, 108.81, 96.03, 70.43, 67.64, 
64.47, 25.82, 24.76, 24.18;  
31P NMR (162 MHz, CDCl3) δ -3.50;  
HRMS calcd for C19H26O9P [M-NH4]-: 429.1320, found 429.1322.  
 
 23
O
PMBO
OBn
BnO
OH
OTMSE
 
2-(Trimethylsilyl)ethyl 2,4-di-O-Benzyl-3-O-p-methoxybenzyl-β-D-galactopyranoside(13). 
2-(Trimethylsilyl)ethyl 2,4-O-dibenzyl 3-O-p-methoxybenzyl-ß-D-galactopyranoside 124141 (210 mg, 
0.36 mmol) was dissolved in 1 M BH3THF (3.62 mL) at 0 °C. Bu2BOTf (1 M in CH2Cl2, 376 µL ) 
was added and the reaction was stirred for 1h. Additional 110 µL  Bu2BOTf (1 M in CH2Cl2) was 
added and the reaction was stirred for other 40 minutes. The reaction was quenched by adding 600 µL  
Et3N. 20 mL CH3OH was added, and the solvents were removed at reduced pressures. The residue 
was purified by silica gel chromatography (hexanes/ethyl acetate 9:1 to 2:1) to afford the product 13 
as a syrup (140 mg, 0.24 mmol, 67%).  
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.26 (m, 12H, ArH), 6.86 (d, J = 8.6 Hz, 2H, ArH), 4.95 (d, J = 
11.7 Hz, 2H, OCH2Ar), 4.77 (d, J = 10.9 Hz, 1H, OCH2Ar), 4.73 (d, J = 11.5 Hz, 1H, OCH2Ar), 4.67 
(d, J = 10.2 Hz, 1H, OCH2Ar), 4.64 (d, J = 11.8 Hz, 1H, OCH2Ar), 4.36 (d, J = 7.7 Hz, 1H, H-1), 
3.99 (dd, J = 17.5, 9.5 Hz, 1H, OCHHCH2TMS), 3.81 (s, 3H, OCH3), 3.79 (t, J = 8.8 Hz, 1H, H-2 ), 
3.78 – 3.74 (m, 1H, H-6a), 3.73 (d, J = 3.1 Hz, 1H, H-4), 3.56 (dd, J = 17.5, 9.5 Hz, 1H, 
OCHHCH2TMS), 3.52 – 3.42 (m, 2H, H-3, H-6b), 3.35 (t, J = 6.1 Hz, 1H, H-5), 1.45 (dd, J = 8.8, 4.1 
Hz, 1H, OH), 1.02 (dd, J = 9.5, 8.0 Hz, 2H, CH2TMS), -0.00 (s, 9H, TMS);  
13C NMR (101 MHz, CDCl3) δ 147.71, 138.78, 133.09, 133.07, 130.42, 129.17, 128.51, 128.29, 
128.15, 127.97, 127.41, 113.70, 103.48, 81.86, 79.67, 75.10, 74.34, 73.99, 72.82, 67.40, 61.70, 55.17, 
30.35, 7.77, -1.49;  
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HRMS calcd for C33H44O7SiNa [M+Na]+:603.2749, found 603.2746.  
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2-(Trimethylsilyl)ethyl 2,4-di-O-Benzyl-6-(Benzyl 2-bromo-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10 
-heptadecafluorodecyl phosphate)-3-O-p-methoxybenzyl-β-D-galactopyranoside (15). Fluorous 
phosphoramidite 7 (111 mg, 0.142 mmol) and 13 (82 mg, 0.142 mmol) was dissolved in 10 mL 
CH2Cl2 at ambient temperature. A 0.45M solution of tetrazole (470 µL , 0.21 mmol) in CH3CN was 
added dropwise and the mixture was stirred for 12 h. A 5-6 M solution of tBuOOH (250 µL ) in 
nonane was then added; the reaction was stirred overnight. The reaction was diluted with CH2Cl2, 
washed with sat NaHCO3 (aq) and dried with anhydrous Na2SO4. Solvents were removed under 
reduced pressure and the mixture was purified using FSPE to afford colorless syrup 15 (130 mg, 
0.102 mmol, 72%).  
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.11 (m, 17H, ArH), 6.86 (d, J = 8.7 Hz, 2H, ArH), 5.07 (ddd, J 
= 9.5, 5.2, 3.3 Hz, 2H, OCH2Ar), 5.00 – 4.89 (m, 2H, OCH2Ar), 4.77 (d, J = 11.0 Hz, 1H, OCH2Ar), 
4.68 (dd, J = 11.2, 3.7 Hz, 2H, OCH2 Ar), 4.62 – 4.55 (m, 1H, OCH2 Ar), 4.51 – 4.36 (m, 2H, CHBr, 
CHHCBr), 4.34 (d, J = 7.7 Hz, 1H, H-1), 4.30 – 4.22 (m, 1H, CHHCBr), 4.21 – 4.14 (m, 1H, H-6a), 
4.11 – 4.03 (m, 1H, H-6b), 3.99 (dd, J = 18.2, 9.5 Hz, 1H, CHHCH2TMS), 3.80 (s, 3H, OCH3), 3.79 
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– 3.77 (m, 1H, H-2), 3.77-3.72 (m, 1H, H-4), 3.56 (d, J = 9.8 Hz, 1H,CHHCH2TMS), 3.49 (dd, J = 
6.8, 2.5 Hz, 1H, H-5), 3.48 – 3.45 (m, 1H, H-3), 1.07 – 0.98 (m, 2H, CH2TMS), 0.11 – -0.15 (m, 9H, 
TMS);  
13C NMR (101 MHz, CDCl3) δ 159.20, 138.80, 138.32, 135.27, 130.44, 129.20, 128.94, 128.91, 
128.72, 128.70, 128.25, 128.23, 128.20, 128.16, 128.08, 127.58, 127.52, 113.77, 103.47, 81.57, 79.42, 
75.17, 74.39, 73.04, 72.89, 72.64, 72.57, 70.09, 70.03, 67.57, 66.44, 64.90, 55.20, 18.46, -1.52, -1.53, 
-1.54;  
31P NMR (162 MHz, CDCl3) δ -1.90, -1.91; 19F NMR (376 MHz, CDCl3) δ -80.73 (t, J = 9.9 Hz, 3F), 
-109.94 (ABq, J = 280 Hz, 1F), -112.89 (ABq, J = 280 Hz, 1F), -118.50 (ABq, J = 295 Hz, 1F), 
-120.24 (ABq, J = 295 Hz, 1F), -121.13 – -122.23 (m, 6F), -122.68 (s, 2F), -126.09 (s, 2F); 
HRMS calcd for C50H53BrF17O10PSiNa [M+Na]+: 1297.1950, found 1297.1956.  
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2-(Trimethylsilyl)ethyl 2,4-di-O-benzyl-6-(benzyl 2-bromo-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10, 10- 
heptadecafluorodecyl phosphate)-β-D-galactopyranoside (16). To a solution of 15 (65 mg, 0.051 
mmol) in CH2Cl2 (5 mL) / H2O (277 µL ) at 0 °C was added 2,3-dichloro-5,6-dicyano-1,4- 
benzoquinone (23 mg, 0.1 mmol). The reaction was allowed to warm to ambient temperature. After 
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stirring for 2.5 h, the reaction was diluted with CH2Cl2, washed with sat NaHCO3 (aq) and dried over 
anhydrous Na2SO4. Solvents were removed under reduced pressure and the mixture was purified 
using FSPE to afford 16 as a syrup (57 mg, 0.049 mmol, 97%).  
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.17 (m, 15H, ArH), 5.08 (ddd, J = 11.1, 5.9, 2.6 Hz, 2H, 
OCH2Ar), 4.98 (d, J = 11.4 Hz, 1H, OCH2Ar), 4.81 (dd, J = 11.6, 4.4 Hz, 1H, OCH2Ar), 4.66 (d, J = 
11.5 Hz, 1H, OCH2Ar), 4.60 (ddd, J = 11.5, 6.1, 1.5 Hz, 1H, OCH2Ar), 4.47 – 4.35 (m, 2H, CHHCBr, 
CHBr), 4.32 (d, J = 7.2Hz, 1H, H-1), 4.30 – 4.24 (m, 1H, CHHCBr), 4.22 – 4.15 (m, 1H, H-6a), 4.12 
– 4.03 (m, 1H, H-6b), 3.97 (dd, J = 17.1, 9.2 Hz, 1H, CHHCH2TMS), 3.77-3.70 (m, 1H, H-4), 3.65 – 
3.48 (m, 4H, CHHCH2TMS, H-3, H-2, H-5), 2.26 (s, 1H, OH), 1.07 – 0.93 (m, 2H, CH2TMS), 0.06 – 
-0.08 (m, 9H, TMS);  
13C NMR (101 MHz, CDCl3) δ 138.42, 138.17, 135.23, 135.17, 128.94, 128.79, 128.71, 128.65, 
128.50, 128.42, 128.29, 128.21, 128.21, 128.17, 128.11, 128.06, 128.02, 127.95, 127.85, 127.67, 
127.56, 126.74, 103.20, 79.15, 74.89, 74.88, 74.58, 74.54, 74.00, 73.98, 72.75, 72.67, 70.11, 70.05, 
67.47, 66.15, 66.10, 64.90, 43.55, 43.47, 29.68, 26.47, 26.09, 18.45, -1.51, -1.52, -1.53;  
31P NMR (162 MHz, CDCl3) δ -1.81, -1.84, -1.86;  
19F NMR (376 MHz, CDCl3) δ -80.73 (t, J = 9.9 Hz, 3F), -109.92 (ABq, J = 285 Hz, 1F), -112.90 
(ABq, J = 285 Hz, 1F), -118.50 (ABq, J = 295 Hz, 1F), -120.24 (ABq, J = 295 Hz, 1F), -121.41 – 
-121.99 (m, 6F), -122.68 (s, 2F), -125.96 – -126.41 (m, 2F);  
HRMS calcd for C42H45BrF17O9PSiNa [M+Na]+:1177.1375, found 1177.1387.  
 
 27
O
OBn
BnO
OTMSE
P
O
OBn
C8F17 Br
O
O
O
BnO
OAc
BnO
O
BnO
 
2-Acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-2-(trimethylsilyl)ethyl 2,4-di-O- 
benzyl-6- (benzyl 2-bromo-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10- heptadecafluorodecyl 
phosphate)-β-D-galactopyranoside (18). To a solution of acceptor 16 (25 mg, 0.022 mmol) in 
CH2Cl2 (5 mL) at 0 °C was added TMSOTf (0.42 µL , 0.0024 mmol). Donor 17 (42 mg, 0.066 mmol) 
in CH2Cl2 (5 mL) was added to the reaction dropwise. The reaction was stirred for 1 h and quenched 
by Et3N. The mixture was concentrated, purified using FSPE to afford product 18 as a syrup (33 mg, 
0.020 mmol, 94%).  
1H NMR (400 MHz, CDCl3) δ 7.53 – 6.86 (m, 30H, ArH), 5.22 – 5.17 (m, 1H, H-2’), 5.15 – 5.01 (m, 
3H, H-1’, OCH2Ph), 4.97 – 4.76 (m, 4H, OCH2Ph), 4.68 – 4.45 (m, 6H, OCH2Ph), 4.46-4.39 (m, 2H, 
CHCBr, CHBr), 4.28 (d, J = 9.4 Hz, 1H, H-1), 4.25 – 4.21 (m, 1H, CHCBr), 4.21 – 4.17 (m, 1H, 
H-6a), 4.14 (d, J = 12.9 Hz, 1H, H-4’), 4.11 – 4.05 (m, 1H, H-6b), 4.03 – 3.93 (m, 3H, H-3’, H-5’, 
CHHCH2TMS ), 3.84-3.78 (m, 1H, H-4), 3.77 – 3.73 (m, 1H, H-3), 3.68 (d, J = 7.7 Hz, 1H, H-2), 
3.61-3.52(m,2H, H-6a’, CHHCH2TMS), 3.53 – 3.44 (m, 2H, H-5, H-6b’), δ 2.18 – 2.13 (m, 3H, OAc), 
1.07 – 0.96 (m, 2H, CH2TMS), -0.00 (s, 9H, TMS);  
13C NMR (101 MHz, CDCl3) δ 172.27, 140.29, 139.83, 139.76, 139.35, 139.31, 136.76, 136.70, 
130.52, 130.48, 130.25, 130.19, 129.91, 129.82, 129.79, 129.78, 129.69, 129.65, 129.55, 129.33, 
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129.31, 129.23, 129.14, 129.05, 129.01, 128.95, 105.05, 95.36, 79.11, 78.72, 77.63, 76.85, 76.64, 
76.47, 75.74, 74.94, 74.46, 73.80, 73.72, 73.31, 72.99, 72.43, 71.66, 71.60, 70.61, 69.96, 69.27, 67.36, 
66.43, 45.11, 31.22, 22.63, 22.61, 20.11, -0.01;  
31P NMR (162 MHz, CDCl3) δ -1.75, -1.80, -1.84;  
19F NMR (376 MHz, CDCl3) δ -80.72 (t, J = 10.0 Hz, 3F), -109.95 (ABq, J = 280Hz, 1F), -112.87 
(ABq, J = 280Hz, 1F), -118.50 (ABq, J = 290Hz, 1F), -120.19 (ABq, J = 287Hz, 1F), -121.36 – 
-122.03 (m, 6F), -122.68 (t, J = 17.2 Hz, 2F), -126.08 (t, J = 15.2 Hz, 2F);  
HRMS calcd for C71H76BrF17O15PSi [M+H]+: 1629.3598, found 1629.3594.  
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2-Acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-2-(trimethylsilyl)ethyl 2,4-di-O- 
benzyl-6-(benzyl ammonium phosphate)-β-D-galactopyranoside (19). 18 (33 mg, 0.021 mmol) 
was dissolved in CH3CN (2 mL) and THF (0.5 mL). NH4HCOO (28 mg, 0.44 mmol) was added to 
the reaction followed by Zn powder (20 mg, 0.30 mmol). The mixture was stirred for 2 h at ambient 
temperature, and then filtered via celite. The solid was washed with CH3OH. The filtrates were 
combined, concentrated, and purified via silica gel column using CH2Cl2/CH3OH (5:1) with 1% 
NH4OH as eluent to afford a white solid. Water was added to the solid and the mixture was 
lyophilized three times to afford the product 19 as a white solid (17 mg, 0.015 mol, 75%).  
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1H NMR (400 MHz, CDCl3) δ 7.48 – 6.69 (m, 34H, ArH, NH4), 5.19 (s, 1H, H-2’), 5.10 (s, 1H, H-1’), 
4.94 (d, J = 7.2 Hz, 2H, OCH2Ph), 4.89 (d, J = 11.6 Hz, 1H, OCH2Ph), 4.79 (d, J = 10.7 Hz, 2H, 
OCH2Ph), 4.73 – 4.65 (m, 1H, OCH2Ph), 4.57 (d, J = 11.8 Hz, 2H, OCH2Ph), 4.49 (dd, J = 19.3, 10.3 
Hz, 2H, OCH2Ph), 4.28 (d, J = 11.9 Hz, 2H, OCH2Ph), 4.17 – 4.05 (m, 2H, H-4’, H-6a), 4.04 – 3.86 
(m, 5H, H-6b, H-3’, H-5’, H-4, CHHCH2TMS), 3.77 – 3.62 (m, 2H, H-3, H-2), 3.61 – 3.42 (m, 3H, 
H-6a’, H-6’, H-5), 2.12 (s, 3H, OAc), 1.06 – 0.91 (m, 2H, CH2TMS), 0.13 – -0.07 (m, 9H, TMS);  
13C NMR (101 MHz, CDCl3) δ 172.18, 140.23, 140.06, 139.66, 139.40, 139.25, 130.35, 129.85, 
129.80, 129.75, 129.64, 129.58, 129.47, 129.30, 129.21, 128.96, 128.90, 128.85, 128.77, 104.93, 
95.27, 79.10, 78.65, 77.77, 76.67, 76.48, 76.41, 75.67, 74.31, 73.32, 73.10, 72.23, 70.41, 69.83, 69.23, 
31.14, 22.55, 20.04, -0.01;  
31P NMR (162 MHz, CDCl3) δ -1.01.  
HRMS calcd for C61H72O15P [M-NH4]-: 1103.4384, found 1103.4392. 
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CHAPTER 3 
Synthesis of a Series of Maltotriose Phosphates and Evaluation of the Utility of a Fluorous 
Phosphate Protecting Group 
 
Abstract 
A series of methyl maltotrioside phosphates were synthesized for application in the determination of 
the actual molecular substrate of the Lafora enzyme involved in Lafora disease. Several different 
synthetic routes were applied for the successful synthesis of six methyl maltotrioside phosphate 
regioisomers. The utility of a new fluorous phosphate protecting group was evaluated, but found not 
to be practical in this particular late stage introduction.  
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Introduction 
 
α-Glucans, including starch and glycogen, are important molecules in biological systems functioning 
as energy storage.1 A series of specific enzymes are involved in the synthesis of starch and glycogens 
and determine their structures and properties.2 Lafora disease,3 or Lafora progressive myoclonic 
epilepsy, is a fatal disease with no cure or treatment today.4 Hyperphosphorylation of glycogen is the 
cause of Lafora disease and it is related to mutations in the genes that code for the protein laforin.5 In 
the synthesis of glycogen, phosphates are added to the 2- or 3-position hydroxyls of glucose at a rate 
of one phosphate in ca. 10000 glucose residues.6,7 Laforin would remove those phosphates groups 
subsequently under normal circumstances.8,9  With the mutated laforin, this dephosphorylation 
cannot be performed and eventually leads to Lafora disease.10,11 However, the actual molecular 
mechanism of the laforin enzyme is still unknown. A detailed understanding of enzyme function 
requires the synthesis of molecules with well-defined chemical structures as substrates. To study the 
dephosphorylation of laforin, a series of maltotriose analogs with phosphate groups at one of either 
the 2- or 3-position hydroxyl was designed and synthesized as substrates for the dephosphorylation 
enzyme. (Figure 1) 
 
Although the synthesis of α-glucans has been extensively studied and reviewed,12 the synthesis of 
maltose analogs with phosphate at the 2-or 3-hydroxyl of a sugar ring remains relatively understudied. 
The desired 1,4-α-glycosidic linkage generally requires non-participating protecting groups at the 
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2-position of the donor, which would be need to be cleaved selectively later to install the phosphate at 
the 2-position. The temporary protecting group at the 3-position should also be chosen carefully, since 
the protecting group could also effect the glycosylation reaction itself.    
 
Figure 1 Six methyl maltotrioside phosphates as substrates for the laforin protein. 
 
In thinking about an efficient strategy to form all six desired regioisomers, we considered the possible 
use of our recently developed fluorous protecting group for phosphate groups.13 This group can easily 
be added to a phosphate and then be used as a tag to separate the sugar chain from other reagents 
using fluorous solid-phase extraction (FSPE).14,15 In our previous work, this approach was used for 
the synthesis of a disaccharide form Leishmania and had to advantage of easy purification and could 
be deprotected under mild conditions. However, in the current case, it was unclear whether 
introduction of the group so close to the anomeric center might negatively affect the glycosylation 
and whether a relatively late stage introduction of the fluorous group would actually facilitate the 
synthesis of the various methyl maltotrioside phosphate regioisomers. In many cases of the synthesis 
of a phosphate bearing compound, the phosphate group is installed in the last few steps.16 We 
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reasoned that if the purification of the non-fluorous phosphate group-bearing compound created a 
problem, it might be useful to perform a late stage fluorous phosphate installation; otherwise it might 
not be very practical to carry out a late stage installation. Opposed to late stage installation, the other 
possibilty is to perform an early stage installation of the fluorous phosphate group and carry the 
fluorous group throughout the synthesis. In this way, the fluorous group functions as a tag. In the 
previous cases of fluorous tag assisted synthesis, most tags were attached at the anomeric position of 
the reducing end of the oligosaccharide, so the tag is away from the reaction center. In the synthesis 
of maltose phosphates, the fluorous phosphate group would be closer to the reaction site inevitably. In 
the massive amount of fluorous literatures, few reports discuss the effect of fluorous tags on the 
reactions. Our concern is although fluorous groups could be used as a convenient way of purification, 
if the stereoselectivity is not ideal in the synthesis of the α-glycosidic linkage, it would be difficult to 
separate the α/β mixture, thus diminishing the usefulness of the fluorous assisted synthesis. Van der 
Marel reported another fluorous phosphate protecting group earlier this year to be used in the 
synthesis of carbohydrates.17 The reaction utilized in their study did not involve the glycosidic bond 
formation, so the fluorous tag proved to be very efficient in their synthesis. Herein we probe how the 
fluorous tag would perform in a situation when the selectivity of the reaction might not be ideal. 
 
Results and discussion 
 
The desired six methyl maltotrioside phosphates could be broken into three categories depending on 
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the position of the phosphate group: phosphates at the reducing end, phosphates at the non-reducing 
end, and phosphates in the middle saccharides.  
 
We started the synthesis of the analogs with phosphates at the reducing end. In this case, the 
temporary protecting group for future installation of phosphates only exists in the acceptor, 
simplifying the glycosylation reaction. Commercially available α-methyl glucoside 1 was used as 
starting material for the acceptor. We proposed by using a p-methoxybenzyl (PMB) group as the 
temporary protecting group, the synthesis could be simplified. After benzylidene formation, 
phase-transfer-catalyzed benzylation using sodium hydroxide as a base yielded an easily separable 
mixture of alcohols 2 and 3.18 PMB was installed to give the two proper protected monosaccharides 4 
and 5, (Scheme 1) which were synthesized by known routes.19,20 
 
Scheme 1 The synthesis of PMB protected reducing end of methyl maltotriose and the benzylidene 
opening reaction.  
 
Unfortunately, problems were encountered in selective opening of the benzylidene acetal in the 
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presence of the PMB group. Various conditions were studied using 5 as a model compound (Scheme 
1). TfOH/Et3SiH21 and NaBH3CN/HCl22 gave a low yield of the desired 4-hydroxyl compound 7 and 
lead to extensive decomposition, which was presumably related to the acid lability of PMB groups.23 
A milder condition using DIBALH in CH2Cl224 gave the desired product in modest yield. However, it 
was found that if the PMB is at the 3-postion, extended reaction times would lead to PMB cleavage 
and afford diol 8.  
 
To circumvent this problem, we attempted to use benzoyl groups instead of acid-labile PMB groups 
as the temporary protecting group at the reducing end of maltotriose. Alocohol 3 was reacted with 
benzoyl chloride and pyridine followed by benzylidene opening using NaBH3CN/HCl22 to provide an 
excellent yield of the desired alcohol 11 which was synthesized via other routes before 25 (Scheme 2).  
 
The maltose donor 9 and 10 were synthesized via a modified known procedure starting from maltose. 
One pot acetylation and bromination of maltose afforded the maltose bromide, which was converted 
to a thioglycoside under phase-transfer conditions.26 Deacetylation, followed by benzylidene 
formation and benzylation yielded the previously reported fully protected maltose thioglycoside 
donor.27 
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Scheme 2. Synthesis of the 3-phosphate methyl maltotrioside via a benzoyl-protected acceptor 
 
The glycosylation reaction was performed using the thioglycoside donor 9 first (Scheme 2). In the 
presence of NIS and TMSOTf at 0 °C in ether/dichloromethane (1:1), the reaction proceeded well to 
give a mixture of α/β glycosides in the ratio of 2:3, and the alpha glycoside was separated in a 22% 
yield. To try to improve the stereoselectivity of this glycosylation reaction, we carried out the 
glycosylation of benzoylated acceptors with maltose imidate donors 10 in light of Motawia’s work on 
the ‘blockwise three-stage glycosylation strategy’28 by converting the thiophenyl group to a 
trichloroacetimidate using standard chemistry.29 In a mixture of ether/dichloromethane, the 
glycosylation between the imidate donor and the acceptor gave the desired α product 12 in 53% yield 
with no β anomer detected.  
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To remove the benzoyl group in 12 at the 3-position, various conditions were tested. Routine 
conditions including using NaOCH3 in methanol or using NaOH or in water/THF could only remove 
the benzoyl group slowly, probably due to steric hindrance. It was found that using cesium hydroxide 
and sodium hydroxide together could speed up the reaction greatly and give a better result for the 
deprotection of the benzoyl ester, possibly due to the cesium effect.26 Proton NMR was used to 
determine when the deprotection reaction had finished. The doublet peak from the benzoyl group 
moves slightly down field, indicating the formation of benzoic acid. We envisioned that if there 
would be any problem in the purification of trisaccharide 14, the fluorous phosphate protecting group 
would be beneficial. After the deprotection, a phosphate group was installed using phosphoramidite 
chemistry30 to yield 14, followed by hydrogenolysis to provide the desired phosphate 15. No 
problems were encountered in the purification of 14—a finding that eliminates the need for installing 
a fluorous phosphate group at this late stage. 
 
If late stage installation of the fluorous phosphate group is not worthwhile, how about performing an 
early stage installation? Van der Marel reported the synthesis of teichoic acids using a fluorous 
phosphate group.17 In their synthesis, the fluorous protecting group is far away from the reaction 
center, and no glycosylation was involved in the synthesis. As a fluorous protecting group instead of a 
tag, it would be closer to the reaction site inevitably. The size of the fluorous protecting group and the 
change of the molecule polarity due to the attachment of the fluorous portion might influence the 
reaction and the following separation in a reaction that might give a mixture of products like 
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glycosylation reactions. Not many reports focus on the situations when the reaction would lead to a 
mixture. If the fluorous protecting group-modified product was inseparable, a fluorous assisted 
synthesis would not be efficient or practical.  
 
 
Scheme 3. Early stage introduction of the fluorous phosphate protecting group.  
 
We decided to use alcohol 3 as a model compound to test the early stage installation of the fluorous 
phosphate protecting group. Compound 3 was coupled with fluorous phosphoramidate followed by 
selective benzylidene opening to provide glycosyl acceptor 21. However, the glycosylation between 
21 and the perbenzylated donor gave an inseparable α/β mixture in low yield. In our synthesis of 
Leishmania saccharide, we also witnessed a phenomenon with change of stereochemical outcomes. 
These results showed that even though fluorous protecting groups and tags could provide a 
convenient way of purification, it could lead to subtle changes in the reaction and might render its 
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usage not practical (Scheme 3). 
 
Since using benzoyl as a temporary protecting group worked well, and the early stage installation of 
the fluorous phosphate group leads to a mixture, we wanted to further examine the possibility of using 
phosphorylated acceptors directly. In this way, the protection/deprotection could be omitted by using 
phosphate directly as the protecting group. The free hydroxyl in compounds 2 or 3 was directly 
protected as dibenzyl phosphates to give 16 or 17. The benzylidene was opened smoothly to give the 
phosphorylated acceptor 18 or 19. The glycosylation reaction between donor 10 and 18 or 19 in ether 
at -20 °C gave a separable α/β mixture of the methyl maltotriose phosphate in the ratio of 3:1. 
Hydrogenolysis of 18 or 19 gave 22 or 23 respectively (Scheme 4). 
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Scheme 4. Synthesis of methyl maltotrioside phosphates using phosphorylated acceptors.  
 
Encouraged by these results, we moved to synthesize the maltotriose with a phosphate at the 
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non-reducing end. To prepare the maltose acceptor, the thiophenyl group on the maltose donor 9 was 
converted to an α-methoxy group by reacting with methanol in the presence of 
N-chlorosuccinimide.27,31 It was found that the formation of methyl glycoside 24 required the 
presence of molecular sieves, otherwise large amounts of side product, presumably NHS-substituted 
maltoside, would be formed. We also found out that using freshly recrystallized NCS would slow the 
reaction down; the un-recrystallized NCS gave much better results. Selective opening of the 
benzylidene group using TfOH/Et3SiH afforded the acceptor 25 with a free hydroxyl group at the 
4-position (Scheme 5). 
 
 
Scheme 5. Preparation of the methyl maltoside acceptor. 
 
To obtain the desired α-linkage, a PMB-substituted donor were used. The PMB-protected glucose 
donor was synthesized from the 4,6-O-benzylidene-protected thioglycoside 26. Tin-mediated 
selective benzylation afforded 3-OBn substituted product 27 or the 3-PMB substituted product 28.32 
Then the 2-position was protected using PMB or Bn groups respectively to give the donors 29 or 30 
in the desired protecting group pattern (Scheme 6).   
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Scheme 6. Synthesis of the glucose donor. 
  
Glycosylation using the thioglycoside donor 29 and maltose acceptor 25 was studied under different 
conditions. Tf2O/PhS2O/TTBP at -78 °C failed to give the desired glycosylation product 31, and using 
NIS/TfOH as the promoter at -45 °C led to an inseparable mixture of α/β products in the ratio of 2:1. 
Changing the donor from thioglycoside to imidate did not improve the stereoselectivity of the 
glycosylation reaction at all. Fortunately the mixture became separable after the cleavage of the PMB 
group. It was found that the deprotection of PMB on 31 using CAN gave a much cleaner reaction than 
using DDQ; however, if the reaction using CAN took too long, the acidic conditions could cleave the 
benzylidene. The desired α product 33 was phosphorylated to give 35, and hydrogenolysis gave the 
final product 37. Compound 38 was synthesized via the same route (Scheme 7). 
 
For the maltotriose with phosphates on the middle saccharide, we surveyed the methods that could 
potentially lead to selective protection and differentiation of hydroxyls on maltose, in the hope of 
finding an easier way of installing the phosphates. However, the selective protection of hydroxyls on 
disaccharides is far from developed, so we decided to synthesize the desired maltotriose via two 
glycosylation reactions.   
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Scheme 7. Synthesis of methyl maltotrioside 2’’ and 3’’-phosphates. 
 
The glycosylation between the donor 29 with a PMB group at the 2-position and acceptor 39 gave an 
inseparable mixture of α/β stereoisomers in the ratio of 3:1. As in the case of the previous 
trisaccharide, the mixture became separable after PMB cleavage. The free hydroxyl in 42 was 
phosphorylated to give 44, followed by selective benzylidene acetal opening to give the disaccharide 
acceptor 46. The glycosylation between 46 and donor 48 in ether gave the desired methyl 
maltotrioside 2’-phosphate 49, followed by hydrogenolysis to give 51. The methyl maltotrioside 
3’-phosphate 52 was synthesized in a similar straightforward fashion to successfully provide the last 
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of the desired phosphate regioisomers (Scheme 8.) 
 
We have reported the first fluorous phosphate protecting group previously13 and would like to 
evaluate if this fluorous protecting group could be used in the synthesis of maltose phosphate isomers 
to facilitate the synthesis. In the studies of Leishmina carbohydrates, we have reported the synthesis 
of a phosphorylated disaccharide utilizing our fluorous phosphate protecting group. When we were 
trying to expand the study, an interesting result caught our attention. In the glycosylation coupling 
between the donor and a per-acetylated galactose donor, a mixture of α/β isomers was formed instead 
of the desired β product, which was not readily separable from the mixture. Interestingly, most of the 
previously reported fluorous assisted synthesis focused on fairly straightforward reactions, so the 
formation of a mixture with a fluorous tag is minimized. For example. in our automated 
solution-phase synthesis of oligosaccharides,33,34 the fluorous tag is attached at the anomeric position 
of the reducing end, so the tag remains far away from the reaction site.  
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Scheme 8 Synthesis of methyl maltotrioside 2’ and 3’ phosphate 
 
 
Conclusion 
A series of methyl maltotrioside phosphate regioisomers were synthesized via a modular synthesis. 
The formation of an α-glucosidic bond is still a significant challenge, as shown in the synthesis of 
maltotriose. Different protecting groups and glycosylations could all alter the outcome of the 
glycosylations. Although fluorous tags and protecting groups can provide a convenient method of 
purification, this work demonstrates that the tag can introduce some subtle changes in reactions at 
nearby sites and provide little advantage when introduced at a late stage of a synthesis. Future studies 
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will use these new methyl maltotrioside phosphate isomers to probe the activity of the Laforin 
enzyme and thereby determine the most likely in vivo substrate for this enzyme. 
 
Experiment section 
 
General Experimental Methods: Reactions were performed using flame-dried glassware under 
argon using anhydrous solvents unless otherwise noted. Thin layer chromatography (TLC) was 
performed using glass-backed silica gel plates w/UV254. Visualization of TLC plates was performed 
by UV light and 5% sulfuric acid/ethanol. NMR spectra were recorded on a 400 MHz for 1H (101 
MHz for 13C, 162 MHz for 31P) spectrometer or on a 600 MHz for 1H (150 MHz for 13C, 243 MHz for 
31P ). 1H NMR and 13C NMR taken in CDCl3 spectra were referenced to the solvent peak at 7.260 
ppm (1H) and 77.0 ppm (13C). 31P NMR was not referenced. High resolution mass spectra (HRMS, 
ESI mode) were obtained using a Q-TOF LC/MS.  
 
General Procedure for Selective Benzylidene Opening Reaction: The substrate (1 eq) was 
dissolved in CH2Cl2 (0.1 M), and ASW-3000 (powder, 100mg/mol) was added. The reaction was 
cooled to -78 °C, and Et3SiH (3 eq) was added followed by TfOH (1.5 eq). The reaction was stirred at 
-78 °C until TLC indicated the conversion had finished. Methanol and Et3N were added, and the 
reaction was filtered, concentrated, and subject to SGC for purification.  
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General Procedure for Thioglycoside Removal: The substrate (1 eq) was dissolved in 
Acetone/water (9:1, 0.1 M). NBS (2 eq) was added and the reaction was stirred until TLC indicated 
the conversion had finished. The reaction was quenched with adding solid NaHCO3, concentrated, 
diluted with EtOAc, washed with Na2S2O3, NaHCO3, brine, dried and concentrated. The crude 
mixture was purified via SGC.  
 
General Procedure for PMB Removal: The substrate (1 eq) was dissolved in CH3CN/H2O (9:1 0.05 
M), and CAN (4 eq) was added. The reaction was stirred at r.t. until TLC indicated the conversion had 
finished. The reaction was diluted with EtOAc, washed with water, NaHCO3 (aq), dried, concentrated 
and purified via SGC.  
 
General Procedure for Glycosylation Using Thioglycoside donor: The acceptor (1 eq) and donor 
(1.5 eq) was co-evaporated with toluene for 3 times and dissolved in Et2O/CH2Cl2 (3:1, 0.05 M). 
ASW-3000 (powder, 100 mg/mmol) was added, and the reaction was cooled to -78 °C. NIS (1.8 eq) 
was added, and the reaction was stirred at -78 °C for 20 min then warmed up to -45 C. TfOH(1.8 eq) 
was added and the reaction was stirred at -45 °C until TLC indicated the conversion had finished. The 
reaction was quenched by adding Et3N, concentrated, and purified via SGC.  
 
General Procedure for Trichloroacetimidate Formation: The substrate (1 eq) was dissolved in 
CH2Cl2 (0.1 M), Cs2CO3 (0.5 eq) was added, followed by CCl3CN (3 eq). The reaction was stirred at 
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r.t. until TLC indicated the conversion had finished. The reaction was filtered through Celite, and 
concentrated to give the crude imidate.  
 
General Procedure for Glycosylation Using Trichloroacetimidate Donor: The acceptor (1 eq) and 
donor (1.5 eq) was co-evaporated with toluene for 3 times and dissolved in Et2O (0.05 M). The 
reaction was cooled to -20 °C, and TMSOTf (0.1 eq, 0.0268 M in CH2Cl2) was added and the reaction 
was stirred at -20 °C until TLC indicated the conversion had finished. The reaction was quenched by 
adding Et3N, concentrated, and purified via SGC.  
 
General Procedure for Phosphorylation: The substrate (1 eq) was dissolved in CH2Cl2 (0.1 M). 
Dibenzyl N,N-di isopropylphosphoramidite (2 eq) was added followed by 1-H tetrazole (3 eq, 0.45M 
in CH3CN). The reaction was stirred at r.t. until TLC indicated the conversion had finished. t-BuOOH 
(5 eq, 5 – 6 M in decane) was added, and the reaction was stirred for 1 h. The mixture was 
concentrated, and purified via SGC. 
 
General Procedure for Global Deprotection: The substrate was dissolved in EtOH, and Pd/C was 
added. The reaction was stirred under 800 psi of H2 for 8 hour, filtered, and concentrated to give the 
product.  
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Methyl 2, 6 di- O-benzyl-3- O-(4-methoxybenzyl)- D-glucopyranoside (7) 5 (101 mg, 0.203 mmol) 
was dissolved in CH2Cl2 (2 mL) at 0 C. DIBAL-H in CH2Cl2 (0.608 mmol) was added, and the 
reaction was stirred for 8 hours. The reaction was purified via SGC (hexanes/EtOAc 2:1) to give 7 
(26 mg, 0.053 mmol, 20%).  
1H NMR (400 MHz, CDCl3) δ 8.22 – 7.91 (m, 14H), 7.72 – 7.51 (m, 2H), 5.69 (d, J = 11.11 Hz, 1H), 
5.54 (d, J = 12.11 Hz, 1H), 5.46 – 5.36 (m, 3H), 5.36 – 5.24 (m, 2H), 4.56 (s, 3H), 4.53 – 4.45 (m, 
1H), 4.43 (q, J = 1.31, 2.06 Hz, 2H), 4.38 – 4.21 (m, 2H), 4.14 (d, J = 2.67 Hz, 3H), 3.07 (d, J = 2.36 
Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 159.33, 138.08, 138.01, 130.91, 129.67, 128.58, 128.46, 128.33, 
128.30, 128.15, 128.10, 127.93, 127.59, 126.32, 114.00, 113.93, 98.19, 81.09, 79.59, 79.57, 75.04, 
73.55, 73.15, 70.60, 69.92, 69.44, 55.26, 55.23. 
HRMS(ESI): calcd for C29H34O7Na [M+Na]+:517.2197, found 517.2194 
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Trichloroacetimido 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl -(1→4)- 2,3,6-tri-O 
-benzyl-D- glucopyranoside (10) Compound 9 (500mg, 0.513mmol) was subjected to the conditions 
in the general method for thiolphenol removal to give the hemiacetal (320mg, 0.367mmol). The 
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hemiacetal was treated with CCl3CN and Cs2CO3 as described in the general procedure for 
trichloroacetimidate formation to give a yellow foam (350 mg, 0.34 mmol, 67% for two steps) and 
used without further purification.  
 
 
Methyl  2,3-di-O-benzyl--4,6-O-benzylidene-α-D-glucopyranosyl-(1→4)- 2,3,6-tri-O- benzyl-α-D 
-glucopyranosyl-(1→4)-2,6-di-O-benzyl-3-benzoyl-α- D-glucopyranoside (12) Donor 9 (98 mg, 
0.98 mmol) and acceptor 11 (28 mg, 0.058 mmol) was glycosylated using the general glycosylation 
method for thioglycoside and purified via SGC (hexanes/EtOAc 3:1) to give 12 (35 mg, 0.026 mmol, 
45%).  
1H NMR (400 MHz, CDCl3) δ 8.09 – 7.94 (m, 2H), 7.54 – 7.00 (m, 43H), 5.88 (t, J = 9.58 Hz, 1H), 
5.73 (d, J = 3.87 Hz, 1H), 5.53 (s, 1H), 4.92 (d, J = 3.24 Hz, 1H), 4.87 (d, J = 11.20 Hz, 1H), 4.81 – 
4.75 (m, 2H), 4.75 – 4.63 (m, 2H), 4.63 – 4.53 (m, 6H), 4.49 (d, J = 11.79 Hz, 1H), 4.42 (dd, J = 5.65, 
12.06 Hz, 2H), 4.19 (d, J = 12.25 Hz, 1H), 4.16 – 4.05 (m, 3H), 4.05 – 3.90 (m, 5H), 3.91 – 3.76 (m, 
3H), 3.71 (dd, J = 3.54, 9.98 Hz, 2H), 3.67 – 3.55 (m, 3H), 3.55 – 3.46 (m, 2H), 3.43 (s, 3H), 3.28 (h, 
J = 5.07 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 165.50, 138.91, 138.70, 138.14, 137.94, 137.87, 137.86, 137.71, 
137.58, 132.69, 130.69, 129.83, 128.81, 128.38, 128.35, 128.31, 128.27, 128.24, 128.23, 128.20, 
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128.16, 128.15, 128.14, 127.98, 127.96, 127.85, 127.80, 127.79, 127.67, 127.61, 127.59, 127.52, 
127.42, 127.38, 126.97, 126.53, 126.05, 101.12, 97.81, 97.69, 96.92, 82.18, 81.26, 79.71, 78.90, 
78.67, 76.89, 75.51, 75.23, 73.79, 73.53, 73.44, 73.29, 73.23, 72.77, 72.41, 71.25, 70.55, 69.86, 68.71, 
63.20, 55.29. 
HRMS (ESI) calcd for C82H84O17Na [M+Na]+:1363.5601, found 1363.5561 
 
 
Methyl  2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4)- 2,3,6-tri-O- benzyl-α- 
D-glucopyranosyl-(1→4) -2,6-tri-O-benzyl-α-D-glucopyranoside (13) Compound 12 (23 mg, 
0.017 mmol) was dissolved in CH3OH (3 mL). CsOH-H2O (50 mg) was added, followed by Na (23 
mg). The reaction was stirred for 16 h, concentrated, extracted with EtOAc, and purified with SGC 
(hexanes/EtOAc 3:1) to give 13 (15 mg, 0.012 mmol, 71%).  
1H NMR (400 MHz, CDCl3) δ 7.61 – 7.04 (m, 40H), 5.69 (d, J = 3.83 Hz, 1H), 5.55 (s, 1H), 5.00 – 
4.79 (m, 5H), 4.79 – 4.66 (m, 4H), 4.66 – 4.52 (m, 5H), 4.51 – 4.41 (m, 2H), 4.35 (d, J = 11.79 Hz, 
1H), 4.15 (dq, J = 5.23, 5.88, 10.96 Hz, 2H), 4.12 – 4.03 (m, 2H), 4.00 (t, J = 9.28 Hz, 2H), 3.83 (td, 
J = 4.50, 9.79 Hz, 1H), 3.78 – 3.42 (m, 10H), 3.37 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 138.62, 138.58, 138.15, 137.88, 137.74, 137.56, 136.80, 128.88, 
128.83, 128.56, 128.43, 128.38, 128.36, 128.32, 128.30, 128.21, 128.18, 128.00, 127.93, 127.81, 
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127.77, 127.74, 127.70, 127.62, 127.58, 127.54, 127.23, 126.50, 126.05, 101.19, 100.39, 98.36, 97.62, 
82.34, 82.14, 82.07, 80.28, 78.74, 78.70, 78.02, 77.26, 75.28, 74.31, 74.26, 74.02, 73.40, 73.35, 73.15, 
71.90, 70.77, 68.96, 68.77, 68.58, 63.40, 55.23, 29.73, 29.69, 22.73, 14.17. 
HRMS (ESI) calcd for C75H80O16Na [M+Na]+:1259.5339, found 1559.5326 
 
 
Methyl  2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl- (1→4)- 2,3,6-tri-O- benzyl-α- 
D-glucopyranosyl-(1→4) -2,6-di-O-benzyl-3-dibenzylphosphate- α-D- glucopyranoside (14) 
Compound 13(15 mg, 0.012 mmol) was subjected to the general procedure for phosphorylation 
described above and purified via SGC (hexanes/EtOAc 3:2) to give 14 (9.3 mg, 0.006 mmol, 52%).  
1H NMR (400 MHz, CDCl3) δ 7.59 – 6.97 (m, 50H), 5.86 (d, J = 3.45 Hz, 1H), 5.76 (d, J = 3.89 Hz, 
1H), 5.53 (s, 1H), 5.05 – 4.76 (m, 9H), 4.70 (s, 2H), 4.63 (td, J = 7.03, 11.35 Hz, 4H), 4.58 – 4.47 (m, 
5H), 4.43 (d, J = 12.19 Hz, 2H), 4.24 (t, J = 9.54 Hz, 2H), 4.17 (t, J = 9.07 Hz, 1H), 4.10 (dd, J = 4.68, 
10.17 Hz, 1H), 4.01 (t, J = 8.84 Hz, 1H), 3.93 (t, J = 9.27 Hz, 1H), 3.90 – 3.74 (m, 4H), 3.72 – 3.56 
(m, 5H), 3.50 (ddt, J = 3.28, 6.35, 10.07 Hz, 3H), 3.28 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 138.83, 138.66, 138.33, 138.21, 137.76, 137.64, 137.52, 135.98, 
128.79, 128.55, 128.51, 128.48, 128.44, 128.38, 128.34, 128.30, 128.26, 128.23, 128.20, 128.18, 
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128.16, 128.13, 128.09, 128.03, 127.90, 127.76, 127.73, 127.64, 127.56, 127.49, 127.47, 127.45, 
127.40, 127.36, 127.29, 127.09, 126.97, 126.73, 126.06, 101.11, 97.44, 96.80, 93.79, 82.25, 81.88, 
81.80, 81.31, 79.81, 79.12, 78.69, 78.65, 75.02, 73.82, 73.52, 73.29, 73.02, 72.34, 71.14, 70.40, 69.85, 
69.82, 69.76, 69.28, 69.23, 68.93, 68.77, 68.71, 68.10, 65.37, 63.14, 55.11, 29.70. 
31P NMR (162 MHz, CDCl3) δ -2.96. 
HRMS (ESI) calcd for C89H93O19PNa [M+Na]+:1519.5914, found 1519.5949 
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Methyl  α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)- 3-phosphate-α-D- glucopyra 
noside (15) Hydrogenolysis of 14 (12 mg, 0.007 mmol) according to the general method for global 
deprotection gave 15 (3 mg, 0.005 mmol, 71%) 
1H NMR (400 MHz, CD3OD) δ 5.44 (d, J = 3.4 Hz, 1H), 5.15 (d, J = 3.7 Hz,1H), 4.69 (d, J = 4.4 
Hz,1H), 3.82 (d, J = 11.41 Hz, 5H), 3.65 (dq, J = 8.78, 11.26, 20.37 Hz, 5H), 3.52 (d, J = 8.68 Hz, 
1H), 3.42 (d, J = 18.32 Hz, 4H), 3.30 (d, J = 2.99 Hz, 12H). 
13C NMR (101 MHz, CD3OD) δ 101.52, 99.43, 99.14, 79.92, 78.24, 75.29, 73.65, 73.35, 72.87, 71.82, 
70.65, 70.07, 61.30, 60.76, 60.67, 54.11, 46.42, 29.33. 
31P NMR (162 MHz, CD3OD) δ 1.57. 
HRMS (ESI) calcd for C19H34O19P [M-H]-:597.1437, found 597.1447 
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Methyl 2-O-benzyl-3-dibenzylphosphate-4,6-O-benzylidene-α-D-glucopyranoside (17) 
Compound 3 (220 mg, 0.59 mmol) was subjected to the general procedure for phosphorylation 
described above and purified via SGC (hexanes/EtOAc 3:2) to give 17 (210 mg, 0.33 mmol, 56%).  
1H NMR (600 MHz, CDCl3) δ 7.73 – 6.95 (m, 20H), 5.52 (s, 1H), 4.98 (dddd, J = 7.30, 12.17, 26.00, 
44.62 Hz, 5H), 4.80 (d, J = 12.19 Hz, 1H), 4.73 – 4.55 (m, 2H), 4.30 (dd, J = 4.86, 10.30 Hz, 1H), 
3.90 (td, J = 4.79, 9.89 Hz, 1H), 3.83 – 3.62 (m, 3H), 3.40 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 137.82, 136.90, 136.25, 136.21, 136.20, 129.18, 128.48, 128.35, 
128.31, 128.28, 128.26, 128.13, 128.08, 128.00, 127.97, 127.55, 127.40, 126.42, 101.98, 98.99, 80.21, 
80.19, 78.38, 78.35, 76.92, 76.88, 73.36, 69.08, 69.05, 69.04, 69.00, 68.96, 62.22, 55.44. 
31P NMR (243 MHz, CDCl3) δ 15.82. 
HRMS (ESI) calcd for C35H38O9PNa [M+H]+:633.2248, found 633.2257 
 
 
Methyl 2-,6-di-O-benzyl-3-dibenzylphosphate-α-D-glucopyranoside (19) Compound 17 (91 mg, 
0.143 mmol) was subjected to the conditions described in the general procedure for selective 
benzylidene opening and purified via SGC (hexanes/EtOAc 3:2) to give 19 (64 mg, 0.101 mmol, 
71%).  
1H NMR (600 MHz, CDCl3) δ 7.35 (s, 20H), 5.25 – 5.00 (m, 2H), 4.81 – 4.69 (m, 3H), 4.69 – 4.57 
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(m, 3H), 3.88 – 3.72 (m, 4H), 3.59 (ddd, J = 4.03, 10.10, 13.15 Hz, 1H), 3.40 (d, J = 12.26 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.20, 137.73, 135.61, 135.57, 128.73, 128.71, 128.63, 128.61, 
128.59, 128.54, 128.49, 128.47, 128.36, 128.32, 128.11, 128.05, 128.02, 127.97, 127.94, 127.65, 
127.62, 127.59, 97.78, 81.95, 81.91, 73.63, 73.22, 70.26, 70.03, 69.99, 69.92, 69.79, 69.75, 68.91, 
55.23. 
31P NMR (243 MHz, CDCl3) δ 18.83. 
HRMS (ESI) calcd for C35H40O9P [M+H]+:635.2404, found 635.2411 
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Methyl 2-dibenzylphosphate-3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (16) 
Compound 2 (76 mg, 0.20 mmol) was subjected to the general procedure for phosphorylation 
described above to and purified via SGC (hexanes/EtOAc 2:1) give 16 (85 mg, 0.134 mmol, 67%). 
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.14 (m, 20H), 5.57 (s, 1H), 5.04 (d, J = 7.51 Hz, 2H), 5.02 – 
4.94 (m, 3H), 4.91 (d, J = 11.35 Hz, 1H), 4.73 (d, J = 11.32 Hz, 1H), 4.41 (ddd, J = 3.81, 7.70, 9.40 
Hz, 1H), 4.30 (dd, J = 4.66, 10.12 Hz, 1H), 4.06 (t, J = 9.28 Hz, 1H), 3.87 (td, J = 4.66, 9.90 Hz, 1H), 
3.76 (t, J = 10.25 Hz, 1H), 3.67 (t, J = 9.34 Hz, 1H), 3.37 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 138.25, 137.19, 135.66, 128.97, 128.52, 128.47, 128.45, 128.33, 
128.23, 128.21, 127.89, 127.84, 127.67, 127.55, 125.99, 101.33, 98.61, 82.03, 82.01, 74.98, 69.37, 
69.32, 69.27, 69.22, 68.94, 62.24, 55.44. 
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31P NMR (162 MHz, CDCl3) δ -1.77. 
HRMS (ESI) calcd for C35H38O9P [M+H]+:633.2248, found 633.2244 
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Methyl 2-dibenzylphosphate-3,6-di-O-benzyl- -α-D-glucopyranoside (18) Compound 16 (104 mg, 
0.165 mmol) was subjected to the conditions described in the general procedure for selective 
benzylidene opening and purified via SGC (hexanes/EtOAc 2:1) to give 18 (84 mg, 0.133 mmol, 
81%).  
1H NMR (400 MHz, CDCl3) δ 7.56 – 7.16 (m, 20H), 5.05 (d, J = 7.64 Hz, 2H), 5.03 – 4.96 (m, 3H), 
4.87 (d, J = 11.45 Hz, 1H), 4.71 (d, J = 11.37 Hz, 1H), 4.64 – 4.52 (m, 2H), 4.36 (ddd, J = 3.67, 7.22, 
9.60 Hz, 1H), 3.84 (t, J = 9.14 Hz, 1H), 3.80 – 3.61 (m, 4H), 3.35 (s, 3H), 2.56 (d, J = 2.75 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 138.40, 137.88, 135.77, 135.70, 135.63, 128.56, 128.52, 128.51, 
128.49, 128.45, 128.43, 128.40, 127.91, 127.88, 127.80, 127.78, 127.71, 127.64, 97.94, 80.15, 80.08, 
76.99, 75.19, 73.63, 71.25, 71.23, 69.79, 69.60, 69.41, 69.36, 69.28, 69.22, 55.32. 
31P NMR (162 MHz, CDCl3) δ -1.59. 
HRMS (ESI) calcd for C35H39O9PNa [M+Na]+:657.2224, found 657.2209 
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Methyl  2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl- (1→4)- 2,3,6-tri-O- benzyl-α- 
D-glucopyranosyl-(1→4)-3-dibenzylphosphate- ,6-di-O-benzyl-α-D-glucopyranoside (20) Donor 
10 (72 mg, 0.071 mmol) and acceptor 18 (30 mg, 0.047 mmol) were subjected to the conditions for 
general method of glycosylation and purified via SGC (hexanes/EtOAc 2:1) to give 20 (27 mg, 0.018 
mmol, 39%).  
1H NMR (400 MHz, CDCl3) δ 7.73 – 6.85 (m, 50H), 5.72 – 5.61 (m, 1H), 5.45 – 5.35 (m, 1H), 4.95 
(td, J = 4.00, 9.37, 9.82 Hz, 4H), 4.83 (tq, J = 4.36, 5.86, 11.30 Hz, 5H), 4.73 – 4.57 (m, 3H), 4.57 – 
4.33 (m, 7H), 5.56 – 5.45 (m, 1H), 4.16 – 3.84 (m, 7H), 3.78 (dd, J = 8.78, 14.01 Hz, 2H), 3.72 – 3.51 
(m, 5H), 3.53 – 3.39 (m, 3H), 3.31 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 138.25, 138.13, 137.97, 137.93, 137.65, 137.56, 137.54, 137.16, 
137.07, 135.27, 135.20, 135.13, 135.05, 128.38, 128.05, 128.03, 127.98, 127.96, 127.86, 127.83, 
127.79, 127.76, 127.70, 127.64, 127.55, 127.42, 127.39, 127.35, 127.33, 127.26, 127.23, 127.21, 
127.18, 127.15, 127.11, 127.09, 127.07, 127.02, 126.98, 126.95, 126.71, 126.68, 126.62, 126.35, 
126.23, 126.11, 125.56, 100.66, 97.26, 97.05, 96.82, 96.28, 91.37, 81.78, 81.23, 80.16, 80.08, 79.87, 
79.79, 79.11, 78.42, 78.17, 74.65, 73.55, 73.51, 73.29, 73.01, 72.95, 72.86, 72.71, 72.55, 71.53, 70.87, 
70.49, 70.09, 69.41, 68.88, 68.83, 68.79, 68.73, 68.68, 68.46, 68.18, 68.01, 62.74, 54.80, 54.67. 
31P NMR (162 MHz, CDCl3) δ -1.74. 
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HRMS (ESI) calcd for C89H93O19PNa [M+Na]+:1519.5914, found 1519.5934 
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Methyl α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)-2-phosphate-α-D-gluco 
pyranoside (22) 
Hydrogenation of 20 (5 mg, 0.003 mmol) according to the general method for global deprotection 
gave 15 (1 mg, 0.002 mmol, 61%). 
1H NMR (400 MHz, CD3OD) δ 5.15 (s, 1H), 5.11 (d, J = 3.14 Hz, 1H), 4.63 – 4.55 (m, 1H), 4.00 (s, 
2H), 3.77 (h, J = 9.54, 10.19 Hz, 7H), 3.70 – 3.51 (m, 5H), 3.45 (q, J = 10.22, 10.70 Hz, 2H), 3.37 (s, 
3H).  
13C NMR (101 MHz, CD3OD) δ 101.45, 101.12, 97.89, 79.84, 79.48, 73.63, 73.49, 73.34, 72.81, 
72.41, 71.99, 71.93, 70.58, 70.21, 70.07, 61.29, 60.68, 60.50, 54.34, 54.21. 
31P NMR (162 MHz, CD3OD) δ -0.43. 
HRMS (ESI) calcd for C19H34O19P [M-H]-: 597.1437, found 597.1433 
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Methyl 2,3,6-tri-O-benzyl-α-D-glucopyranosyl -(1→4)- 2,3,6-tri-O-benzyl-D- glucopyranoside 
(25) Compound 24 (59 mg, 0.066mmol) was subjected to the conditions according to the general 
procedure for selective benzylidene opening to and purified via SGC (hexanes/EtOAc 3:1) afford 25 
(41 mg, 0.046 mmol, 69%) as white foam.  
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.06 (m, 30H), 5.72 (d, J = 3.59 Hz, 1H), 5.07 (d, J = 11.62 Hz, 
1H), 4.91 (d, J = 11.29 Hz, 1H), 4.82 (d, J = 11.70 Hz, 1H), 4.77 – 4.68 (m, 2H), 4.66 – 4.41 (m, 7H), 
4.35 (d, J = 12.09 Hz, 1H), 4.10 (d, J = 8.80 Hz, 2H), 3.96 – 3.81 (m, 2H), 3.81 – 3.42 (m, 8H), 3.40 
(s, 3H), 2.52 (d, J = 2.43 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 138.93, 138.78, 138.22, 137.95, 137.91, 137.87, 128.47, 128.44, 
128.34, 128.32, 128.25, 128.21, 127.94, 127.87, 127.73, 127.71, 127.66, 127.64, 127.39, 127.33, 
127.12, 126.72, 97.74, 96.55, 82.05, 81.27, 80.19, 78.99, 75.32, 74.39, 73.54, 73.35, 73.17, 73.08, 
72.27, 71.46, 70.53, 69.76, 69.53, 69.02, 55.18. 
HRMS(ESI): calcd for C55H61O11 [M+H]+: 897.4206, found 897.4208 
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Methyl  3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4)- 2,3,6-tri-O-benzyl-α- 
D-glucopyranosyl-(1→4) -2 ,3,6-tri-O-benzyl-D-glucopyranoside (33) 
Donor 29 (19 mg, 0.033 mmol) and acceptor 25 (22 mg, 0.023 mmol) was glycosylated using the 
general glycosylation method for thiolglycoside to give a 3:1 alpha/beta mixture of 31(17.5 mg, 0.013 
mmol). 31 was treated with DDQ according to the conditions in the general methods for PMB 
removal, and purified by SGC (hexanes/ethyl acetate 3:1) to give 33 (6 mg, 0.005 mmol, 15% for two 
steps).  
1H NMR (400 MHz, CDCl3) δ 7.64 – 6.95 (m, 40H), 5.69 (dd, J = 3.59, 9.73 Hz, 1H), 5.54 (s, 1H), 
5.19 (d, J = 3.53 Hz, 1H), 5.06 (dd, J = 11.33, 22.77 Hz, 2H), 4.84 – 4.66 (m, 5H), 4.66 – 4.31 (m, 
11H), 4.08 (dq, J = 3.79, 6.48, 11.88 Hz, 4H), 4.00 – 3.81 (m, 6H), 3.80 – 3.42 (m, 11H), 3.39 (d, J = 
4.84 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 137.84, 137.64, 136.99, 136.89, 136.87, 136.64, 136.39, 136.35, 
127.86, 127.43, 127.40, 127.34, 127.31, 127.28, 127.26, 127.24, 127.21, 127.16, 127.01, 126.93, 
126.83, 126.78, 126.75, 126.73, 126.69, 126.62, 126.53, 126.49, 126.42, 126.38, 126.29, 126.12, 
125.68, 125.60, 124.97, 100.11, 100.01, 96.75, 95.02, 80.91, 80.41, 79.27, 79.17, 78.76, 78.27, 74.06, 
73.64, 73.38, 72.58, 72.43, 72.31, 72.20, 71.76, 71.31, 69.99, 68.56, 67.87, 67.30, 62.76, 54.23. 
HRMS (ESI) calcd for C75H80O16Na [M+Na]+:1259.5339, found 1559.5337 
 
  62
O
BnO
BnO
BnO
O
BnO
BnO
BnO
O
OMe
O
(BnO)2PO
BnO
O
O
O
Ph
O
 
Methyl  2-dibenzylphosphate-3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4)- 2,3,6- 
tri-O-benzyl-α- D-glucopyranosyl-(1→4) -2,3,6-tri-O-benzyl-α-D- glucopyranoside (35) 
Compound 33 (13 mg, 0.011 mmol) was subjected to the general procedure for phosphorylation 
described above and purified by SGC (hexanes/ethyl acetate 4:1) to give 35 (8.6 mg, 0.0055 mmol, 
52%).  
1H NMR (400 MHz, CDCl3) δ 7.61 – 6.98 (m, 50H), 5.82 (d, J = 3.69 Hz, 1H), 5.62 (d, J = 3.49 Hz, 
1H), 5.55 (s, 1H), 5.06 – 4.97 (m, 2H), 4.88 (dqd, J = 5.15, 8.96, 10.19, 18.94 Hz, 6H), 4.81 – 4.63 
(m, 6H), 4.63 – 4.37 (m, 11H), 4.15 (q, J = 7.88, 8.73 Hz, 2H), 4.09 – 3.94 (m, 5H), 3.95 – 3.75 (m, 
5H), 3.74 – 3.55 (m, 4H), 3.54 – 3.39 (m, 2H), 3.37 (d, J = 7.73 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 138.89, 138.51, 138.30, 138.08, 137.97, 137.88, 137.35, 128.88, 
128.55, 128.54, 128.49, 128.43, 128.42, 128.38, 128.35, 128.32, 128.25, 128.20, 128.16, 127.92, 
127.84, 127.79, 127.75, 127.71, 127.68, 127.64, 127.60, 127.57, 127.53, 127.50, 127.42, 127.37, 
127.31, 127.25, 127.10, 126.97, 126.73, 126.70, 126.02, 101.22, 97.77, 95.99, 82.21, 81.99, 81.04, 
80.11, 79.64, 77.21, 76.83, 74.79, 74.29, 73.99, 73.41, 73.32, 73.07, 73.00, 72.13, 71.54, 70.47, 69.49, 
69.28, 68.82, 68.65, 68.56, 62.98, 55.19. 
31P NMR (162 MHz, CDCl3) δ -1.19. 
HRMS (ESI) calcd for C89H93O19PNa [M+Na]+:1519.5914, found 1519.5942 
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Methyl  2-phosphate-α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)- 
D-glucopyranoside (37) Compound 35 (8.6 mg, 0.0055 mmol) was subjected to the general 
procedure for global deprotection described above to give 37 (2.7 mg, 0.0045 mmol, 83%). 
1H NMR (400 MHz, CD3OD) δ 5.52 (s, 1H), 5.15 (s, 1H), 4.66 (s, 1H), 4.07 – 3.92 (m, 2H), 3.92 – 
3.72 (m, 11H), 3.72 – 3.56 (m, 2H), 3.56 – 3.34 (m, 6H), 3.12 – 2.83 (m, 2H). 
13C NMR (101 MHz, CD3OD) δ 101.11, 99.70, 98.75, 80.25, 74.79, 73.52, 73.24, 72.67, 72.26, 71.69, 
70.76, 70.54, 61.39, 60.67, 54.20, 45.89, 29.35, 29.04. 
31P NMR (162 MHz, CD3OD) δ 3.43. 
HRMS (ESI) calcd for C19H34O19P [M-H]-:597.1437, found 597.1455 
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Methyl  2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl-α- 
D-glucopyranosyl-(1→4) -2 ,3,6-tri-O-benzyl-α- D-glucopyranoside (34) Donor 30 (72 mg, 0.126 
mmol) and acceptor 25 (63 mg, 0.078 mmol) was glycosylated using the general glycosylation 
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method for thioglycoside to give a 3:1 alpha/beta mixture of 32 (56 mg, 0.040 mmol, 52%). 32 (22 
mg, 0.016 mmol) was treated with DDQ according to the conditions in the general methods for PMB 
removal, and purified by SGC (hexanes/EtOAc 3:1) to give 34 (8 mg, 0.006 mmol, 37%).  
1H NMR (400 MHz, CDCl3) δ 7.55 – 6.82 (m, 40H), 5.68 (d, J = 3.76 Hz, 1H), 5.55 (d, J = 3.52 Hz, 
1H), 5.41 (s, 1H), 4.98 (d, J = 11.65 Hz, 1H), 4.91 (d, J = 11.78 Hz, 1H), 4.73 (q, J = 9.98, 10.69 Hz, 
1H), 4.68 – 4.57 (m, 2H), 4.57 – 4.45 (m, 4H), 4.45 – 4.26 (m, 5H), 4.15 – 3.89 (m, 6H), 3.90 – 3.64 
(m, 5H), 3.54 (dd, J = 7.82, 12.39 Hz, 3H), 3.51 – 3.36 (m, 3H), 3.36 – 3.26 (m, 4H). 
13C NMR (151 MHz, CDCl3) δ 138.83, 138.28, 138.12, 138.03, 137.80, 137.64, 137.30, 129.13, 
128.46, 128.44, 128.36, 128.32, 128.30, 128.28, 128.25, 128.21, 127.95, 127.89, 127.84, 127.73, 
127.69, 127.48, 127.43, 127.40, 127.30, 127.15, 126.76, 126.56, 126.37, 101.85, 97.83, 96.40, 96.02, 
81.95, 81.85, 81.28, 80.09, 79.74, 79.20, 74.38, 73.86, 73.38, 73.16, 72.89, 72.63, 71.39, 70.50, 70.24, 
69.61, 68.92, 68.75, 68.62, 62.89, 55.23, 29.72. 
HRMS (ESI) calcd for C75H80O16Na [M+Na]+:1259.5339, found 1559.5332 
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Methyl  2-O-benzyl- 3-dibenzylphosphate -4,6-O-benzylidene-α-D-glucopyranosyl- (1→4)- 
2,3,6-tri-O-benzyl-α- D-glucopyranosyl-(1→4) -2 ,3,6-tri-O-benzyl- D-glucopyranoside (36) 
Compound 34 (12 mg, 0.01 mmol) was subjected to the general procedure for phosphorylation 
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described above and purified by SGC (hexanes/EtOAc 2:1) to give 36 (8 mg, 0.006 mmol, 60 %). 
1H NMR (600 MHz, CDCl3) δ 7.55 – 7.06 (m, 50H), 5.08 – 4.87 (m, 4H), 4.86 – 4.69 (m, 3H), 4.71 – 
4.60 (m, 3H), 4.60 – 4.38 (m, 8H), 5.53 – 5.43 (m, 1H), 4.14 (td, J = 7.75, 12.95, 15.48 Hz, 4H), 4.07 
(q, J = 7.79, 9.07 Hz, 1H), 3.97 – 3.77 (m, 5H), 3.66 (dt, J = 10.94, 16.65 Hz, 4H), 5.73 – 5.63 (m, 
1H), 3.63 – 3.48 (m, 4H), 5.83 – 5.76 (m, 1H), 3.44 (d, J = 10.38 Hz, 8H). 
13C NMR (151 MHz, CDCl3) δ 139.02, 138.89, 138.30, 138.21, 138.05, 137.62, 137.13, 135.84, 
135.79, 129.14, 128.72, 128.61, 128.57, 128.53, 128.49, 128.46, 128.36, 128.31, 128.28, 128.25, 
128.23, 128.20, 128.08, 128.04, 127.96, 127.93, 127.88, 127.83, 127.67, 127.57, 127.49, 127.47, 
127.39, 127.36, 127.32, 127.30, 127.27, 127.25, 127.13, 127.05, 126.75, 126.50, 126.46, 126.45, 
101.95, 97.82, 96.82, 96.03, 82.02, 81.73, 80.13, 79.71, 78.04, 74.99, 74.36, 73.81, 73.35, 73.33, 
73.07, 72.89, 72.48, 71.73, 70.41, 69.59, 69.33, 69.29, 68.98, 68.95, 68.73, 68.53, 63.03, 55.22. 
31P NMR (243 MHz, CDCl3) δ 16.09. 
HRMS (ESI) calcd for C89H93O19PNa [M+Na]+:1519.5914, found 1519.5944 
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Methyl 3-phosphate-α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)-α-D-gluco 
pyranoside (38) Hydrogenation of 36 (10 mg, 0.006 mmol) according to the general method for 
global deprotection gave 38 (2.5 mg, 0.003 mmol, 50%). 
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1H NMR (600 MHz, MeOD) δ5.23 (d, J = 3.40 Hz, 1H), 5.18 (d, J = 3.71 Hz, 1H), 4.70 (d, J = 3.69 
Hz, 1H), 3.36 – 3.30 (m, 8H), 3.91 – 3.78 (m, 9H), 5.12 – 5.10 (m, 1H), 3.63 (d, J = 11.74 Hz, 5H), 
3.53 (m, 4H) 
13C NMR (101 MHz, MeOD) δ 101.25, 101.18, 99.70, 89.67, 80.23, 80.14, 73.49, 73.01, 72.33, 
71.82, 71.72, 70.71, 61.01, 60.67, 54.20, 52.35. 
31P NMR (162 MHz, MeOD) δ 1.25. 
HRMS (ESI) calcd for C19H34O19P [M-H]-: 597.1437, found 597.1425 
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Methyl  2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4) -2 ,3 ,6-tri-O–benzyl 
-α-D-glucopyranoside (43) Donor 30 (82 mg, 0.144 mmol) and acceptor 39 (38 mg, 0.082 mmol) 
were subjected to the conditions for general method of glycosylation to give 41 as a mixture, followed 
by PMB removal and purified by SGC (hexanes/EtOAc 4:1) to give 43 (33 mg, 0.041 mmol, 50%).  
1H NMR (400 MHz, CDCl3) δ 7.59 – 7.16 (m, 20H), 5.80 (d, J = 3.69 Hz, 1H), 5.50 (s, 1H), 5.12 (d, 
J = 11.73 Hz, 1H), 4.78 (d, J = 11.80 Hz, 1H), 4.71 (d, J = 12.11 Hz, 2H), 4.68 – 4.45 (m, 5H), 4.21 – 
4.05 (m, 4H), 3.93 – 3.78 (m, 3H), 3.74 – 3.57 (m, 3H), 3.48 (t, J = 9.46 Hz, 1H), 3.44 – 3.28 (m, 4H), 
2.48 (bs, 1H). 
13C NMR (101 MHz, CDCl3) δ 138.91, 138.09, 137.87, 137.60, 137.23, 129.12, 128.50, 128.47, 
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128.35, 128.29, 128.26, 128.19, 127.98, 127.94, 127.92, 127.47, 127.43, 127.21, 126.67, 126.32, 
101.80, 97.70, 96.51, 82.14, 81.30, 80.30, 79.06, 74.24, 73.42, 73.26, 72.97, 71.45, 70.20, 69.42, 
68.89, 68.72, 62.96, 55.23. 
HRMS (ESI) calcd for C56H55O4P [M+H]+:821.3832, found 821.3834 
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Methyl  2-O-benzyl-3-dibenzylphosphate- 4,6-O-benzylidene-α-D-glucopyranosyl-(1→4) -2 ,3,6 
-tri-O-benzyl-α-D-glucopyranoside (45) Compound 43 (33 mg,0.041 mmol) was subjected to the 
general procedure for phosphorylation described above and purified by SGC (hexanes/EtOAc 4:1) to 
give 45 (38 mg, 0.036 mmol, 88%). 
1H NMR (600 MHz, CDCl3) δ 7.60 – 6.99 (m, 35H), 5.84 (d, J = 3.67 Hz, 1H), 5.50 (s, 1H), 5.18 – 
5.04 (m, 8H), 5.04 – 4.91 (m, 3H), 4.86 (ddd, J = 7.69, 12.12, 14.64 Hz, 2H), 4.75 – 4.67 (m, 4H), 
4.66 – 4.57 (m, 3H), 4.54 (d, J = 11.69 Hz, 2H), 4.23 – 4.11 (m, 3H), 3.94 (ddd, J = 9.85, 16.41, 
20.21 Hz, 3H), 3.68 (dt, J = 10.19, 20.97 Hz, 5H), 3.61 (dd, J = 3.76, 9.57 Hz, 1H), 3.45 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 139.00, 138.16, 137.92, 137.46, 137.09, 136.25, 136.20, 136.12, 
135.62, 135.58, 129.11, 128.74, 128.72, 128.59, 128.49, 128.32, 128.30, 128.28, 128.27, 128.23, 
128.20, 128.17, 128.08, 128.06, 127.99, 127.95, 127.64, 127.55, 127.45, 127.43, 127.31, 127.14, 
126.62, 126.49, 101.93, 97.73, 96.85, 82.03, 80.36, 80.23, 78.09, 74.14, 73.44, 73.27, 72.92, 71.69, 
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69.39, 69.06, 69.02, 68.99, 68.96, 68.86, 68.75, 67.34, 67.30, 63.20, 55.30. 
31P NMR (243 MHz, CDCl3) δ 16.02. 
HRMS (ESI) calcd for C62H65O14PK [M+K]+:1103.3744, found 1103.3756 
 
 
Methyl  2,6-di-O-benzyl-3-dibenzylphosphate-α-D-glucopyranosyl-(1→4) -2 ,3 ,6-tri-O- 
benzyl-α-D-glucopyranoside (47) Compound 45 (38 mg, 0.036 mmol) was subjected to the 
conditions according to the general procedure for selective benzylidene opening and purified by SGC 
(hexanes/EtOAc 3:2) to afford 47 (29 mg, 0.027 mmol,75 %) as syrup. 
1H NMR (600 MHz, CDCl3) δ 7.55 – 7.09 (m, 35H), 5.77 (d, J = 3.68 Hz, 1H), 5.18 – 4.95 (m, 7H), 
4.73 (dd, J = 11.86, 21.93 Hz, 2H), 4.68 – 4.57 (m, 4H), 4.58 – 4.44 (m, 5H), 4.12 – 4.03 (m, 2H), 
3.84 (qd, J = 2.91, 10.86, 11.77 Hz, 3H), 3.75 (dq, J = 3.62, 4.30, 10.72 Hz, 1H), 3.70 – 3.58 (m, 3H), 
3.51 (ddd, J = 3.08, 10.16, 23.29 Hz, 2H), 3.44 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 139.00, 138.22, 138.18, 137.96, 137.60, 135.60, 135.57, 135.55, 
135.53, 128.73, 128.71, 128.56, 128.49, 128.45, 128.31, 128.28, 128.26, 128.21, 128.19, 128.05, 
127.97, 127.95, 127.91, 127.85, 127.66, 127.62, 127.59, 127.53, 127.43, 127.40, 127.06, 126.65, 
97.73, 96.48, 82.02, 81.96, 81.92, 80.22, 74.26, 73.59, 73.31, 73.22, 73.00, 72.78, 71.11, 69.89, 69.85, 
69.73, 69.69, 69.51, 69.02, 68.63, 67.33, 67.30, 55.27. 
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31P NMR (243 MHz, CDCl3) δ 18.69. 
HRMS (APCI) calcd for C62H68O14P [M+H]+:1067.4341, found 1067.4342 
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Methyl  3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4) -2,3 ,6-tri-O-benzyl- 
α-D-glucopyranoside (42) Donor 29 (50 mg, 0.088 mmol) and acceptor 39 (22 mg, 0.047 mmol) 
were subjected to the conditions for general method of glycosylation to give 40 as a mixture, followed 
by PMB removal and purified by SGC (hexanes/EtOAc 4:1) to give 42 (12 mg, 0.015 mmol, 32 %).  
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.21 (m, 25H), 5.52 (s, 1H), 5.26 (d, J = 3.47 Hz, 1H), 5.09 (d, 
J = 10.91 Hz, 1H), 4.81 – 4.73 (m, 2H), 4.73 – 4.51 (m, 7H), 4.13 (dd, J = 4.84, 10.27 Hz, 1H), 3.99 
(t, J = 9.29 Hz, 1H), 3.95 – 3.80 (m, 3H), 3.77 – 3.51 (m, 7H), 3.46 – 3.30 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 138.60, 137.83, 137.78, 137.66, 137.37, 128.88, 128.51, 128.42, 
128.32, 128.20, 128.06, 127.88, 127.71, 127.62, 127.48, 126.00, 101.17, 100.92, 97.82, 81.47, 80.71, 
80.27, 79.22, 77.19, 76.83, 75.33, 74.74, 73.50, 73.43, 73.19, 69.94, 68.90, 68.46, 63.73, 55.32, 
29.69. 
HRMS (ESI) calcd for C48H52O11PNa [M+Na]+:827.3402, found 827.3402 
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Methyl  2-dibenzylphosphate-3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-(1→4) 
-2 ,3 ,6-tri-O-benzyl-α-D-glucopyranoside (44) Compound 42 (11 mg, 0.015 mmol) was subjected 
to the general procedure for phosphorylation described above and purified by SGC (hexanes/EtOAc 
3:1) to give 44 (13 mg, 0.013 mmol, 85%).  
1H NMR (600 MHz, CDCl3) δ 7.47 – 7.20 (m, 35H), 4.51 – 4.44 (m, 1H), 5.91 (d, J = 3.81 Hz, 1H), 
5.59 (s, 1H), 5.16 – 4.84 (m, 8H), 4.80 – 4.67 (m, 3H), 4.64 (d, J = 3.56 Hz, 1H), 4.59 (dd, J = 6.56, 
12.17 Hz, 2H), 4.21 (dd, J = 4.84, 10.31 Hz, 1H), 4.16 (t, J = 9.15 Hz, 1H), 4.10 (t, J = 9.05 Hz, 1H), 
4.05 (t, J = 9.34 Hz, 1H), 3.96 (ddt, J = 5.43, 9.92, 24.67 Hz, 1H), 3.90 – 3.81 (m, 2H), 3.77 – 3.67 
(m, 3H), 3.61 – 3.47 (m, 3H), 3.40 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.74, 138.36, 138.11, 138.03, 137.41, 137.14, 137.09, 128.73, 
128.71, 128.58, 128.53, 128.47, 128.44, 128.40, 128.34, 128.29, 128.24, 128.20, 128.10, 128.05, 
127.99, 127.97, 127.93, 127.74, 127.60, 127.49, 127.47, 101.27, 97.90, 96.06, 82.20, 81.41, 80.40, 
76.63, 76.59, 74.88, 74.47, 73.50, 73.38, 71.70, 69.54, 69.42, 68.87, 68.77, 67.34, 67.30, 67.24, 67.21, 
63.12, 55.31. 
31P NMR (243 MHz, CDCl3) δ 12.20. 
HRMS (ESI) calcd for C62H65O14PNa [M+Na]+: 1087.4004, found 1087.3988 
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Methyl  3-dibenzylphosphate-2,6-di-O-benzyl- α-D-glucopyranosyl-(1→4) -2 ,3 ,6-tri-O- 
benzyl-α-D-glucopyranoside (46) Compound 44 (8 mg, 0.008 mmol) was subjected to the 
conditions according to the general procedure for selective benzylidene opening and purified by SGC 
(hexanes/EtOAc 3:1) to afford 46 (5 mg, 0.005 mmol, 63%) as syrup.  
1H NMR (400 MHz, CDCl3) δ 7.34 – 6.99 (m, 35H), 5.69 (d, J = 3.57 Hz, 1H), 4.98 – 4.70 (m, 8H), 
4.70 – 4.55 (m, 2H), 4.54 – 4.42 (m, 4H), 4.36 (d, J = 12.00 Hz, 1H), 4.32 – 4.23 (m, 2H), 4.02 – 3.91 
(m, 2H), 3.84 – 3.68 (m, 4H), 3.68 – 3.54 (m, 2H), 3.43 (dtd, J = 4.21, 10.24, 17.47 Hz, 3H), 3.28 (s, 
3H), 2.53 (d, J = 2.51 Hz, 1H). 
13C NMR (151 MHz, CDCl3) δ 138.85, 138.51, 138.12, 137.85, 135.81, 135.76, 128.72, 128.57, 
128.46, 128.43, 128.41, 128.39, 128.34, 128.28, 128.24, 128.10, 128.04, 127.96, 127.92, 127.88, 
127.81, 127.70, 127.65, 127.45, 127.27, 97.88, 95.69, 81.38, 80.24, 79.63, 75.03, 74.50, 73.62, 73.37, 
73.27, 72.45, 72.09, 70.32, 70.06, 69.63, 69.38, 69.34, 68.94, 67.33, 55.27. 
31P NMR (162 MHz, cdcl3) δ -0.99. 
HRMS (ESI) calcd for C62H68O14P [M+H]+: 1067.4341, found 1067.4319 
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Methyl  2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl-(1→4)-3-dibenzylphosphate-2,6-di- 
O-benzyl- α-D-glucopyranosyl-(1→4) -2 ,3 ,6-tri-O-benzyl-α-D-glucopyranoside (50) 
Donor 48 (29 mg, 0.042 mmol) and acceptor 47 (15 mg, 0.014 mmol) was subjected to the conditions 
according to the glycosylation procedure and purified by SGC (hexanes/EtOAc 4:1) to give 50 (16 
mg, 0.010 mmol, 72%). 
1H NMR (600 MHz, CDCl3) δ 7.50 – 6.98 (m, 55H), 5.83 (d, J = 3.58 Hz, 1H), 5.66 (d, J = 3.54 Hz, 
1H), 5.05 – 4.95 (m, 3H), 4.95 – 4.89 (m, 1H), 4.89 – 4.83 (m, 5H), 4.83 – 4.79 (m, 2H), 4.77 (d, J = 
11.12 Hz, 1H), 4.75 – 4.68 (m, 1H), 4.66 – 4.58 (m, 6H), 4.56 – 4.38 (m, 8H), 4.32 (dd, J = 12.11, 
16.95 Hz, 2H), 4.27 (dd, J = 6.52, 9.76 Hz, 1H), 4.06 – 3.99 (m, 2H), 3.99 – 3.94 (m, 1H), 3.83 (dd, J 
= 7.14, 11.48 Hz, 2H), 3.79 – 3.74 (m, 2H), 3.74 – 3.66 (m, 3H), 3.66 – 3.51 (m, 7H), 3.51 – 3.42 (m, 
5H). 
13C NMR (151 MHz, CDCl3) δ 138.93, 138.84, 138.74, 138.39, 138.24, 138.22, 138.14, 137.97, 
137.93, 128.53, 128.45, 128.42, 128.38, 128.30, 128.27, 128.24, 128.21, 128.18, 128.13, 128.06, 
128.00, 127.97, 127.94, 127.87, 127.77, 127.73, 127.69, 127.64, 127.50, 127.44, 127.43, 127.41, 
127.36, 127.28, 127.18, 126.90, 97.78, 95.20, 94.55, 82.02, 81.66, 80.18, 80.07, 75.39, 74.87, 74.30, 
73.36, 73.33, 73.25, 72.89, 72.59, 72.33, 71.84, 71.03, 70.41, 69.50, 69.45, 69.41, 69.24, 69.21, 68.82, 
68.71, 68.50, 55.28. 
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31P NMR (243 MHz, CDCl3) δ 15.13. 
HRMS (ESI) calcd for C96H101O19PNa [M+Na]+: 1611.6567, found 1611.6524 
 
 
Methyl  2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl-(1→4)-2-dibenzylphosphate-3,6-di- 
O-benzyl- α-D-glucopyranosyl-(1→4) -2 ,3 ,6-tri-O-benzyl-α-D-glucopyranoside (49) Donor 48 
(10 mg, 0.012 mmol) and acceptor 46 (5 mg, 0.005 mmol) was subjected to the conditions according 
to the glycosylation procedure and purified by SGC (PhCH3/EtOAc 8:1) to give 50 (5 mg, 0.003 
mmol, 60 %). 
1H NMR (600 MHz, CDCl3) δ 7.65 – 7.00 (m, 50H), 5.73 (d, J = 3.51 Hz, 1H), 5.59 (d, J = 3.63 Hz, 
1H), 5.09 – 4.98 (m, 2H), 4.98 – 4.88 (m, 2H), 4.88 – 4.77 (m, 6H), 4.77 – 4.68 (m, 3H), 4.66 – 4.41 
(m, 11H), 4.32 (d, J = 12.19 Hz, 1H), 4.19 – 4.08 (m, 2H), 4.08 – 4.02 (m, 2H), 4.02 – 3.94 (m, 1H), 
3.94 – 3.87 (m, 2H), 3.80 (d, J = 7.13 Hz, 1H), 3.79 – 3.73 (m, 2H), 3.72 – 3.66 (m, 2H), 3.57 (dd, J = 
2.60, 10.17 Hz, 2H), 3.51 (tt, J = 3.50, 8.64, 9.82 Hz, 2H), 3.41 (dd, J = 2.00, 10.75 Hz, 1H), 3.38 (s, 
3H). 
13C NMR (151 MHz, CDCl3) δ 138.96, 138.72, 138.42, 138.21, 138.00, 128.98, 128.63, 128.40, 
128.32, 128.28, 128.24, 128.19, 128.16, 128.07, 127.98, 127.83, 127.78, 127.73, 127.69, 127.64, 
127.62, 127.53, 127.49, 127.43, 127.38, 127.21, 127.10, 126.74, 97.93, 97.05, 95.65, 82.09, 81.19, 
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80.03, 79.52, 77.60, 75.43, 74.93, 74.66, 73.65, 73.48, 73.34, 73.07, 71.14, 71.08, 69.75, 69.24, 68.81, 
68.20, 55.28. 
31P NMR (243 MHz, CDCl3) δ 16.68. 
HRMS (ESI) calcd for C96H101O19PNa [M+Na]+: 1611.6567, found 1611.6565 
 
 
Methyl α-D-glucopyranosyl-(1→4)- 2-phosphate-α-D-glucopyranosyl-(1→4)-α-D-gluco 
pyranoside (51) Hydrogenation of 50 (3 mg, 0.0018 mmol) according to the general method for 
global deprotection gave 15 (0.5 mg, 0.001 mmol, 48%). 
1H NMR (700 MHz, MeOD) δ 5.75 (s, 1H), 5.24 (s, 1H), 4.73 (s, 1H), 4.20 – 4.02 (m, 3H), 3.99 – 3.81 
(m, 5H), 3.70 (dt, J = 9.96, 44.31 Hz, 6H), 3.54 – 3.14 (m, 6H). 
13C NMR (176 MHz, MeOD) δ 104.08, 102.25, 99.04, 82.14, 80.76, 80.39, 78.37, 76.48, 76.27, 76.11, 
75.46, 74.41, 74.09, 73.01, 72.93, 72.80, 63.98, 63.60, 63.25, 56.85. 
31P NMR (243 MHz, MeOD) δ 3.20. 
HRMS (ESI) calcd for C19H34O19P [M-H]-: 597.1437, found 597.1435 
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Methyl  α-D-glucopyranosyl-(1→4)-3-phosphate-α-D-glucopyranosyl-(1→4)-α-D- gluco 
pyranoside (52) Hydrogenation of 50 (10 mg, 0.006 mmol) according to the general method for 
global deprotection gave 15 (3 mg, 0.004 mmol, 67%). 
1H NMR (600 MHz, MeOD) δ 5.49 (bs, 1H), 5.19 (bs, 1H), 5.14 (bs, 1H), 4.07 – 3.76 (m, 4H), 3.76 
– 3.58 (m, 5H), 3.58 – 3.36 (m, 6H), 3.24 – 3.14 (m, 6H). 
13C NMR (151 MHz, MeOD) δ 99.70, 96.82, 92.57, 76.71, 76.64, 74.91, 73.50, 73.04, 72.46, 71.58, 
71.37, 70.49, 70.36, 61.48, 61.37, 60.86, 54.21. 
31P NMR (162 MHz, MeOD) δ 2.20. 
HRMS (ESI) calcd for C19H34O19P [M-H]-: 597.1437, found 597.1436 
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CHAPTER 4  
Multigram Synthesis of Isobutyl-β-C-galactoside as a Substitute of Isopropylthiogalactoside for 
Exogenous Gene Induction in Mammalian Cells 
A paper published in Journal of Organic Chemistry1 
Lin Liu, Basma Abdel Motaal, Marc Schmidt-Supprian, and Nicola L. B. Pohl 
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Herein we report that isobutyl-β-C-galactoside (IBCG) is also a promising inducer of gene expression 
in mammalian cells and report a new synthetic route to the compound that should make obtaining the 
multigram quantities of material required for animal studies more feasible. A convenient synthesis of 
IBCG—an inducer of genes controlled by the lac operon system in bacterial cells—was achieved in 5 
steps from galactose in 81% overall yield without any chromatographic separation steps. An 
optimized microwave-assisted reaction at high concentration was key to making the C-glycosidic 
linkage. A Wittig reaction on a per-O-silylated rather than per-O-acetylated or -benzylated substrate 
proved most effective in installing the final carbon atom.  
                                                        
1 Reprinted with permission from Journal of Organic Chemistry. Copyright 2012 American Chemical Society.  
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Introduction 
 
Genetic engineering demands a tight regulation system to control the expression of the introduced 
exogenous genes, and this requirement is generally achieved via inducible gene expression systems.1-3 
Among the current available inducible systems, lac operon-based systems are the most widely studied 
and used.4,5 Isopropyl-β-D-thiogalactopyranoside (IPTG), a lactose analog, is routinely used as an 
inducer of the lac operon in bacterial systems for in vitro studies to induce the expression of 
exogenously introduced genes.4,6 This sugar analog binds to lac repressor to activate the gene 
transcription machinery (Figure 1). Studies have also shown that this inducible lac operon/repressor 
system can be implemented in mammalian cells and animal systems.7-10 Such an inducible system in 
mammalian cells ensures the exogenous genes are expressed only when the inducer is added and 
tightly regulates the gene transcription. When IPTG is used as the lac operon inducer in the animal 
models, the inducer is usually dissolved in drinking water and fed to the animals. Since 
decomposition products resulting from IPTG have an unpleasant thiol smell, IPTG solutions have to 
be put into light-protected bottles and carefully monitored.11,12 Even so, IPTG’s rapid-clearance and 
short half-life limit its usage and present a major drawback of using this popular gene induction 
system in animal systems.13-15 
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Figure 1. Lactose analogs such as allolactose, IPTG and IBCG can serve as inducers to bind the lac 
repressor and activate gene transcription in lac operon regulated gene transcription.  
 
To circumvent this stability problem, our group has reported the design and synthesis of a new lac 
inducer, isobutyl-β-C-galactoside (IBCG, 1),16 as a C-glycoside analog of IPTG. Not only does this 
C-glycoside show at least equal gene induction ability in bacterial systems as the S-glycoside, but 
replacement of the S-glycosidic bond by a C-glycosidic bond renders the resulting molecule much 
more stable. Herein we report that IBCG is also a promising inducer of gene expression in 
mammalian cells and report a new synthetic route to the compound that should make obtaining the 
multigram quantities of material required for animal studies more feasible.  
 
Previously, the synthesis of IBCG was achieved via either a Lewis acid-promoted reaction between 
galactose pentaacetate and methallyltrimethylsilane or a Grignard reaction between 
bromoacetogalactose and excess isobutylmagnesium bromide.16 The former method employs a large 
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excess of a relatively expensive material (methallyltrimethylsilane, > $20/g) and shows no α/β 
selectivity in the C-glycosidic bond formation reaction. The latter method utilizes a Grignard 
approach, which is highly exothermic and cumbersome to scale up. Both of the methods require silica 
gel chromatography to purify the product. To satisfy the need for larger amounts of IBCG required 
for animal studies, we hoped to find a new route that could offer a high overall yield on a multigram 
scale without any chromatography steps. 
 
Results and discussion 
 
Obviously key to any successful synthesis of IBCG is the method for installation of the C-glycoside. 
Stereoselective formation of C-glycosidic bonds have attracted significant attentions in the recent 
years.17,18 Among methods for the synthesis of β-C-glycosides, the one step condensation between 
free sugars in aqueous solutions and 2,4-pentanedione was particularly attractive as a way to quickly 
make β-C-glycosidic ketones without prior protection of the carbohydrate hydroxyl groups.19 A 
mixture of C-glycoside stereoisomers are formed in the initial Knoevenagel condensation; however, 
extended heating under basic conditions allow the equilibrium to shift to the β-C-glycosidic pyranose 
ketone (Scheme 1).20 Many recent studies utilized this strategy as a starting point to synthesize 
β-C-glycoside analogs.21-27 Ideally, IBCG could be obtained via a simple methylenation on the ketone 
by using a Wittg-type reaction. However, even though the carbonyl group in the β-C-glycosidic 
ketones obtained from natural reducing sugars should provide an excellent opportunity to perform 
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C-C bond formation via a Wittig-type reaction to obtain other β-C-glycoside analogs, this possibility 
remains relatively unexplored. Most of the existing studies are based on Aldol reactions between the 
β-C-glycosidic ketone and an aldehyde to form an α, β unsaturated ketone. We found this apparent 
absence of Wittig-type reaction on β-C-glycosidic ketones quite intriguing, and speculated that the 
base sensitivity of the ketone substrates might be a contributing factor. We decided to pursue our 
IBCG synthesis through this route with the hope of developing an efficient method for Wittig 
reactions on the β-C-glycosidic ketones. 
 
First, an optimized synthesis of our desired intermediate ketone 4 had to be developed. The synthesis 
of 4 has been reported on a 500-mg scale at 0.15 M concentrations of galactose after heating at 90 °C 
for 24 h.28 Unfortunately, the long reaction time and dilute reaction conditions made the reaction less 
desirable for multigram syntheses. We therefore set out to probe the limits of this reaction. By careful 
monitoring of the reaction by 1H NMR (Figure 2), we found that formation of the C-glycosidic bond 
itself was a relatively fast process; the mixture of isomers (mainly α-pyranose) was then converted to 
the thermodynamically more stable β-pyranose product 4 slowly upon extended heating. The 
characteristic peaks of β-pyranose product 4 are two doublets of doublets at δ 3.02 and 2.74 
corresponding to the protons from H-1’. The disappearance of peaks corresponding to H-1’ from 
α-pyranose product around δ 2.92 indicates the shift of the equilibrium has finished (Figure 2). To 
possibly accelerate the reaction, microwave irradiation was attempted instead of conventional 
heating.29-31 We found that the C-glycosidic bond formation was finished under microwave irradiation 
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in only 30 minutes under reflux at 70 – 75 °C. The top layer of the mixture containing the excess 2, 
4-pentanedione was then discarded and the reaction was heated in the microwave reactor during 
which time the temperature of the reaction was slowly raised to 100 °C as the excess THF evaporated. 
After 5.5 h, 1H NMR showed most of the mixture had been converted to the desired β-C-glycoside 4 
(Figure 2). We also found out that the reaction could be run at much higher concentrations than 
reported. The reaction was run at a concentration from 1.2 M to as high as 4.8 M instead of the 
reported 0.15 M with similar results. The water was removed from the reaction mixture under reduced 
pressure, and then methanol/ethyl acetate was added to separate the product from extra sodium 
bicarbonate. The crude products still contained some sodium acetate, but could be either used directly 
in the following reaction or purified by passing through a short silica gel plug followed by 
recrystallization to give the desired β-C-glycosidic ketone 4 in 92% yield for a 5-gram scale reaction. 
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H2O/THF
extended
heatingmixture of 
isomers
2 3 4  
 Heating method Reaction time Concentration Yield 
Previous28 Conventional, 90 ℃ 24 h 0.15 M 90% 
Modified method Microwave, 70 – 100 ℃ 6 h As high as 4.8 M 92% 
Scheme 1. Comparison of heating methods and reaction concentrations/times for the synthesis of 
β-C-glycosidic ketone 4  
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Figure 2. The 1H NMR spectra in D2O of a 10.00 g reaction (2.4 M) under microwave heating 
conditions. Samples aliquots were removed at 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6 h.  
 
With a method for the larger scale synthesis of the key intermediate ketone 4 in hand, only a few 
steps should allow elaboration of this ketone to the final compound 1. The synthesis of β-C-glycoside 
4 utilizes a well-studied property that 2-carbonylalkyl-C-glycopyranosides tend to do a retro-Michael 
type addition initiated by the enolate formation and followed by ring-opening under mild basic 
conditions.32-35 However, this property that makes for a convenient synthesis of β-C-glycoside 
ketones also makes the following transformations under basic conditions troublesome. A 
straightforward way to do the homologation is to use the Wittig reaction.36 No precedents for such a 
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Wittig reaction on substrates like compound 4 have been reported. Even though the Wittig reagent is 
relatively basic,37 we anticipated that there was a reasonable chance to do the desired methylenation 
on the base sensitive ketone substrate if we could fine tune the electronic properties of the pyranose 
ring to make the homologation, and not the enolate formation and ring opening reaction, more 
favorable. The Tebbe reagent provides a less basic alternative to Wittig regents that could possibly 
give superior results on a base-sensitive substrate,38 but is less desirable in large scale reactions due to 
its high cost. Therefore, we decided to try the Wittig reaction on the per-O-acetylated ketone 5a, since 
the per-O-acetylation of ketone 4 was reported to give a high yield easily28 and provides a readily 
available starting point for the methylenation. The ketone 4 was per-acetylated using acetic anhydride 
and pyridine to give per-O-acetylated compound 5a,28 which was then subjected to a Wittig reaction 
(Scheme 2). However, no combination of varying base, temperature or order of addition was found in 
which the desired alkene 6a was had in over 20% yield. The possible side products in this reaction 
involved a retro-Michael addition under basic conditions, followed by possible polymerization and 
decomposition. The less base-sensitive benzoyl group was then installed in place of acetyl groups, but 
the results were worse. The protected sugar derivative 5b was obtained in only 30% yield, and the 
Wittig reactions on 5b gave the desired product in less than 5% yield. Apparently the Wittig reagent 
was too basic for use with these peracetylated substrates. Non-basic methylenation conditions using 
TiCl4/Mg/CH2Cl239 on substrate 5a were attempted, but the yield was also low (~20%). A Grignard 
reaction using methylmagnesium bromide on 5a to install a methyl group also did not give 
satisfactory results. 
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Scheme 2. Wittig reaction on acyl-protected substrates. 
The electron withdrawing acyl groups appeared to make the retro-Michael addition more favorable, 
hence the side reactions and low yields. Using more electron donating groups like benzyl as the 
hydroxyl protecting groups might help. Per-O-benzylated compound 10 (Scheme 3) has been made 
previously from epimerization under basic conditions of the corresponding α-ketone,33 which was 
obtained via oxymercuration followed by oxidation of α-allyl-C-galactoside. Benzylation of 4 seems 
to be a much more straightforward route to obtain 10. However, this perbenzylation reaction turned 
out to be more problematic than expected. Direct benzylation of the ketone 5a using NaH/BnBr gave 
complex mixtures, presumably due to ring-opening under basic conditions. Similar issues were 
reported on the glucose ketone substrate.40 Using NaOH/BnBr in THF with a phase transfer reagent 
did not give much improvement. We therefore decided to protect the ketone first, although this 
strategy would add undesirable additional steps to the sequence. Using ethylene glycol, PTSA and 
compound 4 in a mixture of acetonitrile/benzene did not yield the ketal, possibly due to the poor 
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solubility of the initial ketone. Interestingly, the glucose analog could react under similar conditions.40 
The attempt at protecting ketone 4 in methanol as a dimethyl ketal also did not proceed well. 
 
Finally the per-acetylated ketone 5a was protected to form ketal 7 using ethylene glycol and 
pyridinium p-toluenesulfonate (PPTS) as a catalyst40 (using TsOH as catalyst led to the 
decomposition of the substrate) in benzene in 3 h (Scheme 3). Deacetylation, followed by benzylation 
and ketal removal gave the per-benzyl substituted ketone 10 in 81% overall yield over 4 steps 
(Scheme 3). 
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Scheme 3. Synthesis of IBCG via a per-benzylated ketone. 
The Wittig reaction on the per-benzyl substituted ketone 10 proceeded better than on the per-acetyl 
substituted ketone. Using two equivalents each of Wittig salt and t-BuOK, the alkene 11 was formed 
in 42% yield. When slightly excess base was used, the yield of 11 dropped significantly. 
Hydrogenation of 11 gave IBCG 1 in 94% yield. This route yields IBCG from galactose in 8 steps in 
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30% overall yield. However, this route is still not very satisfactory, given the low yields and long step 
count.  
 
To further improve the synthesis route, further fine-tuning of the electronic effects was needed. 
Ideally, the Wittig substrate would be even more electron rich than the perbenzylated substrate 
employed. Several examples of protected O-glycosides using silyl groups as temporary protecting 
groups have been reported.41-45 The per-O-TMS protected substrates are readily prepared on large 
scale, and the ease of deprotection makes them very convenient to use. However, the current studies 
mainly focused on utilizing the improved solubility of the per-O-silylated substrate in organic 
solvents and on the Lewis acid-catalyzed reactions of silyl protected hydroxyl groups. In the latter 
case, the silyl groups were used as a proton surrogate.  Only a few studies used per-O-silylation as a 
method to change the electronic properties of the parent compound. For example, Gervay-Hague’s 
studies of glycosyl iodides,42,46,47 showed that the per-O-trimethlysilyl glycosyl iodides were more 
reactive than per-O-benzyl donors in glycosylation reactions. We proposed that by per-silylation, we 
might be able to circumvent the troublesome side reaction encountered in the Wittig reaction by 
making the ketone substrate more electron rich.  
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Scheme 4. Revised synthesis of IBCG using TMS as a protecting group. 
The per-TMS-silylation of 4 was tested under different conditions, including using pyridine, 
Et3N/DMF, and Et3N/CH2Cl2. Fortunately, it was found out that using crude 4 containing large 
amounts of NaOAc from the condensation did not interfere with the per-silylation reaction. Since 
ketone 12 has good solubility in hexanes, it could be extracted from the crude mixture directly to give 
pure product, leaving Et3N•HCl and NaOAc as insoluble salts. The reaction in Et3N/CH2Cl2 is slower 
than in DMF or pyridine, but the work-up process is easier. The Wittig reaction on 12 proceeded 
surprisingly well and gave the methylenation product 13 in high yield. After solvent removal, the 
crude mixture of the Wittig reaction containing 13 and triphenylphosphine oxide was redissolved in 
methanol/water and subjected to acidic silyl group cleavage using Dowex 50X8 (H+ form). After 
filtration and solvent removal, the crude product was redissolved in water and extracted with EtOAc 
to remove triphenylphosphine oxide and provide an aqueous solution of alkene 14. However, we 
experienced problems in the hydrogenation of this alkene. Unlike alkenes 6a or 11, the hydrogenation 
of 14 proceeded very slowly; the reaction required more than 48 h to go to completion under 1000 psi 
of H2. We reasoned that even though the 1H NMR of crude 14 seemed pure, trace amounts of 
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phosphorus-containing compounds left due to the large amount of Wittig salt used in the 
methylenation reaction might be interfering with the hydrogenation reaction. Therefore, the work-up 
procedure for the Wittig reaction was revisited. Most of the solvent was removed, and then hexane 
was added to remove most of the triphenylphosphine oxide by filtration. The resulting filtrate was 
concentrated, and the residue was dissolved in methanol/water and subjected to Dowex 50X8 to 
provide 14. After EtOAc/water extraction, the hydrogenation of 14 in ethanol took less than 1 h under 
high pressure and could be done under atmospheric pressures of H2 in 8 h to give 1 as a white solid. 
The 1H NMR of crude 1 showed that it was sufficiently pure and no further purification was needed. 
By using this modified route, we were able to perform a larger scale synthesis of IBCG from 10.00 g 
of galactose 2 (55.5 mmol), and obtained 9.90 g of 1 (45.4 mmol) in 81% yield over 5 steps (95% 
average yield per step) without any chromatography purification (Scheme 4). The large difference in 
the Wittig reaction using a per-O-benzylated substrate versus a per-O-silylated substrate shows the 
significant affect a change in electronic properties of the substrate can make in reaction yields.  
 
Now that a route was available to readily provide the multigram quantities of IBCG necessary to 
carry out animal studies, the utility of the compound in inducing gene expression in mammalian 
rather than bacterial cells needed to be ascertained. Mammalian cells such as HeLa cells have less 
diverse metabolic capabilities compared to bacterial systems and therefore decomposition of IPTG is 
less of an issue on the time scale of the experiments. Such issues become problematic when whole 
animal experiments are envisioned. However, the permeability of IBCG compared to IPTG was 
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unclear. In other words, would IBCG reach the site of action to induce gene expression? To test if 
IBCG will work as a lac operon inducer in mammalian cells in the induction of protein expression, 
assays of repressor activity utilizing the expression of fluorescent proteins in HeLa cells were 
preformed (Figure 3). To this end we cloned a construct placing the far-red fluorescent protein 
Neptune behind the LacI-repressible Chicken –actin CMV enhancer promoter sequences (CAGop)48 
in between recognition sites for the Sleeping Beauty transposase.49 As control, we used a Sleeping 
Beauty transposon containing green fluorescent protein (GFP) expressed from the original CAG 
promoter. HeLa cells were made transgenic for these constructs by co-transfection with a plasmid 
encoding SB100x,50 an enhanced version of the Sleeping Beauty transposase. HeLa cells expressing a 
fixed ration between Neptune and GFP were purified by cell sorting. We then used SB100x-mediated 
transposition to make the CAGop-Neptune/CAG-GFP HeLa cells transgenic for LacI (Figure 3A). 
Expression of lacI resulted in an over 40-fold repression of Neptune expression, while leaving the 
GFP levels unaltered (data not shown). The addition of the inducers IPTG or IBCG resulted in an 
increase of Neptune expression over time. Our results showed that IBCG was very well tolerated by 
HeLa cells at 1 mM concentration and was comparable to IPTG in inducing gene expression (Figure 
3B). 
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Figure 3. A) Scheme of promoters used to evaluate the induction capabilities of IPTG and IBCG in HeLa 
cells. B) Neptune expression from the CAGop promoter was normalized to GFP expression and to 
maximal Neptune expression in absence of LacI. The relative Neptune expression after induction with 
IPTG or IBCG is shown. Fluorescence intensities were determined by flow cytometry. Data shown are 
the average of two independent experiments. 
 
Conclusion 
 
In summary, a convenient route for the synthesis IBCG (1) from galactose was developed that 
includes as key steps a microwave-assisted synthesis of an intermediate β-C-glycoside and a Wittig 
reaction on a per-O-silylated base-sensitive substrate. Microwave-assisted conditions could 
significantly reduce the reaction time for the β-C-glycoside formation and also easily allows the 
reaction to be run at much higher concentrations. The large yield differences of the Wittig reaction on 
per-acetyl, per-benzyl, and per-silyl-protected substrates further demonstrate the profound impact of 
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protecting groups. TMS groups cannot only be used to improve solubility of poly-hydroxyl bearing 
compounds and react as a proton surrogate under Lewis acid-promoted conditions, they can also 
change the electronic properties of the substrate greatly. The Wittig reaction on the per-silyl 
substituted β-C-glycosidic ketones provides a new and efficient way of synthesizing novel 
β-C-glycoside analogs. In addition, the developed route can produce material sufficiently pure for 
biological studies without a single chromatographic separation. Finally, IBCG has been shown 
capable of inducing lac operon promoters for induction of gene expression in not only bacterial 
systems, but also in mammalian cells.  This improved route amenable to larger scale production of 
IBCG coupled with the promising cell-based studies now sets the stage for testing of this system in 
animal studies.   
 
Experiment section 
 
General Experimental Methods: Reactions were performed using flame-dried glassware under argon 
using anhydrous solvents unless otherwise noted. Microwave-assisted reactions were performed using a 
CEM Discover® Microwave system. Thin layer chromatography (TLC) was performed using glass-backed 
silica gel plates w/UV254. Visualization of TLC plates was performed by UV light and 5% sulfuric 
acid/ethanol. NMR spectra were recorded on a 400 MHz for 1H (100 MHz for 13C) spectrometer. 1H NMR 
and 13C NMR taken in CDCl3 spectra were referenced to the solvent peak at 7.260 ppm (1H) and 77.0 ppm 
(13C). Due to the severe overlap of 13C signals from aromatic carbons in the range of 129 – 127 ppm 
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in the 13C NMR of the tetra-benzyl protected compounds 9 and 11, only clearly discernable peaks 
from aromatic carbons on the benzyl groups are reported. The assignments of 1H NMR peaks were 
made primarily from 2D 1H-1H COSY and edited 1H-13C HSQC spectra. High resolution mass spectra 
(HRMS, ESI mode) were obtained using a Q-TOF LC/MS.  
 
1-C-(β-D-Galactopyranosyl)-propan-2-one (4). To a round bottom flask was added 
D-galactopyranose 2 (4.00 g, 22.2 mmol), NaHCO3 (7.40 g, 88.8 mmol), water (20 mL) and THF (10 
mL). 2, 4-Pentanedione 3 (4.6 mL, 44 mmol, freshly distilled) was added; the reaction started to turn 
light yellow. The flask was attached to a condenser and put into a microwave reactor. The 
temperature of the reaction was measured using the external sensor equipped in the microwave 
reactor. The reaction was heated to reflux at 70-75 °C at 80 W with stirring. After 30 min, 1H NMR 
spectrum showed that all the galactose had been consumed, and the top layer was separated and 
discarded. The remaining solution was extracted with EtOAc (20 mL); then the undissolved solid was 
returned to the flask, the aqueous solution was heated at 75 °C at 80 W for another 30 min, and then 
gradually heated to 90 °C for 3 h, then to 100 °C for another 2 h. The 1H NMR spectrum indicated 
that the reaction was finished, and the yellow/orange reaction mixture was cooled and concentrated 
under reduced pressure at room temperature. Methanol/ethyl acetate (1:1) (100 mL) was added to the 
mixture to dissolve the product, and then the remaining salt was removed by filtration. The solution 
was concentrated to give a crude product of 4 containing NaOAc, which could be used directly in the 
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following experiments. The crude product was passed through a short column using methanol/ethyl 
acetate 1:4 as eluting solvent, and recrystallization using methanol/ethyl acetate gave 4 as white 
crystals (3.21 g, 14.5 mmol). The mother liquor was concentrated and purified by silica gel column 
chromatography to give additional 4 (1.02 g, 4.6 mmol). 1H NMR data matches data reported in the 
literature.28  
The reaction was also performed on a 10.00 g scale and on a 20.00 g scale of galactose at 
concentrations of 2.4 M and 4.8 M respectively.   
O
AcO
AcO
OAcOAc
O O
 
1-C-(2, 3, 4, 6-Tetra-O-acetyl-β-D-galactopyranosyl)-propan-2-one ethylene ketal (7). To a 
solution of 5a (500 mg, 1.30 mmol) in benzene (15 mL) was added ethylene glycol (0.145 mL, 2.60 
mmol), and pyridinium p-toluenesulfonate (50 mg, 0.2 mmol). The reaction was heated to reflux with 
a Dean-Stark apparatus. After 3 h, 1H NMR indicated completion of the reaction. The solvent was 
removed under reduced pressure. The resulting residue was dissolved in dichloromethane, washed 
with NaHCO3 (aq), and then dried over Na2SO4. Solvents were removed under reduced pressure to 
provide 7 (550 mg, 1.27 mmol) as a white foam that was used without further purification.  
1H NMR (400 MHz, CDCl3) δ 5.40 (dd, J = 1.2, 3.3 Hz, 1H, H-4), 5.05 (t, J = 9.7 Hz, 1H, H-2), 5.02 
(dt, J = 3.3, 9.7 Hz, 1H, H-3), 4.13 (dd, J = 7.2, 11.3 Hz, 1H, H-6a), 4.05 (dd, J = 6.1, 11.3 Hz, 1H, 
H-6b), 3.98-3.82 (m, 5H, -OCH2CH2O-, H-5), 3.64 (dt, J = 1.6, 9,3 Hz, 1H, H-1), 2.14 (s, 3H, OAc), 
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2.04 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.96 (s, 3H, OAc), 1.91 (dd, J = 8.5, 14.7 Hz, 1H, H-1’a), 1.75 
(dd, J = 1.6, 14.7 Hz, 1H, H-1’b), 1.37 (s, 3H, CH3) 
13C NMR (100 MHz, CDCl3) δ 170.2, 170.1, 169.9, 169.7, 108.4, 75.1, 74.0, 72.1, 68.9, 67.7, 64.4, 
64.3, 61.8, 39.9, 24.5, 20.6, 20.53, 20.49, 20.42. 
HRMS(ESI): calcd for C19H28NaO11 [M+Na]+: 455.1524, found 455.1517. 
O
BnO
BnO
OBnOBn
O O
 
1-C-(2, 3, 4, 6-Tetra-O-benzyl-β-D-galactopyranosyl)-propan-2-one ethylene ketal (9). 
Compound 7 (550 mg, 1.27 mmol) was dissolved in CH3OH (15 mL), cooled to 0 °C, and treated 
with Na (23 mg, 1.0 mmol). After 2 h, the solvent was removed under reduced pressure to yield crude 
8. The crude product was dissolved in DMF (10 mL) and cooled to 0 °C. NaH (262 mg, 60%, 7.8 
mmol) was added and the reaction was stirred for 30 min. Benzyl bromide (0.8 mL) was added, and 
the reaction was stirred at room temperature for 6 h before methanol (1 mL) was added. The mixture 
was extracted with EtOAc, washed with water, and dried over Na2SO4. The solvents were removed 
under reduced pressure to yield 9 as a syrup that was used without further purification. 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.29 (m, 20H, PhH), 5.05 (d, J = 11.2 Hz, 1H, -OCHPh), 5.01 
(d, J = 11.8 Hz, 1H, -OCHPh), 4.82 (d, J = 11.8 Hz, 1H, -OCHPh), 4.74 (d, J = 11.8 Hz, 1H, 
-OCHPh), 4.73 – 4.67 ( m, 2H, -CH2Ph), 4.58 (d, J = 11.9 Hz, 1H, -OCHPh), 4.53 (d, J = 11.9 Hz, 1H, 
-OCHPh), 4.06 (d, J = 2.5 Hz,, H-4), 3.99 – 3.83 ( m, 4H, -OCH2CH2O-), 3.75 – 3.65 (m, 2H, H-2, 
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H-3), 3.64 – 3.59 (m, 3H, H-6a, H-6b, H-5), 3.52 (t, J = 9.0 Hz, 1H, H-1), 2.19 (d, J = 15.5 Hz, 
1H,H-1’a), 1.87 (dd, J = 9.0, 15.5 Hz, 1H,H-1’b), 1.48 (s, 3H, CH3) 
13C NMR (100 MHz, CDCl3) δ 138.8, 138.6, 138.4, 138.1, 128.6, 128.49, 128.45, 128.40, 128.37, 
128.28, 127.98, 127.91, 127.78, 127.70, 127.67, 127.65, 127.60, 126.99, 109.4, 85.1, 78.6, 77.0, 
76.87, 76.83, 73.8, 73.5, 72.4, 69.2, 65.3, 64.39, 64.35, 39.6, 24.7. 
HRMS(ESI): calcd for C39H44NaO7 [M+Na]+: 647.2979, found 647.2987. 
 
1-C-(2, 3, 4, 6-tetra-O-benzyl-β-D-galactopyranosyl)-propan-2-one (10). Crude benzyl ketal 9 was 
dissolved in CH2Cl2/TFA/H2O (10:1:0.1, 10 mL total) and the reaction was stirred for 30 min. The 
reaction was diluted with CH2Cl2, washed with water and saturated NaHCO3 solution, and dried over 
Na2SO4. Silica gel chromatography purification using hexanes/ethyl acetate 5:1 to 3:1 afforded the 
product as a white solid (675 mg, 1.16 mmol, 89.2% for 4 steps). The 1H and 13CNMR of 10 spectra 
matches previously reported data.33  
 
2-(1-C-(2, 3, 4, 6-Tetra-O-benzyl-β-D-galactopyranosyl) methyl)-propene (11). To a flask 
containing PPh3CH3Br (830 mg, 2.32 mmol) and THF (5 mL) was added tBuOK (1 M in THF, 2.9 
mL, 2.9 mmol) at 0 °C and the reaction was stirred for 30 min. A solution of 10 (675 mg, 1.16 mmol) 
in THF (7 mL) was added dropwise into the reaction, and the mixture was stirred for 8 h. A saturated 
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NH4Cl solution (10 mL) was added to quench the reaction, and the reaction was extracted with 
EtOAc, washed with water, and dried over Na2SO4. Solvents were removed under reduced pressure, 
and silica gel column purification using hexanes/ethyl acetate 6:1 to 4:1 offered the product 11 (281 
mg, 0.49 mmol, 42%). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 20H, PhH), 4.96 (d, J = 11.2 Hz, 1H, -OCHPh), 4.95 
(d, J = 11.6 Hz, 1H, -OCHPh), 4.77 (m, 2H, C=CH2), 4.76 (d, J = 12.9 Hz, 1H, -OCHPh), 4.68 (d, J = 
12.9 Hz, 1H, -OCHPh), 4.66 (d, J = 11.2 Hz, 1H, -OCHPh), 4.64 (d, J = 11.6 Hz, 1H, -OCHPh), 
4.45(ABq, J = 11.8 Hz, 2H, -OCH2Ph), 3.99 (m, 1H, H-4), 3.67 (t, 1H, J = 8.8  Hz, H-2), 3.63(dd, 
1H, J = 2.5, 8.8 Hz, H-3), 3.59-3.48 (m, 3H, H-6a, H-6b, H-5), 3.41 (dt, J = 1.6, 9.4 Hz, H-1), 2.57 ( d, 
1H, J = 14.6 Hz, H-1’a), 2.25 (dd, 1H, J = 9.4, 14.6 Hz, H-1’b), 1.76 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 143.1, 138.8, 138.5, 138.4, 138.1, 128.42, 128.36, 128.19, 128.14, 
128.02, 127.85, 127.68, 127.65, 127.62, 127.55, 127.53, 112.1, 85.0, 78.9, 78.7, 77.2, 75.4, 74.4, 73.8, 
73.5, 72.3, 69.2, 39.8, 23.0. 
HRMS(ESI): calcd for C38H42NaO5 [M+Na]+: 601.2924, found 601.2939. 
 
Isobutyl-C-galactoside (1) by the benzyl ketone route: To a solution of 11 (281 mg, 0.49 mmol) in 
methanol was added 10% Pd/C (50 mg), and the reaction was stirred under H2 for 8 h. The reaction 
was filtered and concentrated to give 1 as a hygroscopic white foam (101 mg, 0.46 mmol, 94%). The 
1H and 13C NMR data of 1 matches the reported.16  
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1-C-(2, 3, 4, 6-Tetra-O-trimethylsilyl-β-D-galactopyranosyl)-propan-2-one (12). Crude 4 (22.60 g) 
was synthesized from galactose (10.00 g, 55.5 mmol), NaHCO3 (18.65 g, 222 mmol), and 
2,4-pen-tanedione 3 (11.45 mL, 111 mmol, freshly distilled) in water (50 mL) and THF (25 mL) 
according to the above procedure. The crude product obtained from methanol/ethyl acetate extraction 
contained ca. 10.40 g NaOAc as indicated by 1H NMR and used directly.  
To a round bottom flask containing crude 4 was added CH2Cl2 (100 mL), and Et3N (263 mL, 1.89 
mol). The reaction was cooled to 0 °C, and freshly distilled chlorotrimethylsilane (48.3 mL, 380 
mmol) was added dropwise. The reaction was stirred at ambient temperature for 16 h before the 
solvents were removed at reduced pressure. Hexanes were added to the mixture, and the solution was 
filtered through Celite, washed with hexanes, and concentrated to yield crude 12 as a yellow liquid 
that was used without further purification. 
1H NMR (400 MHz, CDCl3) δ 3.88( d, J = 2.3 Hz, 1H, H-4), 3.65 – 3.60 (m, 2H, H-1, H-5), 3.57 
-3.47 (m, 2H, H-6a, H-6b), 3.45-3.38 (m, 2H, H-2, H-3), 2.68 (dd, J = 1.8, 15.6 Hz, 1H, H-1’a), 2.58 
(dd, J = 7.0, 15.6 Hz, 1H, H-1’b), 2.18 (s, 3H, CH3), 0.17 (s, 9H, TMS), 0.13 (s, 9H, TMS),0.128 (s, 
9H, TMS), 0.08 (s, 9H, TMS) 
13C NMR (101 MHz, CDCl3) δ 208.07, 79.43, 78.16, 77.23, 72.68, 71.84, 61.49, 46.88, 31.27, 1.50, 
1.26, 0.97, 0.03. 
HRMS(ESI) calcd for C21H48NaO6Si4 [M+Na]+ 531.2420 found 531.2408 
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2-(1-C-β-D-Galactopyranosyl methyl)-propene (14). To a round bottom flask was added anhydrous 
PPh3CH3Br (29.80 g, 83.4 mmol) and tBuOK (9.36 g, 83.4 mmol). The reaction was cooled to 0 °C 
and THF (200 mL) was added via cannula. The resulting yellow solution was stirred at 0 °C for 5 min 
and warmed up to room temperature in 25 min. The solution was stirred at room temperature for 
another 30 min and re-cooled to 0 °C. A solution of crude 12 in THF (30 mL) was added dropwise to 
the reaction over 10 min. After stirring at 0 °C for another 10 min, the ice bath was removed and the 
reaction was stirred for 90 min. Acetone (5 mL) was added, the reaction was partially concentrated to 
slurry, diluted with hexanes and filtered. The filtrate was concentrated to yield crude 13 as a yellow 
liquid that was used without purification.  
The crude product 13 was dissolved in methanol/water (120 mL/10 mL). Dowex 50X8 (H+ form, 
10.00 g) was added, and the reaction was stirred for 25 min, filtered, and concentrated under reduced 
pressure. The resulting residue was suspended in water (250 mL) and extracted with ethyl acetate (3 x 
100 mL). The aqueous layer was concentrated to give crude 14 as a pale yellow liquid that was used 
without further purification. 
1H NMR (400 MHz, D2O) δ 4.70 (d, 2H, J = 9.8 Hz, C=CH2), 3.79 (d, 1H, J = 3.3 Hz, H-4), 3.58 – 
3.48 (m, 2H, H-6ab), 3.48 – 3.41 (m, 2H, H-3, H-5), 3.31 – 3.26 (m, 2H, H-1, H-2), 2.44 (d, J = 15.7 
Hz, 1H, H-1’a), 2.03 (dd, J = 9.0, 15.7 Hz, H-1’b), 1.61 (s, 3H, CH3). 
13C NMR (100 MHz, D2O) δ 143.9, 111.9, 78.5, 77.6, 73.9, 71.0, 70.0, 61.2, 39.2, 21.6. 
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HRMS(ESI): calcd for C20H36NaO10 [2M+Na]+:459.2201, found 459.2201. 
 
Isobutyl-C-galactoside (1) from the per-O-silylated ketone. Crude 14 was dissolved in ethanol 
(100 mL) and a slurry of 10% Pd/C (950 mg) in water (5 mL) was added. The reaction was stirred in 
a Parr apparatus under H2 at 1000 psi for 1 h. The pressure was dropped to 800 psi and then stayed 
stable, indicating the hydrogenation had finished. The mixture was filtered and concentrated to give 1 
as a white solid (9.90 g, 45.4 mmol, 81% for 5 steps). The 1H and 13CNMR of 1 spectra matches 
previously reported data.16 
Induction of lac operon using IBCG in Hela cells.  
HeLa cells were cultured in DMEM (Dubelcco’s Modified Eagle Medium) supplemented with 10% 
FCS (fetal calf serum) and penicillin/streptomycin at 37 °C with 5% CO2. A detailed description of 
the construct cloning and generation of transgenic cells will be reported elsewhere. For the induction 
1 mM IPTG (Fermentas GmbH) or 1 mM IBCG (both dissolved in water) were added. At the 
indicated time points HeLa cells were trypsinized and acquired on a FACSCanto II (BD Biosciences). 
Dead cells were excluded from the analysis by staining with 7-aminoactinomyxin (7-AAD). Data 
analysis was conducted with FlowJo software (Tree Star). For calculating the normalized Neptune 
values, mean fluorescent Neptune intensities were divided by the mean fluorescent intensities of GFP 
in the same cells. This value was then divided by the Neptune to GFP ratio in 
CAGop-Neptune/CAG-GFP HeLa cells lacking lacI and multiplied by 100.  
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CHPATER 5 
Studies Towards the Automated Synthesis of Hyaluronic Acid Fragments 
 
Abstract 
 
Hyaluronic acid is repeating polymer of two sugar building blocks that serves a variety of biological 
functions and is structurally the simplest of the larger class of glycosaminoglycans. To synthesize 
hyaluronic acid oligosaccharide fragments for applications such as mass spectrometry and for 
biological assays, six different synthetic strategies were studied and compared. To overcome the 
severely reduced reactivity due to the strong electron withdrawing properties of the uronic acid 
building block—one of the major difficulties in glycosaminoglycan synthesis—a new method was 
developed to install benzyl groups at the 4-,6- positions on the trichloroacetyl-protected glucosamine 
building block and at the 2-,3- positions on glucuronic acid. This strategy allowed the synthesis of the 
more electron rich hyaluronic disaccharide building blocks that provided the best results in 
subsequent glycosylation reactions of the disaccharide unit. Using fluorous-assisted synthesis and 
conditions amenable to solution-phase automated synthesis, a tetrasaccharide fragment of hyaluronic 
acid was successfully synthesized as the first step towards the automated synthesis of fragments of 
this size and longer. 
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Introduction 
 
Hyaluronic acid (HA) is a linear, unbranched repeating polymer of N-acetyl glucosamine and 
D-glucuronic acid. It is the only member of the glycosaminoglycan family that is not sulfated and 
therefore is a relatively simple structure. Hyaluronic acid is distributed widely throughout connective, 
epithelial, and neural tissues and is involved with myriad functions including cellular proliferation, 
cell–cell recognition, and cell migration.1,2 As the main function of this glycosaminoglycan family 
member was believed to be as a polymer for lubrication of joints, HA has received relatively little 
attention for years. However, more recently biological functions of shorter hyaluronic acid fragments 
are being discovered.3 The degradation products of hyaluronic acid, small oligosaccharides with 
varying lengths, exhibit pro-angiogenic properties.4 Short fragments of hyaluronic acid can induce 
inflammatory responses in macrophages and dendritic cells in tissue injury and in skin transplant 
rejection.5 Hyaluronic acid is also the main component of the capsular polysaccharide of Group A 
streptococci (Streptococcus pyogenes or GAS).6 Abundant production of hyaluronic acid in GAS is a 
key virulence determinant and is related with severe GAS infections.7,8 Low molecular weight 
hyaluronic acid is now being studied as a treatment and prevention of infection and disease caused by 
group A and group C Streptococci.9 
 
Given the increasing biological interest in HA, there have been many reports on the synthesis of 
hyaluronic acid fragment;10 those syntheses mainly differ in the choice of protecting groups 
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(especially on the amino group), the choice of anomeric activating group and the strategy of the 
oxidation.11-21 In recent years, great advancements were made in this area. For example, van der 
Marel and coworkers have reported the synthesis of the tri-, penta-, and heptamer of hyaluronic 
acid.22,23 Huang and coworkers have reported the synthesis of a dodecamer of hyaluronic acid.10,24,25 
Nonetheless, it is still a daunting task to perform the synthesis to obtain different lengths of 
hyaluronic acid fragments; ideally a strategy amenable to automation could be developed to eliminate 
some of the tedium in producing this class of glycosaminoglycans to accelerate biological studies.  
 
The major difficulty in the synthesis of hyaluronic acid is also the biggest issue in the synthesis of 
glycosaminoglycans.26-28 The uronic acid residues in the glycosaminoglycan structure have very low 
chemical relativities. The strong electron withdrawing nature of the uronic acid makes the building 
block relatively electron deficient, making it both a weak glycosyl donor and also a weak glycosyl 
acceptor, especially when functioning as a donor at the 4-position with a uronic acid at the 6-position. 
At the monosaccharide stage, the low reactivity issue is not so severe; however, the reactivity 
becomes a serious issue when the oligosaccharides get longer. As the chain lengthens, the reactivity of 
the donor and acceptor are reduced even more. The synthesis of HA fragments also requires a 
sophisticated protecting group strategy to achieve the desired coupling patterns.   
 
In addition to the challenges of finding a suitable protecting group pattern for each building block, a 
second challenge is finding methods to automate the process of stringing together the building blocks. 
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Recently the Pohl group has developed an automated solution-phase synthesis platform based in part 
on fluorous solid-phase extractions.29,30 This new automation platform provides a promising new way 
of synthesizing oligosaccharides without the use of large excesses of building blocks at each coupling 
stage as is required for biphasic processes such as solid-phase synthesis. The fluorous tag used to aid 
in the automated purification scheme can also function as the immobilization tail for fluorous 
microarrays,31-34 providing a convenient way of detecting the binding of sugars with biomolecules 
such as lectins. However, the existing methods for the synthesis of hyaluronic acid are not suitable for 
the automated solution-phase synthesis. Herein we report studies toward developing a simple and 
efficient strategy which is amenable to automation for the solution and fluorous-assisted synthesis of 
HA fragments.  
 
Results and discussion 
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Scheme 1 The retrosynthesis of hyaluronic acid 
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Due to the polymeric nature of hyaluronic acid, we decided to use a disaccharide building block—the 
basic repeating unit of the polymer—approach in the synthesis (Scheme 1). Both pre-oxidation and 
post-oxidation have been used in the synthesis of hyaluronic acids. It is reported that post-oxidation 
sometimes causes problems on larger oligosaccharide,24 so we first chose to use pre-oxidation at the 
monosaccharide stage. To alleviate the low reactivity problems caused by the strong electron 
withdrawing group by the uronic acid, glucosamine was put at the reducing end of the disaccharide 
building block. This way, the disaccharide donor could have better reactivity in glycosylation 
reactions. Both literature and our previous studies indicated that phthalamide group as N-protecting 
group had problems in removal,10 so trichloroacetyl group was used as the protecting group for the 
amino group. We have use thiol phenol group as the temporary protecting group at the anomeric 
position of the disaccharide, but it suffered from low yield during removal when forming the 
disaccharide hemiacetal. After a survey of different protecting groups for anomeric positions, allyl 
group was chosen as the temporary protecting group for glucosamine at the anomeric position for its 
stability under various conditions and also for it could be removed under mild conditions in high yield. 
A transition metal catalyzed isomerization followed by mild hydrolysis should provide the 
hemiacetal.  
 
The glucuronic trichloroacetimidate donor 1 was synthesized from glucose in 10 steps via a modified 
route from literature procedure.35,36 TBS group was chosen as the temporary protecting group for 4 
position on the glucuronic acid building block, and the 2, 3 position were protected as benzoyl esters. 
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The allyl NHTCA-glucosamine donor 2 was synthesized from glucosamine in 6 steps.37 4,6 position 
of the glucosamine building block was protected as benzylidene acetal. The glycosylation between 
the glucuronic acid donor 1 and the glucosamine acceptor 2 in the presence of TMSOTf as a promoter 
in CH2Cl2 worked smoothly to give the disaccharide 3 with allyl group at the anomeric position, 
through an orthoester intermediate, in 90% yield. (Scheme 2) 
 
Scheme 2 Synthesis of disaccharide building block 3. 
 
However, we encountered problems when trying to remove the anomeric allyl protecting group on 3 
to synthesis the disaccharide donor. Route catalyst for the isomerization of the alkene didn’t work. 
The widely used  [Ir(COD)(PMePh2)2]PF6 catalyst38 gave a very slow reaction, which only gave 
~3% conversion after 7 days. Wilkinson's catalyst and Pd(PPh3)4 gave no isomerization reaction at all. 
(Scheme 3)  
 
Scheme 3 Isomerization problem with the benzylidene-protected disaccharide 3 
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This was quite an unexpected situation. In Hsieh-Wilson’s synthesis of chondroitin sulfates,35 they 
had encountered a similar situation when trying to remove the anomeric allyl on a trichloroacetyl 
protected galactosamine monosaccharide building block. They proposed that the problem encountered 
in the isomerization was from the trichloroacetyl group, because the allyl group on a NHAc substrate 
instead of on the NHTCA substrate isomerized without any problem. In their study, they finally used 
the Grubbs’ second-generation catalyst to perform the isomerization. We found out that using Grubbs’ 
catalyst gave very unreliable results. The conversion we achieved ranged from 0% to 95%, depending 
on different batches of catalyst used. Grubbs had reported the actual active catalyst for the alkene 
isomerization reaction was a decomposition product of Grubbs’ catalyst,39,40 and we thought the 
irreproducibility of this reaction might had been caused by the batch and age differences of the 
Grubbs’ catalyst.  
 
Another choice to remove the allyl group is to use stoichiometric metal reagents. In Sleeman and 
Brãse’s synthesis of hyaluronic acid,37 they used 2 eq of PdCl2 in neat acetic acid to cleave the allyl 
group. Given that most of the catalytic version of the alkene isomerization reaction only requires less 
than 1mol% catalyst, apparently the deallylation on trichloroacetyl protected amino sugars was still a 
problem.  
 
Before switching to other anomeric protecting group like silyl groups, we tried to find out why the 
catalytic alkene isomerization wouldn’t work on the NHTCA substrate. Finally, the 4, 6 benzylidene 
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acetal on the glucosamine building block caught our attention. Benzylidene acetal is one of the most 
common protecting groups used in carbohydrate chemistry. 4, 6-benzylidene would form a 
six-membered ring. Fused with glucose, the whole molecule would form a trans-decalin structure. 
This decalin structure provided a very rigid ring structure, a scaffold suitable to serve as metal ligand 
if proper groups were presented correctly. Indeed, in several cases, benzylidene protected 
carbohydrates-derived diarylphosphinites were used to as ligands for metal.4 In Hsieh-Wilson’s 
studies, they proved that trichloroacetyl group was involved with the isomerization problem. In our 
study, we found out that even though Iridium catalyzed reaction couldn’t give a useable conversion, 
there was still some conversion. Apparently the deactivation of the catalyst occurred in the reaction.  
 
Based on these examples, we reasoned that due to the presence of benzylidene on the glucosamine 
building block, the trichloroacetyl group and double bond were close with each other in space due to 
the rigid conformation.(Scheme 3) Both the rigid conformation led by the benzylidene and the 
presence of trichloroacetyl group could contribute to the binding. What exactly was the deactivating 
mechanism for the catalyst was unknown. If benzylidene could be removed, the hexose ring could flip 
freely, so the alkene and the trichloroacetyl group might not be in a pre-arranged configuration, the 
isomerization reaction might be able to work. And since 4, 6- dibenzyl group would increase the 
electron density of the ring, the isomerization could be benefited from the increased electron density.  
 
To test this hypothesis, we decide to remove the benzylidene on the glucosamine building block and 
    113
use benzyl groups on the 4 and 6 positions instead. However, looking into the literature of 
carbohydrate chemistry, there were very few examples with 4, 6 dibenzyl protecting groups on a 
trichloroacetyl protected 2-amion sugar. Even though the 4, 6-dibenzyl protection was widely used on 
the 2-azido glucosamine building blocks, it was rarely used on trichloroacetyl protected glucosamine. 
Apparently synthesizing 4, 6-dibenzyl trichloroacetyl protected glucosamine was non trivial at all 
because of the base sensitivity of trichloroacetyl group. Benzylation of the 3-OH on the 
trichloroacetyl protected glucosamine had been achieved using NaH/BnBr at low temperatures; 
however, using the routine conditions to benzylate the 4, 6 position would cleave the trichloroacetyl 
group, and then the amine would be benzylated. A few existing examples either started with the 
2-azide protected glucosamine,41 or involved the selective opening of the benzylidene acetal to form a 
primary alcohol at 6 position,42 and then the 6-OH was benzylated under non-basic conditions like 
BnBr/Ag2O or 2-Benzyloxy-1-methylpyridinium triflate.43 However, none of these methods gave 
satisfactory results due to low yield of the benzylation step and the long step count.  
 
The ongoing chemistry being developed in our lab allowed the installation of benzyl groups 
selectively on the trichloroacetyl protected glycosamines by using benzyl bromide with sodium 
hydroxide powder in the presence of catalytic amount of 18-crown-6 in THF. Due the inherent steric 
hindrance, if the reaction was monitored carefully, on a 3,4, 6 triol, the 4, 6 position would be 
benzylated selectively, leaving 3-OH unprotected. No N-benzylation or trichloroacetyl group 
cleavage was detected in the reaction. The method was further modified in this study by using a large 
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excess of sodium hydroxide, and adding equal weight of 18-crown-6 as sodium hydroxide. These 
modifications greatly speed up the reaction. This method provide a way of synthesizing the desired 4, 
6-dibenzyl protected NHTCA protected glucosamine building block.  
 
Utilizing an InCl3 promoted glycosylation between easily prepared glycosyl bromide 6 and allyl 
alcohol,37 the allyl 3,4,6-tri acetyl 2-trichloroacetyl amino glucosamine 7 was obtained in high yield 
and could be used without purification. Under the BnBr/NaOH/18-crown-6 conditions, the desired 
4,6-dibenyl product was obtained in 57% yield along with small amount of tri-benzyl protected 
product in grams scale in a single step.(Scheme 4) If the routine benzylidene opening-non-basic 
benzylation route was used, it would have to use 6 steps with very low yield.   
 
 
Scheme 4 Synthesis of 4,6 dibenzyl NHTCA building block 8 using phase transfer conditions.  
 
The glycosylation between the new glucosamine acceptor 8 and the glucuronic donor 1 worked 
without problem to give the disaccharide in 93% yield. If our hypothesis is correct, the catalytic allyl 
isomerization reaction should work much better than the benzylidene protected version. As expected, 
the Ir catalyzed isomerization worked very nicely with full conversion in only 2 hours with 1% of 
    115
catalyst loading to give 10. The isomerized alkene 10 was hydrolyzed, and converted to the 
trichloroacetimidate donor 12. (Scheme 5) More detailed studies would be needed to elucidate the 
exact deactivating mechanism of the Iridium catalyst. This again proved that the protecting groups 
used in carbohydrate chemistry cannot be treated as inert groups severing solely protecting functions; 
they can also have a profound influence of the reactivity of the substrate.  
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Scheme 5 Ally deprotection and synthesis of the disaccharide donor. 
 
Fluorous tag 13 44 was used as the acceptor in the glycosylation reaction with donor 12 to install the 
fluorous handle for FSPE purification. The TBS group was removed by using HF/pyridine to afford 
the disaccharide acceptor 14 with the free 4-OH on the guluronic acid residue as the chain elongation 
point. However, we encountered problems in the [2+2] coupling reaction. The disaccharide acceptor 
15 and donor 12 were reacted in CH2Cl2 in the presence of catalytic amount of TMSOTf as promoter. 
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The majority of the imidate donor formed oxazoline byproduct 17; only trace amount of the desired 
tetrasaccharide 16 was formed. Using various conditions to improve the reaction failed. Failure of the 
glycosylation was attributed to the low reactivity of the acceptor, possibly due to the strong electron 
withdrawing ester group and disarming benzoyl groups.  
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Scheme 6 Attempt 2+2 glycosylation to synthesis the tetrasaccharide 
 
Since the electron withdrawing uronic acid lowered the reactivity of the acceptor, post oxidation 
strategy was probed in the synthesis of hyaluronic oligomers and analogs. Acceptor 8 was 
glycosylated with 4,6 benzylidene protected glucose donor 18, which was synthesized from glucose 
in 7 steps.45 The glycosylation gave the disaccharide 19, which was suitable for post-oxidation. The 
    117
allyl group on 19 was removed, and the anomeric hydroxyl was activated using 
N-phenyltrifluoroacetimidates.46 Trifluoroacetimidates could give the donor a little more 
stability.(Scheme 7) 
 
Scheme 7 Synthesis of disaccharide donor 21 used in post oxidation 
 
The coupling of the trifluo imidate 21 with fluorous tag as the acceptor proceeded smoothly at 0 °C in 
CH2Cl2 in 94% yield. After benzylidene removal, the primary hydroxyl at 6’ -position was protected 
with TBS group using TBSCl in CH2Cl2 in the presence of DMAP using Et3N as base.47 The reaction 
was very slow at room temperature, but we found out that the solution could be heated to 38 – 40 °C 
to speed up the reaction greatly. The [2 + 2] glycosylation was attempted under different conditions, 
however, only tract amount of the product was detected. In CH2Cl2 at 0 °C using 0.1 eq TMSOTf, the 
donor hydrolyzed very quickly. In toluene as the solvent, the donor was considerably more stable; 
however, the coupling was still not going. (Scheme 8) The reason of the failed glycosylation was 
attributed to the steric hindrance from the TBS group at the 6’ position and the dibenzoyl disarming 
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protecting groups. 
  
 
Scheme 8 Attempt synthesis of tetrasaccharide applying post-oxidation strategy 
 
When the donor and acceptor became larger, their reactivity decreased due to steric and electronic 
reasons. So increasing the reactivity, especially for uronic acid disaccharide acceptor had become 
more important. To increase the reactivity of the acceptor, more electron donating groups, instead of 
electron withdrawing groups should be installed on the glucuronic building block. In the former 
synthesis of hyaluronic acids, 2-Bz 3-Bn protected uronic acid building blocks had been used several 
times to improve the activity issue.25,48 We reasoned that if we could synthesize a disaccharide 
building block with a uronic acid residue bearing 2,3-dibenzyl protecting groups, the reactivity of the 
building block might be further improved. 2-Bz 3-Bn protected uronic acid building blocks could be 
synthesized fairly easily; however, synthesizing a disaccharide building block with a 2, 3-dibenzyl 
uronic acid residue was much more difficult and hadn’t been reported. The benzyl group cannot be 
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installed on the 2 position glucuronic building block prior to glycosylation since the neighboring 
group participation from acyl group was needed to form beta-glycosidic bond. Therefore, a method to 
do benzylation on the disaccharide had to be developed to synthesize the disaccharide building block 
with a 2,3-dibenzyl glucuronic acid residue.  
 
We decide to use the benzylation method which was applied earlier using BnBr/NaOH/18-crown-6 in 
THF in the synthesis of the 4,6 dibenzyl NHTCA building block to perform the 2, 3 dibenzylation on 
the disaccharide. In this case, oxidation after the formation of the benzyl ether at the disaccharide 
stage to the glucuronic acid had to be used.  
 
The 2, 3-dibenzoyl disaccharide was subject to the BnBr/NaOH/18-crown-6 benzylation reaction, and 
the 2, 3 –dibenzyl disaccharide was isolated in 68% yield, along with the 3-Bn product in 20% yield. 
(Scheme 9)  
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Scheme 9 Synthesis of the tetra benzyl substituted disaccharide. 
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With the desired tetra- benzyl substituted disaccharide in hand, the benzylidene was cleaved, primary 
alcohol oxidized into carboxylic acid using BAIB/TEMPO and protected as methyl ester using 
TMSCHN2. The 4-OH was then protected using TBS group with TBSOTf/Lutidine. Ally group was 
removed, and the disaccharide was transformed into the imidate donor in 3 steps. (Scheme 10) 
 
Scheme 10 Synthesis the disaccharide uronic acid donor 33. 
The imidate 33 was coupled with the fluorous tag. TBS group was removed with HF/py to furnish the 
disaccharide acceptor. (Scheme 11) In the initial experiment, the desired tetrasaccharide 35 was 
obtained in about 10% yield in CH2Cl2. The glycosylation on this tetra-benzyl disaccharide worked 
better than the previous di benzyl building blocks. Further optimization is still under way.  
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Scheme 11 Synthesis of the tetrasaccharide 35 using the tetra benzyl donor and acceptor 
 
Conclusion  
In the studies toward the synthesis of hyaluronic acid oligomers, several different protecting group 
patterns were tested. We encountered an unexpected problem when performing the transitional metal 
catalyzed terminal alkene isomerization on the benzylidene acetal protected NHTCA glucosamine. 
This problem was solved by changing the protection pattern to 4,6-dibenzyl. An optimized method 
was developed for the benzylation of NHTCA substrates. A tetra-benzyl substituted disaccharide 
building block was synthesized, and in the initial glycosylation studies, it showed better reactivity 
than the previously used di-benzoyl building blocks. The optimization of the glycosylation is the next 
work in this study.  
 
Experiment section  
General Methods: Reactions were performed using flame-dried glassware under argon using 
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anhydrous solvents unless otherwise noted. Ambient temperature in the laboratory was usually 20 °C. 
CH2Cl2 were distilled freshly from CaH2. Commercially available reagents were obtained from 
Aldrich, Fisher or TCI and used as received. 
 
Thin layer chromatography (TLC) was performed using glass backed Silica Gel HL TLC plates 
w/UV254 from Sorbent Technologies. Visualization of TLC plates was performed by UV, 5% sulfuric 
acid/ethanol, or p-anisaldehyde/ethanol. Silica gel flash chromatography was performed using silica 
gel (60 Å, 40-63 µm) from ZEOChem AG. 
 
NMR spectra were recorded on a Agilent-Varian 400MR (400 MHz for 1H, 101 MHz for 13C, 
376MHz for 19F, 162 MHz for 31P), Varian VXR400 (400 MHz for 1H, 101 MHz for 13C) , Bruker 
DRX400 (400 MHz for 1H, 101 MHz for 13C, 162 MHz for 31P), or Bruker AVIII600 (600 MHz for 
1H, 150 MHz for 13C, 564MHz for 19F). Chemical shifts are reported in parts per million (ppm) on the 
δ scale. 1H NMR and 13C NMR taken in CDCl3 was referenced the solvent peak at 7.260 ppm (1H) 
and 77.0 ppm (13C). The assignments of 1H NMR peaks were made primarily from 2D 1H-1H COSY 
and edited 1H-13C HSQC spectra. 1H-13C HMBC and 1H-1H TOCSY spectra were obtained to aid the 
assignments when necessary. 
 
High resolution mass spectra (HRMS, ESI mode) were obtained using an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS at Iowa State University. 
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General Procedure for Fluorous Solid Phase Extraction (FSPE): A FSPE cartridge (2 g. Fluorous 
Technologies, Inc., Pittsburgh, PA) was preconditioned by passing 80:20 MeOH:H2O (6 mL) through 
it under a vacuum.  The crude mixture was loaded onto the cartridge by using no more than 2 mL of 
a 9:1 DMF:H2O solution. The non-fluorous containing compounds were eluted by passing 6-8 mL of 
80:20 MeOH:H2O through the cartridge. The fluorous containing compounds were eluted by passing 
6-8 mL of MeOH through the cartridge. The MeOH wash was concentrated under reduced pressure 
and the residue was coevaporated with toluene to provide the fluorous compounds. The cartridge was 
regenerated by washing using acetone.  
 
General Procedure for Deallylation Reaction: Allyl protected compound (1 eq) and 
[Ir(COD)(PMePh2)2]PF6 catalyst (0.01 eq) was dissolved in THF (0.05 M) to give a pink solution. H2 
was applied to the reaction for 5 – 10 seconds until the reaction turned yellow. The H2 gas was purged 
out with Ar, then the reaction was stirred at room temperature until the NMR indicated the reaction 
was finished.  
 
The solvent was removed under reduced pressure, and the crude mixture was dissolved in 
acetone/water 5/1. HgCl2 (0.6 eq) and HgO (0.6 eq) was added, and the reaction was stirred until TLC 
indicated the reaction had finished. The reaction was filtered through Celite, concentrated, 
re-dissolved with CH2Cl2, washed with KI (aq), and dired with Na2SO4. The crude mixture was 
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purified using SGC.  
 
General Procedure for Benzylidene Removal: The benzylidene bearing compound was dissolved in 
a mixture of CH2Cl2:TFA:H2O (0.06 M, 10/1/0.1) and stirred at room temperature for 1 h. The 
reaction was diluted with CH2Cl2, washed with water, NaHCO3 (aq), dried with Na2SO4, and 
concentrated. The crude mixture was purified using SGC.  
General Procedure for Oxidation and Methylation of Primary Alcohol to Methyl Ester: The diol 
substrate (1 eq) was dissolved in CH2Cl2/H2O 2:1 (0.3 M). TEMPO (0.2 eq) and BAIB (2.5 eq) was 
added, and the reaction was stirred until TLC indicated the oxidation had finished. The reaction 
mixture was extracted with EtOAc, washed with Na2S2O3 (aq), dried and concentrated. The crude 
acid was dissolved in toluene/methanol 4:1 (0.1 M), and TMSCHN2 (2 M in ether, 2 eq) was added. 
The yellow mixture was stirred for 30 min and quenched with HOAc. The reaction was concentrated 
and purified via SGC.   
 
General Procedure for Trichloroacetimidate Formation: The substrate (1 eq) was dissolved in 
CH2Cl2 (0.1 M), Cs2CO3 (0.5 eq) was added, followed by CCl3CN (3 eq). The reaction was stirred at 
r.t. until TLC indicated the conversion had finished. The reaction was filtered through Celite, and 
concentrated to give the crude imidate.  
 
General Procedure for Glycosylation Reaction: The acceptor (1 eq) and donor (1.5 eq) was 
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co-evaporated with toluene for 3 times and dissolved in CH2Cl2 (0.05 M). The reaction was cooled to 
0 °C, and TMSOTf (0.1 eq, 0.0268 M in CH2Cl2) was added and the reaction was stirred at 0 °C until 
TLC indicated the conversion had finished. The reaction was quenched by adding Et3N, concentrated, 
and purified via SGC.  
 
General Procedure for Selective TBS Protection: The diol substrate (1 eq) was dissolved in CH2Cl2, 
and Et3N (10 eq), TBSCl (8 eq), DMAP (1 eq) was added. The reaction was stirred at 35 – 40 °C for 8 
h. The reaction was quenched by adding methanol, concentrated, and purified by SGC.  
 
General Procedure for TBS Cleavage: The substrate (1 eq) was dissolved in THF (0.1 M), and 
HF-pyridine (150 eq) was added. The reaction was stirred at r.t. until TLC indicated the conversion 
had finished. EtOAc was added to the reaction, and the mixture was washed with water, NaHCO3(aq), 
brine, dried and concentrated. The crude mixture was purified via SGC.  
 
 
 
Allyl O-(methyl 2,3–O–di–benzoyl–4–O-tert-butyldimethylsilyl-β-D- glucopyrafnosyl 
uronate)-(1→3)-4,6-O-benzylidene-2-deoxy-2-trichloroacetamido-β-D- glucopyranoside (3) To a 
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round bottom flask was added acceptor 2 (100 mg, 0.221 mmol), donor 1 (224 mg, 0.331 mmol). The 
reactants were co-evaporated with toluene.5 mL CH2Cl2 was added, and the reaction was cooled to 0 
°C. 4 μL TMSOTf was added, and the reaction was stirred at 0 °C for 50 min, then warmed up to 
room temperature. The reaction was quenched by adding 400 μL Et3N, and concentrated. Purification 
using silica gel chromatography using hexanes/ethyl acetate 4:1 as eluting solution give product 3 
(175 mg, 0.181 mmol, 82%) as a white solid.   
1H NMR (400 MHz, CDCl3) 7.84 (d, J = 7.4 Hz, 4H, OBz), 7.54 – 7.24 (m, 11H, PhH), 6.81 (d, J 
= 7.0 Hz, 1H, NH), 5.85 – 5.72 (m, 1H, -HC=CH2), 5.53 (s, 1H, PhCH), 5.44 (t, J = 9.1 Hz, 1H, H-3’), 
5.34(t, J = 7.5 Hz, 1H, H-2’), 5.22 (dd, J = 1.6, 17.7 Hz, 1H, C=CHH), 5.16 (dd, J = 1.6, 10.0 Hz, 1H, 
C=CHH), 5.07 (d, J = 8.7 Hz, 1H, H-1), 4.99 (t, J = 7.4 Hz, 1H, H-1’), 4.66 (t, J = 9.5 Hz, 1H, H-3), 
4.38 – 4.24 (m, 3H, H-6a, H-4’, OCHHC=CH2), 4.03 (dd, J = 6.6, 12.8 Hz, 1H, OCHHC=CH2), 3.91 
(d, J = 8.7 Hz, 1H, H-5’), 3.84 – 3.71 (m, 2H, H-4, H-6b), 3.67(s, 3H, COOCH3), 3.55 – 3.49 (m, 1H, 
H-5), 3.29 (dd, J = 7.0, 16.5 Hz, 1H, H-2), 0.70 (s, 9H, 3*CH3), -0.07 (s, 3H, SiCH3), -0.23 (s, 3H, 
SiCH3); 
13C NMR (101 MHz, CDCl3) δ 168.3, 165.6, 165.1, 161.9, 137.1, 133.2, 133.1, 133.0, 129.9, 129.65, 
129.38, 128.99, 128.94, 128.33, 128.28, 126.11, 118.54, 101.21, 99.96, 97.9, 91.9, 79.72, 77.20, 
76.41, 75.85, 75.14, 72.31, 70.78, 70.63, 68.58, 66.14, 59.52, 52.41, 25.64, 25.39, 17.71, -4.46, -5.19. 
HRMS(ESI): calcd for C45H53Cl3NO14Si [M+H]+: 964.2295, found 964.2285 
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Methyl 2,3–O–di–benzoyl–4–O-tert-butyldimethylsilyl-β-D-glucopyrafnosyluronate- (1→3)- 
4,6-O-benzylidene-2-deoxy-2-trichloroacetamido-β-D-glucopyranoside 
3 (66 mg, 0.068 mmol) and Grubbs’ 2nd catalyst (14.3 mg, 20 mol %) was dissolved in CH2Cl2 (2 mL). 
The reaction was stirred for 8 h and NMR indicated the reaction has finished. The reaction was 
concentrated, dissolved in Acetone/water (5 mL/1 mL), and added HgO(13 mg), HgCl2 (13 mg). The 
reaction was stirred for 16 h, concentrated and purified via SGC (hexanes/ethyl acetate 2:1) to give 
the product (53 mg, 0.058 mmol, 85%) 
1H NMR (400 MHz, CDCl3) δ 7.91 – 7.77 (m, 4H), 7.56 – 7.27 (m, 11H), 6.75 (d, J = 8.3 Hz, 1H), 5.58 (s, 
1H), 5.44 (t, J = 8.7 Hz, 1H), 5.32 (t, J = 3.8 Hz, 1H), 5.23 (t, J = 8.1 Hz, 1H), 5.17 (d, J = 7.5 Hz, 1H), 
4.34 – 4.22 (m, 3H), 4.21 – 4.13 (m, 1H), 4.10 (dd, J = 9.9, 4.8 Hz, 1H), 3.90 – 3.83 (m, 2H), 3.83 – 3.76 
(m, 1H), 3.71 (s, 3H), 3.00 (dd, J = 3.8, 1.6 Hz, 1H), 0.69 (s, 9H), -0.07 (s, 3H), -0.23 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.29, 165.61, 165.15, 161.71, 137.02, 133.11, 129.89, 129.83, 129.74, 
129.70, 129.44, 129.19, 129.13, 128.35, 128.32, 128.27, 128.23, 126.16, 126.10, 101.59, 99.74, 91.51, 
80.48, 77.20, 75.15, 74.91, 73.22, 70.35, 68.80, 62.74, 54.87, 53.75, 52.45, 29.70, 29.25, 25.40, 17.71, 
-4.45, -5.23. 
HRMS(ESI): calcd for C42H48Cl3NO14Si [M+Na]+: 946.1802, found 946.1803 
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Allyl 4,6-O–di-benzyl-2-deoxy-2-trichloroacetamido-β-D-glucopyranoside (8) 
To a round bottom flask was added 7 (4.2 g, 8.5 mmol) and powdered NaOH (1.71 g, 42.8 mmol). 50 
mL THF was added and the reaction was stirred for 5 h. Another portion of NaOH (1.71 g, 42. 8 
mmol) and 18-crown-6 (3.6 g) was added. After 25 min, BnBr (2.14 mL, 18 mmol) was added 
dropwisely. The reaction was stirred for 12 h, and then HOAc (5.1g, 85.6 mmol) was added to the 
reaction slowly. The solvent was removed at reduced pressure, and EtOAc was added to the mixture 
to extract the product. The organic phase was washed with sat. NH4Cl (aq), water, brine, and dried by 
Na2SO4. Solvents were removed under reduced pressure, and the product was purified using silica gel 
chromatography with hexanes/ethyl acetate 2:1 as eluting solution to give product 8 as a white solid 
(2.68 g, 4.9 mmol, 57%).  
1H NMR (400 MHz, CDCl3) 7.41 – 7.22 (m, 10 H, PhH), 7.20 (d, J = 6.4 Hz, 1H, NH), 5.93 – 5.81 
(m, 1H, -HC=CH2), 5.28 (d, J = 17.0 Hz, 1H, C=CHH), 5.19 (dd, J = 9.9 Hz, 1H, C=CHH), 4.79 – 
4.71 (m, 2H, H-1, PhCHH), 4.67 – 4.51 (m, 3H, PhCHH, PhCH2), 4.36 (dd, J = 5.7, 13.2 Hz, 1H, 
OCHHC=CH2), 4.14 – 4.03 (m, 2H, OCHHC=CH2, H-3), 3.79 – 3.70 (m, 2H, H-6a, H-6b), 3.69 – 
3.56 (m, 3H, H-2, H-4, H-5), 3.21 (br, 1H, OH).  
13C NMR (101 MHz, CDCl3) δ 171.5, 162.4, 137.9, 133.4, 128.5, 128.4, 128.0, 127.9, 127.8, 127.7, 
118.0, 98.6, 92.5, 78.2, 74.8, 74.5, 73.5, 72.6, 70.0, 68.9, 58.2 
HRMS(ESI): calcd for C25H28Cl3NO6Na [M+Na]+: 566.0874, found 566.0874 
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Allyl O-(methyl 2,3–O–di–benzoyl–4–O-tert-butyldimethylsilyl-β-D-glucopyrafnosyl 
-uronate)-(1→3)- 4,6-O–di-benzyl-2-deoxy-2-trichloroacetamido-β-D- glucopyranoside (9) To a 
round bottom flask was added acceptor 8 (44 mg, 0.081 mmol), donor 1 (110 mg, 0.162 mmol). The 
reactants were co-evaporated with toluene.5 mL CH2Cl2 was added, and the reaction was cooled to 0 
°C. 1.4 μL TMSOTf was added, and the reaction was stirred at 0 °C for 4 h, then quenched by adding 
300 μL Et3N, and concentrated. Purification using silica gel chromatography using hexanes/ethyl 
acetate 4:1 as eluting solution give product 9 (79 mg, 0.075 mmol, 93%) as a white solid.   
1H NMR (400 MHz, CDCl3) 7.83 (t, J = 8.4 Hz, 4H, OBz), 7.47 – 7.16 (m, 16H, PhH), 6.93 (d, J = 
7.8 Hz, 1H, NH), 5.62 – 5.52 (m, 1H, -HC=CH2), 5.44 (t, J = 9.8 Hz, 1H, H-3’), 5.34(t, J = 8.4 Hz, 
1H, H-2’), 5.06 (d, J = 17.3 Hz, 1H, C=CHH), 5.01 (d, J =10.0 Hz, 1H, C=CHH), 4.95 (d, J = 7.3 Hz, 
1H, H-1’), 4.90 (d, J = 11.4 Hz, 1H, PhCHH), 4.73 (d, J = 7.3 Hz, 1H, H-1), 4.51 – 4.39 (m, 4H, H-6a, 
PhCHH, PhCH2, H-3 ), 4.27 (t, J = 8.4 Hz, 1H, H-4’), 4.08 – 3.95 (m, 2H, OCHHC=CH2, H-5’), 
3.85(dd, J = 6.7, 12.6Hz, 1H, OCHHC=CH2), 3.66 – 3.57 (m, 7H, COOCH3, H-4, H-5, H-6a, H-6b), 
3.30 (dd, J = 8.4, 16.5 Hz, 1H, H-2), 0.65 (s, 9H, 3*CH3), -0.09 (s, 3H, SiCH3), -0.26 (s, 3H, SiCH3) 
13C NMR (101 MHz, CDCl3) δ 168.2, 165.7, 165.3, 163.6, 161.8, 138.0, 137.9, 133.3, 133.2, 133.1, 
129.8, 129.7, 129.66, 129.62, 129.4, 129.0, 128.4, 128.4, 128.34, 128.30, 127.8, 127.70, 127.6, 117.9, 
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100.3, 97.1, 92.3, 77.4, 76.7, 76.6, 75.8, 74.9, 74.5, 74.1, 73.3, 72.0, 71.0, 69.8, 69.0, 57.5, 52.4, 
25.41, 25.39, 17.7, -3.6, -4.4, -5.2. 
HRMS(ESI): calcd for C52H60Cl3NO14SiNa [M+Na]+: 1078.2741, found 1078.2765 
 
 
Methyl 2,3–O–di–benzoyl–4–O-tert-butyldimethylsilyl-β- D- glucopyrafnosyluronate) - (1→3) - 
4, 6- O – di - benzyl - 2 - deoxy - 2- trichloroacetamido - β - D - glucopyranoside 
(11) Compound 9 (79 mg, 0.075 mmol) and Ir (3.4 mg, 0.004 mmol) was added to a round bottom 
flask. THF (5 mL) was added. The reaction was subject to H2 balloon for a few seconds until the red 
color faded, and then stirred for 2 h. NMR indicated the isomerization had finished, and solvents were 
removed under reduced pressure.  
The crude mixture was dissolved in acetone (5 mL) and water (1 mL), and then HgO (40 mg, 0.18 
mmol), HgCl2 (40 mg, 0.15 mmol) was added. The reaction was stirred overnight, filtered through 
Celite, concentrated, diluted with EtOAc, washed with KI(aq), brine, and dried with Na2SO4. The 
solution was concentrated and purified by SGC to give product 11 as white foam (65 mg, 0.064 mmol, 
85%). 
1H NMR (400 MHz, CDCl3) 7.91 – 7.83 (m, 4H, OBz), 7.53 – 7.27 (m, 16H, PhH), 6.91 (d, J = 
10.0 Hz, 1H, NH), 5.47 (t, J = 9.3 Hz, 1H, H-3’), 5.34 (t, J = 8.4 Hz, 1H, H-2’), 5.12 – 5.00 (m, 3H, 
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H-1’, H-1, PhCHH), 4.51 – 4.43 (m, 3H, PhCHH, PhCH2), 4.36 – 4.24 (m, 2H, H-4’, H-3), 4.15 – 
4.01 (m, 3H, H-2, H-5’, H-5), 3.74 (s, 3H, COOCH3),  3.67 – 3.61 (m, OH, H-6a), 3.59 – 3.53 (m, 
, 75.1, 74.8, 73.5, 72.2, 72.1, 71.0, 70.5, 69.1, 54.7, 52.5, 29.7, 25.7, 25.4, 17.7, 1.0, 
RMS(ESI): calcd for C49H56Cl3NO14SiNa [M+Na]+: 1038.2428, found 1038.2433 
 
H-6b), 3.50 (t, J = 8.4 Hz, 1H, H-4), 0.73 (s, 9H, 3*CH3), -0.02 (s, 3H, SiCH3), -0.20 (s, 3H, SiCH3) 
13C NMR (101 MHz, CdCl3) δ 168.0, 165.7, 165.5, 163.4, 161.2, 137.9, 137.6, 133.1, 133.0, 130.0, 
129.6, 129.4, 128.9, 128.7, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.7, 100.3, 92.6, 91.0, 77.2, 
76.9, 76.8, 75.8
-4.3, -5.1, -5.2 
H
 
Trichloroacetimido Methyl 2,3–O–di–benzoyl–4–O-tert-butyldimethylsilyl-β- D- 
glucopyrafnosyluronate) - (1→3) - 4, 6- O – di - benzyl - 2 - deoxy - 2- trichloroacetamido - β - D 
– glucopyranoside  (12) 11 (65 mg, 0.064 mmol) was dissolved in CH2Cl2 (5 mL), and CCl3CN 
(139 mg, 0.9 mmol), DBU (4 mg, 0.026 mmol) was added. The reaction was stirred at 0 °C for 30 
min. The reaction was concentrated and passed through a silica gel plug using hexanes/acetate 2:1 as 
eluting solvent to give the crude imidate (64 mg, 0.055 mmol) and used directly without further 
purification.  
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cis-4-(1H, 1H, 2H, 2H, 3H, 3H -Perfluoroundecyloxy) -2-butenyl O-(methyl 2,3 –O– di – 
benzoyl–4 –O-tert-butyldimethylsilyl - β- D - glucopyrafnosyluronate) - (1→3) - 4,6- O – 
di-benzyl-2-deoxy-2- trichloroacetamido-β-D-glucopyranoside (14) To a round bottom flask was 
added acceptor 13 (10 mg,  0.019 mmol), donor 12 (23 mg, 0.020 mmol). The reactants were 
co-evaporated with toluene. CH2Cl2 (1.5 mL) was added, and the reaction was cooled to 0 °C. 
TMSOTf (0.7 μL, 0.002 mmol) was added, and the reaction was stirred at 0 °C for 90 min, then 
quenched by adding 100 μL Et3N, and concentrated. Purification using FSPE give product 14 (22.5 
mg, 0.014 mmol, 76 %) as a white solid. 
1H NMR (400 MHz, CDCl3) 7.84 (dd, J = 6.9, 9.7Hz, 4H, OBz), 7.46 – 7.19 (m, 16H, PhH), 6.85 
(d, J = 6.9 Hz, 1H, NH), 5.58 – 5.50 (m, 1H, -HC=CH-), 5.47 (t, J = 9.8 Hz, 1H, H-3’), 5.35 (m, 2H, 
-HC=CH-, H-2’), 4.91 (d, J =7.9 Hz, 1H, H-1’), 4.90 (d, J = 9.8 Hz, 1H, PhCHH), 4.74 (d, J = 6.3 Hz, 
1H, H-1), 4.50 – 4.39 (m, 4H, H-3, PhCHH, PhCH2), 4.27 (t, J = 9.7 Hz, 1H, H-4’), 4.07 – 3.96 (m, 
3H, C=C-CH2-O, H-5’), 3.84 (dd, J = 2, 6Hz, 2H, C=C-CH2-O), 3.65 – 3.59 (m, 7H, COOCH3, H-4, 
H-5, H-6a, H-6b), 3.29 (t, J = 6.4 Hz, 2H, CH2-CF2), 3.23 (dd, J = 8.4, 14.6 Hz, 1H, H-2), 2.16 – 1.97 
(m, 2H, CH2CH2CF2),  1.81 – 1.69 (m, 2H, CH2CH2CF2), 0.66 (s, 9H, 3*CH3), -0.09 (s, 3H, SiCH3), 
-0.25 (s, 3H, SiCH3) 
13C NMR (101 MHz, CDCl3) δ 168.0, 165.5, 165.1, 161.7, 138.0, 137.8, 133.3, 133.1, 130.2, 129.9, 
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129.7, 129.6, 129.4, 129.0, 128.6, 128.5, 128.4, 128.33, 127.8, 127.76, 127.73, 127.67, 127.6, 100.4, 
96.7, 92.2, 77.2, 76.6, 75.8, 74.8, 74.4, 74.2, 74.1, 73.3, 72.0, 70.9, 69.1, 68.6, 66.3, 64.1, 57.4, 52.4, 
29.6, 27.9, 25.3, 20.7, 17.7, -4.4, -5.1. 
19F NMR (376 MHz, CDCl3)   -80.73 (t, J = 9.9 Hz, 3F), -114.4 (t, J = 20 Hz, 2F), -121.60 - -122.0 
(m, 6F), -122.73 (m, 2F), -123.44 (m, 2F), -126.10 (m, 2F);  
HRMS(ESI): calcd for C64H67Cl3F17NO15SiNa [M+Na]+: 1568.2966, found 1568.2974 
 
cis-4-(1H, 1H, 2H, 2H, 3H, 3H -Perfluoroundecyloxy) -2-butenyl O-(methyl 2,3–O–di– 
benzoyl-β-D-glucopyrafnosyluronate)-(1→3)-4,6-O–di-benzyl-2-deoxy-2-trichloroacetamido - β 
- D – glucopyranoside (15)  14 (18.5 mg, 0.012 mmol) was dissolved in pyridine (1.5 mL) and THF 
(4 mL). HF/py (450 μL) was added at 0 °C, and the reaction was stirred for 18 h, diluted with EtOAc, 
washed with 10% CuSO4, NaHCO3(aq), and purified with FSPE to give the product 15 (17 mg, 0.012 
mmol, 98%).  
1H NMR (400 MHz, CDCl3) 7.98 – 7.91 (m, 4H, OBz), 7.56 – 7.17 (m, 16H, PhH), 7.02 (d, J = 6.9 
Hz, 1H, NH), 5.51 – 5.37 (m, 3H, -HC=CH-, H-3’, H-2’), 4.99 (d, J =7.5 Hz, 1H, H-1’), 4.93 (d, J = 
11.0 Hz, 1H, PhCHH), 4.80 (d, J = 6.3 Hz, 1H, H-1), 4.60 – 4.45 (m, 4H, H-3, PhCHH, PhCH2), 4.22 
– 4.15 (m, 1H, H-4’), 4.13 – 4.01 (m, 3H, C=C-CH2-O, H-5’), 3.90 (d, J = 6.2 Hz, 2H, C=C-CH2-O), 
3.65 – 3.59 (m, 7H, COOCH3, H-4, H-5, H-6a, H-6b), 3.41 – 3.32 (m, 3H, H-2, CH2-CF2), 3.29 (br, 
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1H, OH), 2.21 – 2.04 (m, 2H, CH2CH2CF2),  1.87 – 1.77 (m, 2H, CH2CH2CF2); 
13C NMR (151 MHz, CDCl3) δ 168.97, 166.47, 165.16, 161.79, 138.05, 137.99, 133.48, 130.88, 
130.28, 129.90, 129.83, 129.01, 128.92, 128.81, 128.55, 128.41, 128.37, 128.30, 128.09, 127.82, 
127.78, 127.70, 127.67, 100.23, 96.89, 92.28, 75.74, 74.86, 74.60, 74.29, 74.25, 73.39, 71.37, 70.67, 
69.20, 68.69, 68.18, 66.83, 66.35, 64.16, 52.84, 38.76, 31.94, 30.43, 30.38, 29.71, 29.61, 29.37, 28.94, 
28.00, 24.50, 23.81, 23.77, 23.00, 22.98, 22.70, 14.12, 14.05, 10.99, 10.97, 1.03. 
19F NMR (376 MHz, CDCl3)   -80.70 (t, J = 10.0 Hz, 3F), -114.5 (t, J = 20 Hz, 2F), -121.60 - 
-122.0 (m, 6F), -122.73 (m, 2F), -123.44 (m, 2F), -126.10 (m, 2F);  
HRMS(ESI): calcd for C58H53Cl3F17NO15Na [M+Na]+: 1454.2102, found 1454.2090 
 
 
Allyl O - (2, 3 –O–di – benzoyl – 4,6 –O-benzylidene-β-D-glucopyrafnosyl)-(1→3)- 4,6- O 
–di-benzyl-2-deoxy-2- trichloroacetamido-β-D-glucopyranoside (19) To a round bottom flask was 
added acceptor 8 (530 mg, 0.97 mmol), donor 18 (724 mg, 1.17 mmol). The reactants were 
co-evaporated with toluene. 15 mL CH2Cl2 was added, and the reaction was cooled to 0 °C. TMSOTf 
(8.7 μL, 0.048 mmol) was added, and the reaction was stirred at 0 °C for 2 h, then quenched by 
adding 500 μL Et3N, and concentrated. The crude product was purified with SGC to afford 19 as 
white foam (910 mg, 0.91 mmol, 94%). 
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1H NMR (400 MHz, CDCl3) δ 8.04 – 7.87 (m, 4H), 7.59 – 7.16 (m, 21H), 6.93 (d, J = 7.4 Hz, 1H), 
5.75 – 5.60 (m, 2H), 5.54 – 5.42 (m, 2H), 5.19 – 5.05 (m, 2H), 4.99 (d, J = 7.9 Hz, 1H), 4.94 (d, J = 
10.7 Hz, 1H), 4.85 (d, J = 7.0 Hz, 1H), 4.69 – 4.59 (m, 1H), 4.59 – 4.47 (m, 2H), 4.35 (d, J = 5.7 Hz, 
1H), 4.14 (dd, J = 13.3, 5.9 Hz, 1H), 3.94 (dd, J = 13.0, 6.4 Hz, 1H), 3.87 (t, J = 8.7 Hz, 1H), 3.77 – 
3.55 (m, 5H), 3.29 (q, J = 7.6 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ165.5, 165.2, 161.8, 138.1, 138.0, 136.6, 133.5, 133.3, 133.1, 129.8, 
129.7, 129.3, 129.05, 129.01, 128.57, 128.43, 128.38, 128.29, 128.18, 127.95, 127.83, 127.78, 127.67, 
126.1, 118.1, 101.5, 100.8, 96.9, 92.2, 78.8, 75.8, 74.3, 74.2, 73.4, 72.6, 71.9, 70.0, 68.9, 68.5, 66.7, 
58.1. 
HRMS(ESI): calcd for C52H50Cl3NO13Na [M+Na]+: 1024.2240, found 1024.2251 
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2,3–O–di–benzoyl–4,6–O-benzylidene-β-D-glucopyrafnosyl-(1→3)-4,6-O–di-benzyl-2-deoxy-2-tr
ichloroacetamido-β-D-glucopyranoside (20) Compound 19 (200 mg, 0.2 mmol) was subjected to 
the conditions in the general deallylation method. The mixture was purified via SGC to afford 
compound 20 (142 mg, 0.15 mmol, 75%) as a white foam. 
1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 7.77, 12.45 Hz, 4H), 7.52 – 7.10 (m, 21H), 6.78 (d, J = 
9.58 Hz, 1H), 5.60 (t, J = 9.56 Hz, 1H), 5.47 – 5.33 (m, 2H), 5.05 (d, J = 7.78 Hz, 1H), 4.99 – 4.88 (m, 
    136
2H), 4.52 – 4.38 (m, 3H), 4.38 – 4.30 (m, 1H), 4.26 (t, J = 9.05 Hz, 1H), 4.02 (ddt, J = 5.36, 11.04, 
18.39 Hz, 4H), 3.83 – 3.70 (m, 1H), 3.69 – 3.51 (m, 4H), 3.43 (t, J = 8.90 Hz, 1H), 3.37 – 3.21 (m, 
1H). 
13C NMR (101 MHz, CDCl3) δ 165.74, 165.57, 161.11, 138.09, 137.46, 136.62, 133.17, 130.15, 
129.78, 129.20, 129.16, 128.97, 128.59, 128.41, 128.36, 128.29, 128.26, 128.20, 128.11, 127.87, 
126.17, 101.51, 100.37, 92.68, 91.05, 79.02, 76.56, 75.79, 74.89, 73.48, 72.62, 71.96, 70.57, 69.12, 
68.56, 66.67, 57.03, 56.84, 54.72, 11.89, 11.86. 
HRMS(ESI): calcd for C49H46Cl3NO13Na [M+Na]+: 984.1927, found 984.1926  
 
 
2,3–O–di–benzoyl–4,6–O-benzylidene-β-D-glucopyrafnosyl-(1→3)-4,6-O–di-benzyl-2-deoxy-2-tr
ichloroacetamido-β-D–glucopyranosideN-Phenyl-2,2,2-trifluoroacetimidate (21) Compound 20 
(35 mg, 0.036 mmol) was dissolved in CH2Cl2, and Cs2CO3 (20.3 mg, 0.054 mmol) was added, 
followed by N -phenyltrifluoroacetimidoyl chloride (13 mg, 0.054 mmol) and stirred for 8 h. The 
reaction was filtered and purfied via SGC (hexanes/EtOAc 4:1) to give 21 (22 mg, 0.022 mmol, 
61%).  
1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 3.76, 7.86 Hz, 4H), 7.54 – 7.13 (m, 21H), 7.00 (t, J = 
7.44 Hz, 1H), 6.63 (t, J = 7.96 Hz, 3H), 6.16 (bs, 1H), 5.63 (t, J = 9.57 Hz, 1H), 5.48 – 5.32 (m, 2H), 
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5.07 (d, J = 7.67 Hz, 1H), 4.89 (d, J = 10.72 Hz, 1H), 4.52 (d, J = 10.02 Hz, 2H), 4.44 (d, J = 12.01 
Hz, 1H), 4.38 – 4.16 (m, 3H), 4.10 – 3.96 (m, 1H), 3.90 (d, J = 8.97 Hz, 1H), 3.86 – 3.68 (m, 3H), 
3.68 – 3.49 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 165.62, 165.50, 161.19, 142.82, 137.78, 137.72, 136.58, 133.31, 
133.17, 130.93, 129.99, 129.77, 129.22, 129.12, 128.82, 128.77, 128.46, 128.43, 128.33, 128.31, 
128.22, 128.07, 127.99, 127.94, 127.82, 126.12, 124.60, 119.17, 101.55, 100.43, 93.20, 92.34, 78.73, 
74.92, 74.73, 73.57, 73.30, 72.81, 71.86, 68.48, 67.80, 66.86, 53.65, 27.73, 19.17. 
HRMS(ESI): calcd for C63H66Cl3F3NO13Na [M+Et3N+H]+: 1234.3608, found 1034.3584 
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cis-4-(1H,1H,2H,2H,3H,3H-Perfluoroundecyloxy)-2-butenyl (2,3–O–di–benzoyl–4,6–O- 
benzylidene-β-D–glucopyrafnosyl)-(1→3)-4,6-O–di-benzyl-2-deoxy-2-trichloroacetamido-β-D-gl
ucopyranoside (22) Donor 21 (22 mg, 0.020 mmol) and acceptor 13 (11 mg, 0.020 mmol) were 
subjected to the conditions in the general glycosylation method. The reaction was purified via FSPE 
to give 22 (16 mg, 0.011 mmol, 55%). 
1H NMR (600 MHz, CDCl3) δ 8.05 – 7.99 (m, 2H), 7.99 – 7.94 (m, 2H), 7.59 – 7.30 (m, 21H), 6.91 
(d, J = 7.33 Hz, 1H), 5.73 (t, J = 9.64 Hz, 1H), 5.70 – 5.62 (m, 1H), 5.57 – 5.44 (m, 3H), 5.01 (d, J = 
7.89 Hz, 1H), 4.97 (d, J = 10.75 Hz, 1H), 4.88 (d, J = 6.97 Hz, 1H), 4.67 – 4.63 (m, 1H), 4.63 – 4.52 
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(m, 3H), 4.38 (d, J = 5.62 Hz, 1H), 4.22 – 4.16 (m, 1H), 4.16 – 4.07 (m, 1H), 3.95 (dd, J = 1.52, 6.47 
Hz, 2H), 3.90 (ddd, J = 1.52, 7.17, 9.12 Hz, 1H), 3.77 (d, J = 2.25 Hz, 2H), 3.73 – 3.67 (m, 2H), 3.65 
(d, J = 7.09 Hz, 2H), 3.41 (td, J = 2.52, 6.10 Hz, 2H), 3.29 (d, J = 7.67 Hz, 1H), 2.29 – 2.10 (m, 2H), 
1.89 – 1.80 (m, 2H). 
13C NMR (151 MHz, CDCl3) δ 165.49, 165.23, 161.84, 138.10, 138.05, 136.66, 133.50, 133.14, 
130.41, 129.86, 129.77, 129.32, 129.07, 128.59, 128.40, 128.32, 128.20, 127.96, 127.83, 127.81, 
127.77, 127.71, 126.13, 101.50, 100.90, 96.80, 92.24, 78.86, 76.99, 75.82, 74.36, 74.32, 73.44, 72.68, 
71.93, 69.01, 68.90, 68.69, 68.47, 66.77, 66.53, 66.34, 64.30, 58.11, 29.72, 28.00, 20.82. 
19F NMR (564 MHz, CDCl3)  -80.74 (t, J = 8.9 Hz, 3F), -114.4 (t, J = 20 Hz, 2F), -121.60 - -122.0 
(m, 6F), -122.70 (m, 2F), -123.41 (m, 2F), -126.10 (m, 2F);  
HRMS(ESI): calcd for C64H57Cl3F17NO14SiNa [M+Na]+: 1514.2465, found 1514.2439 
 
 
cis-4-(1H,1H,2H,2H,3H,3H-Perfluoroundecyloxy)-2-butenyl (2,3–O–di–benzoyl-β-D– 
glucopyrafnosyl)-(1→3)-4,6-O–di-benzyl-2-deoxy-2-trichloroacetamido-β-D-glucopyranoside 
(23) Compound 22 (16 mg, 0.011 mmol) was subjected to the condtion in the general benzylidene 
cleavage method and purified by FSPE to give 23 (14 mg, 0.010 mmol, 91%). 
1H NMR (600 MHz, CDCl3) δ 8.14 – 7.87 (m, 4H), 7.68 – 7.25 (m, 16H), 7.10 (d, J = 7.75 Hz, 1H), 
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5.69 (ddt, J = 6.43, 12.05, 23.92 Hz, 1H), 5.53 (dt, J = 6.72, 12.01 Hz, 1H), 5.44 (dd, J = 7.88, 9.85 
Hz, 1H), 5.35 (t, J = 9.44 Hz, 1H), 4.94 (t, J = 8.89 Hz, 2H), 4.80 (d, J = 7.08 Hz, 1H), 4.68 – 4.45 (m, 
4H), 4.32 – 4.04 (m, 3H), 3.96 (d, J = 6.39 Hz, 2H), 3.93 – 3.81 (m, 2H), 3.81 – 3.57 (m, 5H), 3.57 – 
3.43 (m, 2H), 3.41 (td, J = 2.10, 6.08 Hz, 2H), 2.18 (dtt, J = 9.09, 18.17, 27.04 Hz, 2H), 2.01 – 1.67 
(m, 2H). 
13C NMR (151 MHz, CDCl3) δ 167.30, 165.37, 162.59, 138.00, 137.95, 133.59, 133.45, 130.35, 
129.92, 129.82, 129.12, 128.98, 128.83, 128.59, 128.53, 128.46, 128.38, 127.93, 127.82, 127.79, 
127.71, 127.54, 99.92, 97.37, 92.39, 77.25, 77.09, 77.03, 76.96, 76.82, 76.70, 76.22, 75.69, 74.45, 
74.18, 73.41, 71.66, 69.90, 69.02, 68.71, 66.37, 64.30, 61.90, 57.59, 29.71, 27.98, 20.81, 1.06. 
19F NMR (564 MHz, CDCl3)  -80.74 (t, J = 8.9 Hz, 3F), -114.4 (t, J = 20 Hz, 2F), -121.60 - -122.0 
(m, 6F), -122.70 (m, 2F), -123.41 (m, 2F), -126.10 (m, 2F);  
HRMS(ESI): calcd for C57H53Cl3F17NO14Na [M+Na]+:1426.2152, found 1426.2131 
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cis-4-(1H,1H,2H,2H,3H,3H-Perfluoroundecyloxy)-2-butenyl (2,3–O–di–benzoyl-6–O- 
tert-butyldimethylsilyl-β-D–glucopyrafnosyl)-(1→3)-4,6-O–di-benzyl-2-deoxy-2-trichloroacetam
ido -β-D-glucopyranoside (24) 
Compound 23 (14 mg, 0.010 mmol) was subjected to the conditions for selective TBS protection and 
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purified by FSPE to give compound 24 (16 mg, 0.010 mmol, 96%). 
1H NMR (600 MHz, CDCl3) δ 8.07 – 7.94 (m, 4H), 7.59 – 7.20 (m, 17H), 7.04 (d, J = 7.47 Hz, 1H), 
5.63 (dq, J = 8.05, 9.71, 16.16 Hz, 1H), 5.50 (q, J = 9.36 Hz, 1H), 5.44 (td, J = 7.24, 10.20 Hz, 2H), 
4.98 – 4.89 (m, 2H), 4.86 (d, J = 6.59 Hz, 1H), 4.61 – 4.53 (m, 3H), 4.51 (d, J = 12.04 Hz, 1H), 4.10 
(dd, J = 6.66, 23.55 Hz, 2H), 4.01 – 3.88 (m, 4H), 3.79 – 3.69 (m, 5H), 3.67 (dq, J = 3.69, 7.39 Hz, 
1H), 3.60 (ddd, J = 5.22, 7.08, 9.33 Hz, 1H), 3.46 – 3.30 (m, 3H), 2.17 (ddq, J = 7.93, 8.60, 18.39, 
27.18 Hz, 2H), 1.92 – 1.76 (m, 2H), 0.91 (s, 9H), 0.17 – 0.06 (m, 6H). 
13C NMR (151 MHz, CDCl3) δ 166.53, 165.32, 161.80, 138.09, 138.02, 133.36, 133.23, 130.29, 
129.90, 129.80, 129.24, 128.52, 128.36, 128.31, 128.26, 127.91, 127.85, 127.76, 127.74, 127.65, 
99.86, 96.79, 92.26, 76.28, 75.71, 74.23, 74.06, 73.96, 73.37, 73.00, 71.76, 69.25, 68.67, 66.34, 65.08, 
64.13, 57.19, 29.71, 28.00, 25.89, 25.85, 20.81, 18.18, 1.16. 
19F NMR (564 MHz, CDCl3)  -80.74 (t, J = 8.9 Hz, 3F), -114.4 (t, J = 20 Hz, 2F), -121.60 - -122.0 
(m, 6F), -122.70 (m, 2F), -123.41 (m, 2F), -126.10 (m, 2F);  
HRMS(ESI): calcd for C63H67Cl3F17NO14SiNa [M+Na]+:1540.3017, found 1540.2978 
 
 
 
Allyl O - (2, 3 –O–di – benzyl – 4,6 –O-benzylidene-β-D-glucopyrafnosyl)-(1→3)- 4,6- O 
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–di-benzyl-2-deoxy-2- trichloroacetamido-β-D-glucopyranoside (27) Compound 19 (990 mg, 0.99 
mmol) was dissolved in THF (15 mL). NaOH (450 mg, 11.25 mmol) added, and the reaction was 
stirred for 8 h. To the milky mixture was added 18-crown-6 (410 mg), and the reaction was stirred for 
40 min. BnBr (0.31 mL, 22 mmol) was added. After 8 hours, NaOH (450mg, 11.25 mmol) and BnBr 
(0.31 mL, 22 mmol) was added. The reaction was stirred for another 8 h and diluted with EtOAc, 
washed with water, dried with Na2SO4. Silica gel chromatography using Hexanes/EtOAc 4:1 as 
eluting solution gave product 27 (660 mg, 0.67 mmol, 68%).  
1H NMR (400 MHz, CDCl3) δ 7.60 – 7.16 (m, 25H), 7.02 (d, J = 7.0 Hz, 1H), 5.86 (ddt, J = 16.4, 
10.8, 5.6 Hz, 1H), 5.55 (s, 1H), 5.26 (d, J = 17.2 Hz, 1H), 5.16 (dd, J = 15.4, 8.9 Hz, 2H), 4.98 (dd, J 
= 11.1, 3.9 Hz, 2H), 4.94 (d, J = 10.5 Hz, 1H), 4.86 (d, J = 11.5 Hz, 1H), 4.80 (d, J = 10.4 Hz, 1H), 
4.71 – 4.56 (m, 3H), 4.56 – 4.46 (m, 2H), 4.36 (dd, J = 13.0, 5.3 Hz, 1H), 4.28 (dd, J = 10.5, 4.9 Hz, 
1H), 4.08 (dd, J = 13.0, 6.0 Hz, 1H), 3.82 (d, J = 3.3 Hz, 2H), 3.70 (dtd, J = 17.6, 9.0, 4.0 Hz, 4H), 
3.59 (t, J = 10.2 Hz, 1H), 3.49 (t, J = 8.1 Hz, 1H), 3.36 (dq, J = 8.8, 5.4, 3.5 Hz, 2H). 
13C NMR (CDCl3, 101 MHz) δ 161.5, 138.3, 138.23, 138.17, 138.13, 137.2, 133.7, 129.0, 128.7, 
128.5, 128.44, 128.43, 128.28, 128.26, 128.24, 128.15, 128.08, 128.05, 127.89, 127.83, 127.79, 
127.75, 126.0, 117.5, 103.8, 101.1, 97.3, 92.1, 82.5, 81.8, 81.0, 79.2, 76.1, 76.0, 75.0, 74.4, 74.3, 73.6, 
70.2, 69.0, 68.7, 66.2, 59.7. 
HRMS(ESI): calcd for C52H54Cl3NO4Na [M+Na]+: 996.2655, found 996.2644 
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Allyl O - (2, 3 – O – di – benzyl - β- D - glucopyrafnosyl) - (1→3) - 4, 6- O – di - benzyl - 2 - 
deoxy - 2- trichloroacetamido - β - D – glucopyranoside (29) 28 (163 mg, 0.17 mmol) was 
dissolved in CH2Cl2/TFA/H2O (10:1:0.1, 5 mL) and stirred at r.t. for 1 h. The reaction was diluted 
with EtOAc, washed with water, sat. NaHCO3 (aq), dried with Na2SO4, and concentrated. The crude 
mixture was passed through a short silica gel plug to give 29 (127 mg, 0.14 mmol, 85%).  
1H NMR (400 MHz, CDCl3) 7.40 – 7.21 (m, 20H, PhH), 7.05 (d, J = 7.3 Hz, 1H, NH), 5.88 – 5.77 
(m, 1H, -HC=CH2), 5.24 (dd, J = 1.6, 17.2 Hz, 1H, C=CHH), 5.15 (dd, J = 1.4, 10.3 Hz, 1H, 
C=CHH), 5.09 – 4.97 (m, 3H, H-1, PhCHH , PhCHH), 4.88 (d, J = 11.0 Hz, 1H, PhCHH), 4.86 (d, J 
= 11.0 Hz, 1H, PhCHH), 4.80 (d, J = 11.0 Hz, 1H, PhCHH), 4.69 (d, J = 11.7 Hz, 1H, PhCHH), 4.64 
(d, J = 12.2 Hz, 1H, PhCHH) 4.58 – 4.51 (m, 3H, PhCH2, H-1’), 4.39 – 4.28 (m, 2H, H-3, 
OCHHC=CH), 4.05 (dd, J = 6.6, 12.8 Hz, 1H, OCHHC=CH), 3.82 (dd, J = 3.0, 10.6 Hz, 1H, H-6a), 
3.78 – 3.69 (m, 2H, H-4, H-6b), 3.69 – 3.60 (m, 2H, H-5a, H-6’a), 3.54 – 3.42 (m, 3H, H-2, H-4’, 
H-6’b), 3.39 – 3.30 (m, 2H, H-2’, H-3’), 3.21 – 3.15 (m, 1H, H-5’), 2.16 (d, J = 2.7 Hz, 4’-OH), 1.83 
(t, J = 6.9 Hz, 6’-OH) 
13C NMR (100 MHz, CDCl3): δ 161.5, 138.4, 138.3, 138.0, 137.9, 133.7, 128.7, 128.52, 128.47, 
128.45, 128.40, 128.38, 128.04, 128.00, 127.98, 127.93, 127.90, 127.8, 117.5, 103.2, 98.3, 92.5, 83.8, 
82.2, 78.2, 76.0, 75.7, 75.2, 75.1, 74.5, 74.2, 73.6, 70.5, 70.1, 68.8, 62.4, 58.4 
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HRMS(ESI): calcd for C45H50Cl3NO11Na [M+Na]+: 908.2343, found 908.2353 
 
 
Allyl O-(methyl 2,3–O–di–benzyl–4–O-tert-butyldimethylsilyl-β-D-glucopyrafnosyl 
-uronate)-(1→3)-4,6-O-benzylidene-2-deoxy-2-trichloroacetamido-β-D- glucopyranoside (31) 
The diol 29 (127 mg, 0.14 mmol) was dissolved in CH2Cl2H2O (2 mL/1 mL). BAIB (113 mg, 0.35  
mmol) and TMEPO (4 mg, 0.03 mmol) was added, and the reaction was stirred for 1 h. Na2S2O3( aq, 
10%, 10 mL) was added, and the reaction was extracted with EtOAc for 3 times, dried with Na2SO4, 
and concentrated to give the crude acid.  
The crude acid was dissolved in toluene/methanol (12 mL/3 mL), and TMSCHN2 (2 M in ether, 0.14 
mL, 0.28 mmol) was added. After stirring for 50 min, HOAc (0.15 mL) was added, and the reaction 
was concentrated to give the crude ester.  
The crude ester was dissolved in CH2Cl2 (5 mL). 2,6 – Lutidine (0.1 mL, 0.84 mmol) and TBSOTf 
(0.1 mL, 0.56 mmol) was added, and the reaction was stirred for 12 h, quenched by adding CH3OH 
(0.1 mL), washed with 10% CuSO4, NaHCO3 (aq), dried with Na2SO4, and concentrated. Silica gel 
chromatography using hexanes/EtOAc 4:1 to 3:1 as eluting solution gave the product 33 (96 mg, 
0.093 mmol, 67% for 3 steps).  
1H NMR (400 MHz, CDCl3) 7.43 – 7.20 (m, 20H, PhH), 7.05 (d, J = 8.0 Hz, 1H, NH), 5.88 – 5.76 
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(m, 1H, -HC=CH2), 5.23 (d, J = 16.6Hz, 1H, C=CHH), 5.14 (d, J =10.3 Hz, 1H, C=CHH), 5.09 – 
4.97 (m, 3H, H-1, PhCHH , PhCHH), 4.86 – 4.69 (m, 2H, PhCHH , PhCHH), 4.70 – 4.54 (m, 3H, 
H-1’, PhCH2), 4.50 (d, J = 10.0 Hz, 1H, PhCHH), 4.42 (t, J = 6.9 Hz, 1H, H-3), 4.32 (dd, J = 5.2, 
12.7 Hz,1H, OCHHC=CH), 4.04 (dd, J = 5.6, 12.7 Hz,1H, OCHHC=CH), 3.97 (t, J = 8.9, 1H, H-4’), 
3.86 – 3.67 (m, 5H, H-5’, H-4, H-5, H-6a, H-6b), 3.64 (s, 3H, COOCH3), 3.52 (t, J = 8.9 Hz, 1H, 
78.9, 76.3, 75.9, 
RMS(ESI): calcd for C52H64Cl3NO12SiNa [M+Na]+: 1050.3156, found 1050.3145 
 
H-2’), 3.47 – 3.38 (m, 2H, H-2, H-3;), 0.85 (s, 9H, 3*CH3), 0.00 (s, 6H, 2*SiCH3) 
 13C NMR (101 MHz, CDCl3) δ 168.5, 161.2, 138.3, 137.9, 137.8, 137.6, 133.4, 128.4, 128.2, 128.1, 
128.0, 127.9, 127.8, 127.6, 127.4, 126.9, 126.5, 117.1, 103.2, 97.1, 91.9, 83.9, 82.2, 
75.1, 74.7, 74.2, 74.1, 73.2, 72.0, 69.8, 68.9, 58.5, 51.9, 25.5, 17.7, -4.1, -5.4, -5.7. 
H
O
C8F17O
HN
O
BnO
BnO
O
O
COOMe
O
CCl3
BnO
BnO
HO
 
cis-4-(1H,1H,2H,2H,3H,3H-Perfluoroundecyloxy)-2-butenyl O-(methyl 2,3–O–di– benzyl 
–β-D-glucopyrafnosyluronate)-(1→3)-4,6-O-benzylidene-2-deoxy-2-trichloroacetamido - 
β-D-glucopyranoside (34) 31 (75 mg, 0.073 mmol) and Ir (3.4 mg, 0.004 mmol) was added to a 
round bottom flask. THF (5 mL) was added. The reaction was subject to H2 balloon for a few seconds 
until the red color faded, and then stirred for 2 h. NMR indicated the isomerization had finished, and 
solvents were removed under reduced pressure.  
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The crude mixture was dissolved in acetone (5 mL) and water (1 mL), and then HgO (70 mg, 0.32 
mmol), HgCl2 (70 mg, 0.26 mmol) was added. The reaction was stirred overnight, filtered through 
Celite, concentrated, diluted with EtOAc, washed with KI(aq), brine, and dried with Na2SO4. The 
solution was concentrated and passed through a short silica gel column to give crude product 32 and 
neral methods and used without further 
 silyl removal using the methods depicted in the general 
, 3.51 – 3.32 (m, 5H), 2.88 (bs, 1H), 2.15 (dp, J = 
.37, 74.25, 74.13, 73.47, 72.08, 
80.56 (m, 3F), -114.30 (m, 2F), -121.60 (m, 6F), -122.62 (m, 2F), 
used directly without purification.  
Imidate 33 was formed using the method depicted in the ge
purification (35 mg, 0.032 mmol, 43% overall for 3 steps).  
Glycosylation of 33 and 13 followed by
method gave 34 (63% overall, 2 steps).  
1H NMR (400 MHz, CDCl3) δ 7.30 (m, 20H), 7.08 (d, J = 7.1 Hz, 1H), 5.63 (tp, J = 11.5, 6.0 Hz, 2H), 
5.06 (d, J = 7.1 Hz, 1H), 4.99 (d, J = 10.6 Hz, 1H), 4.89 (q, J = 11.4 Hz, 2H), 4.84 – 4.75 (m, 2H), 
4.59 (dd, J = 9.5, 2.6 Hz, 2H), 4.53 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 10.8 Hz, 1H), 4.42 (t, J = 7.7 Hz, 
1H), 4.33 (dd, J = 12.7, 5.5 Hz, 1H), 4.16 (dd, J = 12.5, 6.5 Hz, 1H), 3.96 (d, J = 5.7 Hz, 2H), 3.86 (t, 
J = 8.9 Hz, 1H), 3.80 – 3.63 (m, 5H), 3.58 (s, 3H)
22.5, 7.9 Hz, 3H), 1.83 (dq, J = 12.0, 6.1 Hz, 2H). 
13C NMR (101 MHz, cdcl3) δ 169.61, 161.42, 138.24, 138.20, 137.99, 137.92, 130.06, 128.63, 
128.54, 128.37, 128.33, 128.23, 128.18, 128.08, 128.03, 127.98, 127.91, 127.79, 127.70, 127.58, 
103.40, 97.12, 92.09, 83.09, 81.39, 79.25, 76.13, 75.58, 75.31, 74
69.10, 68.64, 66.41, 64.60, 58.88, 52.53, 29.69, 27.98, 20.81, 20.76. 
19F NMR (376 MHz, CDCl3)  δ -
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-123.32 (m, 2F), -126.10 (m, 2F). 
HRMS(ESI): calcd for C58H57Cl3F17NO13SiNa [M+Na]+: 1426.2516, found 1426.2498 
 
 
Allyl O - (2, 3 – O – di – benzoyl – 6 – O - tert-butyldimethylsilyl - β- D - glucopyrafnosyl) -(1→3) 
- 4, 6- O – di - benzyl-2-deoxy-2-trichloroacetamido-β-D-glucopyranoside (37) 
Compound 29 (12 mg, 0.014 mmol) was treated with the conditons in the selective TBS protection 
followed by FSPE to give 37 (9 mg, 0.009 mmol, 65%). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.17 (m, 20H), 7.01 (d, J = 7.1 Hz, 1H), 5.77 (ddt, J = 16.3, 
10.8, 5.6 Hz, 1H), 5.17 (dd, J = 17.1, 1.7 Hz, 1H), 5.09 (dd, J = 10.3, 1.7 Hz, 1H), 5.02 (d, J = 7.2 Hz, 
1H), 4.87 (d, J = 11.9 Hz, 3H), 4.81 – 4.69 (m, 2H), 4.57 (d, J = 12.1 Hz, 1H), 4.53 – 4.43 (m, 3H), 
4.26 (dd, J = 12.9, 5.2 Hz, 1H), 3.99 (dd, J = 12.9, 6.0 Hz, 1H), 3.46 – 3.27 (m, 3H), 3.23 (ddd, J = 
9.3, 7.3, 4.7 Hz, 1H), 0.06 – -0.06 (m, 6H), 4.38 (dt, J = 8.0, 3.4 Hz, 1H), 3.81 – 3.68 (m, 3H), 3.69 – 
3.59 (m, 3H), 3.56 (dd, J = 10.0, 7.2 Hz, 1H), 0.83 (s, 9H). 
13C NMR (151 MHz, CDCl3) δ161.5, 138.7, 138.4, 138.3, 138.1, 133.7, 128.6, 128.44, 128.40, 128.3, 
128.2, 128.1, 127.99, 127.91, 127.8, 127.68, 127.64, 117.5, 103.1, 97.3, 92.2, 84.2, 81.9, 78.6, 76.1, 
75.5, 75.3, 74.9, 74.4, 74.1, 73.5, 73.3, 70.2, 69.2, 65.4, 59.1, 29.7, 25.9, 18.2, -5.5, -5.6. 
HRMS(ESI): calcd for C51H64Cl3NO11Na [M+Na]+: 1022.3206, found 1022.3216 
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Allyl O - (2, 3 – O – di – benzoyl – 4 - O – acetyl – 6 – O - tert-butyldimethylsilyl - β- D - 
glucopyrafnosyl) - (1→3) - 4, 6- O – di - benzyl - 2 - deoxy - 2- trichloroacetamido - β - D – 
glucopyranoside (38) Compound 37 (8 mg, 0.008 mmol) was dissolved in pyridine (3 mL). Ac2O 
(0.5 mL) was added followed by DMAP (4 mg). The reaction was stirred for 4 h, and concentrated. 
SGC (hexances/EtOAc 3:1) afford the product (8 mg, 0.076 mmol, 95%).  
1H NMR (600 MHz, CDCl3) δ 7.37 – 7.17 (m, 20H), 7.14 (d, J = 7.6 Hz, 1H), 5.75 (ddt, J = 16.0, 
10.5, 5.3 Hz, 1H), 5.16 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.5 Hz, 1H), 4.96 – 4.88 (m, 2H), 4.85 – 
4.73 (m, 3H), 4.67 (d, J = 10.8 Hz, 1H), 4.62 – 4.54 (m, 2H), 4.54 – 4.44 (m, 3H), 4.34 (t, J = 7.0 Hz, 
1H), 4.24 (dd, J = 12.8, 5.2 Hz, 1H), 3.99 (dd, J = 12.9, 6.2 Hz, 2H), 3.78 – 3.63 (m, 4H), 3.63 – 3.45 
(m, 5H), 3.38 (t, J = 8.5 Hz, 2H), 3.30 (dt, J = 9.1, 4.3 Hz, 1H), 1.86 (s, 3H), 0.79 (s, 9H), -0.08 (d, J 
= 5.9 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ169.6, 161.3, 138.2, 138.1, 138.1, 138.0, 133.6, 128.5, 128.39, 128.37, 
128.28, 128.23, 128.13, 127.96, 127.93, 127.77, 127.69, 127.67, 117.5, 102.5, 97.5, 92.2, 82.4, 81.9, 
77.6, 77.2, 75.7, 75.3, 75.1, 74.8, 74.3, 73.7, 73.4, 70.8, 69.9, 69.5, 63.0, 57.6, 29.7, 25.9, 20.9, 18.3, 
-5.45, -5.47.  
HRMS(ESI): calcd for C53H66Cl3NO12SiNa [M+Na]+: 1064.3312, found 1064.3321 
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2, 3–O–di–benzoyl–4-O–acetyl–6–O-tert-butyldimethylsilyl-β-D-glucopyrafnosyl-(1→3)- 4,6-O– 
di-benzyl-2-deoxy-2- trichloroacetamido - β - D – glucopyranoside (39) Compound 38 (46 mg, 
0.04 mmol,was treated with the general deallylation proceudre to yield compound 39 (25 mg, 0.025 
mmol, 63%).   
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.09 (m, 20H), 7.06 – 6.96 (m, 1H), 5.23 (d, J = 3.06 Hz, 1H), 
4.96 – 4.89 (m, 1H), 4.85 (dd, J = 6.26, 10.34 Hz, 2H), 4.77 – 4.68 (m, 2H), 4.69 – 4.61 (m, 1H), 4.56 
(dd, J = 8.13, 11.56 Hz, 3H), 4.52 – 4.45 (m, 1H), 0.06 – -0.04 (m, 6H), 4.45 – 4.36 (m, 1H), 4.33 (td, 
J = 3.23, 9.40 Hz, 1H), 4.12 (dt, J = 3.99, 8.66 Hz, 1H), 3.67 (d, J = 4.00 Hz, 2H), 3.64 – 3.57 (m, 
2H), 3.51 (dt, J = 8.72, 14.17 Hz, 2H), 3.41 (ddt, J = 4.21, 9.56, 14.62 Hz, 2H), 3.31 (d, J = 3.59 Hz, 
1H), 1.94 (s, 3H), 0.86 (d, J = 3.13 Hz, 9H), 0.02 (s, 3H), 0.01 (s, 3H).  
13C NMR (101 MHz, CDCl3) δ 175.29, 166.95, 143.88, 143.71, 143.57, 143.17, 134.21, 134.07, 
134.01, 133.95, 133.85, 133.81, 133.73, 133.71, 133.66, 133.62, 133.47, 133.45, 133.22, 133.12, 
133.09, 107.73, 98.12, 96.63, 87.85, 86.99, 82.74, 81.45, 81.00, 80.76, 80.58, 80.36, 80.11, 78.98, 
76.49, 76.34, 74.40, 68.77, 60.60, 35.21, 31.41, 26.47, 23.79, 6.55, 0.19, 0.00. 
HRMS(ESI): calcd for C50H62Cl3NO12SiNa [M+Na]+: 1024.2999, found 1024.3008 
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cis-4-(1H,1H,2H,2H,3H,3H-Perfluoroundecyloxy)-2-butenyl O-(methyl 2,3–O–di– benzyl -4– O - 
ns of general glycosylations. After FSPE purification, and the mixture was further purified by 
m, 3H), 4.44 – 
(m, 2H), 1.95 – 1.85 (m, 2H), 0.86 (s, 9H), 0.00 (s, 3H), -0.02 (s, 
C NMR (101 MHz, CDCl3) δ 174.48, 174.02, 166.71, 166.16, 143.29, 133.82, 133.67, 133.59, 
38, 133.26, 133.16, 133.11, 132.93, 132.81, 132.38, 132.16, 108.32, 103.06, 102.44, 
7.40, 89.16, 81.47, 80.89, 80.84, 80.23, 79.69, 79.69, 79.56, 78.79, 78.61, 77.54, 74.45, 74.36, 74.28, 
tert-butyldimethylsilyl –β-D-glucopyrafnosyluronate)-(1→3)-(4,6-O-benzylidene -2-deoxy-2- 
trichloroacetamido - β-D-glucopyranosyl)-(1→4)- (methyl 2,3–O–di– benzyl –β-D- 
glucopyrafnosyluronate)- (1→3)-(4,6-O-benzylidene-2-deoxy-2-trichloroacetamido - β-D- 
glucopyranoside (35) 
Donor 33 (36mg, 0.031 mmol) and acceptor 34 (16 mg, 0.011 mmol) were reacted under the 
conditio
SGC (hexanes/EtOAc 2:1) to give 35 (2.3 mg, 0.001 mmol, 10%).  
1H NMR (400 MHz, CDCl3) δ 7.48 – 7.16 (m, 40H), 0.06 – -0.06 (m, 7H), 7.08 (d, J = 8.90 Hz, 1H), 
6.93 (d, J = 8.69 Hz, 1H), 5.75 – 5.61 (m, 2H), 5.09 (d, J = 7.36 Hz, 1H), 5.06 – 4.92 (m, 4H), 4.85 
(dd, J = 5.64, 10.91 Hz, 1H), 4.81 – 4.68 (m, 3H), 4.68 – 4.53 (m, 4H), 4.53 – 4.43 (
4.32 (m, 2H), 4.27 – 4.18 (m, 2H), 4.06 – 3.91 (m, 3H), 3.91 – 3.76 (m, 3H), 3.76 – 3.57 (m, 9H), 
3.58 – 3.30 (m, 6H), 2.25 – 2.10 
3H).  
13
133.51, 133.
9
    150
74.10, 73.93, 73.93, 71.72, 71.72, 64.32, 57.46, 35.00, 31.00, 23.20, 19.42, 1.32, 0.00. 
19F NMR (376 MHz, CDCl3)  δ -80.74 (m, 3F), -114.41 (m, 2F), -121.81 (m, 6F), -122.70 (m, 2F), 
-123.43 (m, 2F), -126.10 (m, 2F). 
HRMS(ESI): calcd for C107H115Cl6F17N2O24SiNa [M+Na]+: 2395.5361, found 2395.5396 
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CHAPTER 6 
Conclusions and future directions 
 
In this dissertation, methods for the solution and fluorous-assisted synthesis of complex 
carbohydrates including maltotriose phosphate analogs and an oligomer of hyaluronic acid have been 
developed along with the development of process scale synthesis of a C-glycoside as a substitute for 
IPTG.  
 
The first fluorous protecting group for phosphate was developed. In future work, this tag and 
additional novel fluorous tags could be tested for their utility in the automated synthesis of 
oligosaccharides. The fluorous phosphate protecting group was then evaluated in the synthesis of 
maltotriose phosphate analogs. A series of maltotriose phosphates was synthesized for the study of 
Lafora disease. The α/β mixtures resulting from the glycosylation reactions proved difficult to 
separate, but in the end six maltotriose phosphate analogs were synthesized for the first time. The 
usage of the fluorous phosphate protecting group was evaluated. In case of reactions that would give a 
mixture of fluorous tagged product, it might not be very convenient to use a fluorous assisted 
synthesis. In the future, this fluorous protecting group could be used together with other fluorous tags, 
combined with F-HPLC to perform mix-tag synthesis.  
 
We developed a much more efficient and practical synthesis for the larger scale synthesis of IBCG 
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that should enable future experiments in mice. This work demonstrated the problems which can be 
encountered during optimizing and scaling up of a synthetic route. In synthetic carbohydrate 
chemistry, one of the major practical difficulties is to synthesize building blocks in large amounts. 
The automated solution-phase synthesis of carbohydrates also calls for multi-gram-scale building 
block synthesis. In the future, optimization of the syntheses for the existing building blocks is clearly 
an important direction.  
 
Finally, an approach amenable to automation for the synthesis of hyaluronic acid fragments was 
developed. The synthesis of glycosaminoglycans is still a daunting challenge, but a protecting group 
pattern that shows promise has been found for each of the constituent building blocks. This initial 
work sets the stage for future studies in the automated synthesis of a range of glycosaminoglycans. 
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APPENDIX A.  CHAPTER 2  1H AND 13C NMR SPECTRA  
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APPENDIX B.  CHAPTER 3  1H AND 13C NMR SPECTRA  
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APPENDIX D.  CHAPTER 5  1H AND 13C NMR SPECTRA  
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